P-value | ln(P) | Term | GO Tree | GO ID | # of Genes in Term | # of Target Genes in Term | # of Total Genes | # of Target Genes | Common Genes |
1.275e-10 | -22.78 | PRNP (prion protein (Kanno blood group)) | protein interactions | 5621 | 1118 | 18 | 19454 | 50 |
LSAMP,SORBS1,PTPRZ1,MACF1,GPM6A,MSI2,CLU,SPARCL1,AQP4,TRPS1,NHSL1,SLC1A3,QKI,ABLIM1,APOE,CPE,MAML2,SLC4A4 |
7.292e-07 | -14.13 | soft_tissue | COSMIC cancer mutations | soft_tissue | 5828 | 34 | 16828 | 49 |
CLU,MAML2,PON2,APOE,COL5A3,FBXL7,PCDH9,NKAIN3,FGFR3,GLI3,NHSL1,CDH20,PAMR1,ARHGAP24,GPM6A,SORBS1,PREX2,NFIA,TRPS1,PARD3B,MACF1,GLIS3,SPON1,SLC1A3,PTPRZ1,AQP4,MEIS2,NPAS3,RYR3,CTNND2,SLC1A2,LSAMP,GPC5,SPARCL1 |
1.343e-06 | -13.52 | blood_vessel | COSMIC cancer mutations | blood_vessel | 2211 | 20 | 16828 | 49 |
MEIS2,ARHGAP24,CDH20,LSAMP,PREX2,GPM6A,RYR3,SLC1A2,CTNND2,GPC5,MAML2,COL5A3,FBXL7,FGFR3,GLI3,PTPRZ1,SPON1,PCDH9,SLC1A3,NKAIN3 |
1.475e-06 | -13.43 | cerebellum | COSMIC cancer mutations | cerebellum | 769 | 12 | 16828 | 49 |
CPE,QKI,NPAS3,MEIS2,CTNND2,RYR3,GPC5,PARD3B,ABLIM1,MAML2,PCDH9,PTPRZ1 |
1.565e-06 | -13.37 | nervous system development | biological process | GO:0007399 | 2185 | 19 | 18204 | 49 |
PTPRZ1,SLC1A3,LSAMP,CTNND2,APOE,CLU,MSI2,PCDH9,GLI3,CTNNA2,MEIS2,GPM6A,NFIA,NDRG2,QKI,PREX2,NTM,SLC1A2,BMPR1B |
1.606e-06 | -13.34 | cell morphogenesis | biological process | GO:0000902 | 687 | 11 | 18204 | 49 |
NFIA,PREX2,BMPR1B,GLI3,GPM6A,CTNNA2,CLU,CDH20,PTPRZ1,CTNND2,SLC1A3 |
1.845e-06 | -13.20 | prostate-carcinoma | COSMIC cancer mutations | prostate-carcinoma | 9000 | 42 | 16828 | 49 |
SPARCL1,GPC5,LSAMP,CTNND2,SLC1A2,RYR3,NTM,NPAS3,MEIS2,SLC4A4,ATP13A4,QKI,CPE,PTPRZ1,SLC1A3,SPON1,GLIS3,BMPR1B,PITPNC1,MACF1,PARD3B,TRPS1,NFIA,PREX2,SORBS1,GPM6A,ARHGAP24,MSI2,CDH20,NHSL1,GLI3,FGFR3,NKAIN3,PCDH9,FBXL7,COL5A3,APOE,PON2,MAML2,DTNA,ABLIM1,CLU |
3.226e-06 | -12.64 | Burkitt_lymphoma | COSMIC cancer mutations | Burkitt_lymphoma | 2119 | 19 | 16828 | 49 |
MAML2,GLI3,NKAIN3,SLC1A3,PCDH9,SPON1,FBXL7,BMPR1B,NHSL1,NPAS3,ATP13A4,CPE,GPC5,LSAMP,PREX2,SLC1A2,CTNND2,GPM6A,RYR3 |
3.226e-06 | -12.64 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-Burkitt_lymphoma | 2119 | 19 | 16828 | 49 |
BMPR1B,FBXL7,PCDH9,SPON1,NKAIN3,SLC1A3,GLI3,MAML2,RYR3,GPM6A,CTNND2,SLC1A2,PREX2,LSAMP,GPC5,ATP13A4,CPE,NPAS3,NHSL1 |
3.494e-06 | -12.56 | acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | acute_myeloid_leukaemia_therapy_related | 1523 | 16 | 16828 | 49 |
GLI3,PCDH9,SPON1,NKAIN3,SLC1A3,COL5A3,ACSS1,FBXL7,MAML2,GPC5,LSAMP,PREX2,RYR3,CTNND2,MEIS2,QKI |
3.494e-06 | -12.56 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-acute_myeloid_leukaemia_therapy_related | 1523 | 16 | 16828 | 49 |
MEIS2,QKI,GPC5,LSAMP,PREX2,RYR3,CTNND2,MAML2,GLI3,PCDH9,SPON1,SLC1A3,NKAIN3,COL5A3,ACSS1,FBXL7 |
3.516e-06 | -12.56 | tibia | COSMIC cancer mutations | tibia | 836 | 12 | 16828 | 49 |
LSAMP,PREX2,GPM6A,CTNND2,QKI,CPE,FGFR3,NDRG2,NKAIN3,ACSS1,MACF1,ABLIM1 |
3.650e-06 | -12.52 | MAPT (microtubule associated protein tau) | protein interactions | 4137 | 948 | 12 | 19454 | 50 |
LSAMP,NTM,SORBS1,GPM6A,SLC1A2,CTNND2,CLU,SLC1A3,APOE,ABLIM1,CTNNA2,NDRG2 |
4.655e-06 | -12.28 | cell periphery | cellular component | GO:0071944 | 6020 | 31 | 19108 | 49 |
ATP13A4,CTNNA2,GPC5,AQP4,PARD3B,SPARCL1,NKAIN3,CDH20,RYR3,PTPRZ1,CTNND2,DTNA,MACF1,LSAMP,GPM6A,FGFR3,SLC4A4,BMPR1B,PCDH9,CLU,CST3,PON2,APOE,PREX2,SLC1A3,SLC1A2,SPON1,NTM,COL5A3,SORBS1,CPE |
4.679e-06 | -12.27 | cell junction | cellular component | GO:0030054 | 2224 | 18 | 19108 | 49 |
CDH20,SLC1A3,PTPRZ1,SLC1A2,CTNND2,DTNA,NFIA,GPM6A,FGFR3,SORBS1,PCDH9,CLU,CTNNA2,QKI,APOE,ARHGAP24,SPARCL1,PARD3B |
4.871e-06 | -12.23 | diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | diffuse_large_B_cell_lymphoma | 4151 | 27 | 16828 | 49 |
SPON1,SLC1A3,MACF1,RYR3,SLC1A2,CTNND2,LSAMP,GPC5,SPARCL1,CPE,ATP13A4,AQP4,QKI,MEIS2,ACSS1,FBXL7,PCDH9,NKAIN3,GLI3,FGFR3,CLU,DTNA,MAML2,GPM6A,PREX2,TRPS1,CDH20 |
5.357e-06 | -12.14 | angiosarcoma | COSMIC cancer mutations | angiosarcoma | 2192 | 19 | 16828 | 49 |
CDH20,ARHGAP24,MEIS2,GPC5,RYR3,GPM6A,CTNND2,SLC1A2,PREX2,LSAMP,MAML2,PCDH9,SPON1,SLC1A3,NKAIN3,GLI3,PTPRZ1,COL5A3,FBXL7 |
5.357e-06 | -12.14 | soft_tissue-blood_vessel-angiosarcoma | COSMIC cancer mutations | soft_tissue-blood_vessel-angiosarcoma | 2192 | 19 | 16828 | 49 |
GLI3,PTPRZ1,PCDH9,SPON1,SLC1A3,NKAIN3,COL5A3,FBXL7,MAML2,GPC5,LSAMP,PREX2,RYR3,GPM6A,SLC1A2,CTNND2,ARHGAP24,CDH20,MEIS2 |
7.388e-06 | -11.82 | pharynx | COSMIC cancer mutations | pharynx | 2696 | 21 | 16828 | 49 |
NHSL1,NPAS3,ATP13A4,QKI,SLC4A4,PARD3B,NFIA,GPC5,PREX2,RYR3,SLC1A2,CTNND2,SORBS1,PITPNC1,MACF1,CLU,DTNA,FGFR3,PTPRZ1,PCDH9,AMZ2 |
8.073e-06 | -11.73 | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymph_node-lymphoid_neoplasm-mantle_cell_lymphoma | 476 | 9 | 16828 | 49 |
ATP13A4,MAML2,MEIS2,RYR3,GPM6A,CTNND2,LSAMP,GPC5,PCDH9 |
8.240e-06 | -11.71 | adherens junction | cellular component | GO:0005912 | 188 | 6 | 19108 | 49 |
CTNND2,SORBS1,CTNNA2,ARHGAP24,PARD3B,CDH20 |
9.341e-06 | -11.58 | anatomical structure morphogenesis | biological process | GO:0009653 | 2225 | 18 | 18204 | 49 |
BMPR1B,QKI,FGFR3,NFIA,PREX2,CTNNA2,ABLIM1,MEIS2,GPM6A,GLI3,CLU,ARHGAP24,SLC1A3,CTNND2,APOE,PTPRZ1,CPE,CDH20 |
1.097e-05 | -11.42 | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 24 | 16828 | 49 |
GPC5,RYR3,CTNND2,LSAMP,CPE,SLC4A4,NPAS3,MEIS2,SPON1,SLC1A3,PTPRZ1,BMPR1B,PITPNC1,MACF1,PARD3B,PREX2,MSI2,PAMR1,PCDH9,AMZ2,GLI3,FBXL7,CLU,DTNA |
1.097e-05 | -11.42 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-chronic_lymphocytic_leukaemia-small_lymphocytic_lymphoma | 3511 | 24 | 16828 | 49 |
GLI3,PCDH9,AMZ2,FBXL7,CLU,DTNA,PARD3B,PREX2,PAMR1,MSI2,PTPRZ1,SPON1,SLC1A3,BMPR1B,PITPNC1,MACF1,GPC5,LSAMP,RYR3,CTNND2,NPAS3,MEIS2,CPE,SLC4A4 |
1.167e-05 | -11.36 | system development | biological process | GO:0048731 | 3533 | 23 | 18204 | 49 |
CTNNA2,GPM6A,MEIS2,PCDH9,GLI3,NTM,BMPR1B,SLC1A2,PREX2,FGFR3,NDRG2,NFIA,QKI,LSAMP,SLC1A3,APOE,TRPS1,CTNND2,CPE,PTPRZ1,CLU,MSI2,ARHGAP24 |
1.310e-05 | -11.24 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma | 7205 | 36 | 16828 | 49 |
NHSL1,PAMR1,GPM6A,SORBS1,PREX2,NFIA,TRPS1,PARD3B,ABLIM1,MAML2,PON2,COL5A3,ACSS1,FBXL7,PCDH9,NKAIN3,GLI3,FGFR3,CPE,ATP13A4,QKI,SLC4A4,NPAS3,MEIS2,NTM,RYR3,CTNND2,SLC1A2,LSAMP,GPC5,MACF1,PITPNC1,GLIS3,SPON1,SLC1A3,PTPRZ1 |
1.425e-05 | -11.16 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-acute_lymphoblastic_B_cell_leukaemia | 3828 | 25 | 16828 | 49 |
GLIS3,BMPR1B,PTPRZ1,SPON1,SLC1A3,MEIS2,CPE,ATP13A4,SLC4A4,NTM,LSAMP,RYR3,CTNND2,SLC1A2,GPC5,MAML2,COL5A3,FBXL7,GLI3,PCDH9,NKAIN3,PAMR1,PREX2,GPM6A,NFIA |
1.425e-05 | -11.16 | acute_lymphoblastic_B_cell_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_B_cell_leukaemia | 3828 | 25 | 16828 | 49 |
MAML2,COL5A3,FBXL7,PCDH9,NKAIN3,GLI3,PAMR1,GPM6A,PREX2,NFIA,BMPR1B,GLIS3,SPON1,SLC1A3,PTPRZ1,CPE,ATP13A4,SLC4A4,MEIS2,NTM,RYR3,SLC1A2,CTNND2,LSAMP,GPC5 |
1.468e-05 | -11.13 | lymph_node | COSMIC cancer mutations | lymph_node | 1703 | 16 | 16828 | 49 |
TRPS1,GPC5,PARD3B,CTNND2,GPM6A,RYR3,LSAMP,ARHGAP24,ATP13A4,MEIS2,SLC1A3,PCDH9,FGFR3,ACSS1,DTNA,MAML2 |
1.509e-05 | -11.10 | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | COSMIC cancer mutations | central_nervous_system-cerebellum-primitive_neuroectodermal_tumour-medulloblastoma-SHH_subtype | 653 | 10 | 16828 | 49 |
MAML2,NPAS3,MEIS2,ABLIM1,CPE,CTNND2,RYR3,PTPRZ1,PARD3B,PCDH9 |
1.529e-05 | -11.09 | SHH_subtype | COSMIC cancer mutations | SHH_subtype | 654 | 10 | 16828 | 49 |
RYR3,CTNND2,PCDH9,PARD3B,PTPRZ1,CPE,ABLIM1,MAML2,NPAS3,MEIS2 |
1.782e-05 | -10.94 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-diffuse_large_B_cell_lymphoma | 3608 | 24 | 16828 | 49 |
MAML2,CLU,FGFR3,GLI3,NKAIN3,PCDH9,ACSS1,FBXL7,CDH20,PREX2,GPM6A,MACF1,SPON1,MEIS2,ATP13A4,AQP4,QKI,CPE,SPARCL1,GPC5,LSAMP,CTNND2,SLC1A2,RYR3 |
1.847e-05 | -10.90 | brainstem | COSMIC cancer mutations | brainstem | 3102 | 22 | 16828 | 49 |
CDH20,PREX2,GPM6A,MAML2,FBXL7,FGFR3,GLI3,NKAIN3,PCDH9,MEIS2,NPAS3,QKI,ATP13A4,CPE,LSAMP,CTNND2,SLC1A2,RYR3,GPC5,PTPRZ1,SLC1A3,SPON1 |
2.276e-05 | -10.69 | multicellular organism development | biological process | GO:0007275 | 3957 | 24 | 18204 | 49 |
CTNNA2,GPM6A,GLI3,SLC1A2,NDRG2,QKI,PREX2,SLC1A3,TRPS1,CPE,CDH20,CLU,MSI2,MEIS2,PCDH9,NTM,BMPR1B,FGFR3,NFIA,LSAMP,CTNND2,APOE,PTPRZ1,ARHGAP24 |
3.199e-05 | -10.35 | cell adhesion | biological process | GO:0007155 | 942 | 11 | 18204 | 49 |
COL5A3,NTM,SPON1,PCDH9,CDH20,CTNNA2,LSAMP,SPARCL1,CTNND2,SORBS1,PARD3B |
3.599e-05 | -10.23 | neurogenesis | biological process | GO:0022008 | 1334 | 13 | 18204 | 49 |
GLI3,CTNNA2,GPM6A,QKI,NFIA,PREX2,NTM,BMPR1B,PTPRZ1,SLC1A3,CTNND2,APOE,CLU |
4.330e-05 | -10.05 | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-astrocytoma_Grade_IV | 2531 | 19 | 16828 | 49 |
FBXL7,SPON1,PCDH9,SLC1A3,NKAIN3,GLI3,PTPRZ1,MAML2,GPM6A,RYR3,CTNND2,LSAMP,PREX2,GPC5,ATP13A4,CPE,QKI,MEIS2,CDH20 |
4.917e-05 | -9.92 | Neurotransmitter uptake and Metabolism In Glial Cells | REACTOME pathways | R-HSA-112313 | 4 | 2 | 10285 | 30 |
SLC1A3,SLC1A2 |
4.917e-05 | -9.92 | Astrocytic Glutamate-Glutamine Uptake And Metabolism | REACTOME pathways | R-HSA-210455 | 4 | 2 | 10285 | 30 |
SLC1A2,SLC1A3 |
5.275e-05 | -9.85 | central nervous system development | biological process | GO:0007417 | 995 | 11 | 18204 | 49 |
CLU,NDRG2,QKI,MSI2,BMPR1B,SLC1A2,PTPRZ1,PCDH9,GLI3,CTNNA2,MEIS2 |
5.762e-05 | -9.76 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm | 764 | 10 | 16828 | 49 |
MAML2,NKAIN3,GPC5,PCDH9,SLC1A2,RYR3,FBXL7,LSAMP,COL5A3,PREX2 |
6.151e-05 | -9.70 | rhabdomyosarcoma | COSMIC cancer mutations | rhabdomyosarcoma | 4150 | 25 | 16828 | 49 |
NPAS3,AQP4,RYR3,CTNND2,SPARCL1,MACF1,GLIS3,PTPRZ1,SPON1,SLC1A3,NHSL1,PAMR1,CDH20,PREX2,SORBS1,PARD3B,NFIA,TRPS1,MAML2,PON2,CLU,APOE,COL5A3,GLI3,FGFR3 |
6.375e-05 | -9.66 | negative regulation of amyloid-beta formation | biological process | GO:1902430 | 29 | 3 | 18204 | 49 |
SPON1,CLU,APOE |
6.535e-05 | -9.64 | mantle_cell_lymphoma | COSMIC cancer mutations | mantle_cell_lymphoma | 2849 | 20 | 16828 | 49 |
SLC1A2,CTNND2,GPM6A,RYR3,LSAMP,PREX2,TRPS1,GPC5,PARD3B,ATP13A4,CPE,MEIS2,ARHGAP24,FBXL7,SLC1A3,NKAIN3,SPON1,PCDH9,GLI3,MAML2 |
6.856e-05 | -9.59 | high-affinity L-glutamate transmembrane transporter activity | molecular function | GO:0005314 | 5 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
6.856e-05 | -9.59 | glutamate:sodium symporter activity | molecular function | GO:0015501 | 5 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
7.061e-05 | -9.56 | D-aspartate transmembrane transport | biological process | GO:0070777 | 5 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
7.061e-05 | -9.56 | positive regulation of amyloid fibril formation | biological process | GO:1905908 | 5 | 2 | 18204 | 49 |
CLU,APOE |
7.061e-05 | -9.56 | D-aspartate import across plasma membrane | biological process | GO:0070779 | 5 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
7.813e-05 | -9.46 | negative regulation of amyloid precursor protein catabolic process | biological process | GO:1902992 | 31 | 3 | 18204 | 49 |
APOE,CLU,SPON1 |
7.981e-05 | -9.44 | neuron development | biological process | GO:0048666 | 859 | 10 | 18204 | 49 |
GLI3,PTPRZ1,CTNND2,GPM6A,APOE,SLC1A3,CTNNA2,PREX2,BMPR1B,NTM |
8.255e-05 | -9.40 | NTM (neurotrimin) | protein interactions | 50863 | 33 | 3 | 19454 | 50 |
NTM,GPM6A,LSAMP |
8.334e-05 | -9.39 | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-alveolar | 2414 | 18 | 16828 | 49 |
NPAS3,NHSL1,PAMR1,CDH20,PREX2,RYR3,SORBS1,PARD3B,NFIA,TRPS1,SPARCL1,MACF1,PON2,CLU,APOE,FGFR3,SPON1,SLC1A3 |
8.334e-05 | -9.39 | alveolar | COSMIC cancer mutations | alveolar | 2414 | 18 | 16828 | 49 |
NHSL1,PAMR1,CDH20,NPAS3,NFIA,TRPS1,SPARCL1,PARD3B,RYR3,SORBS1,PREX2,APOE,CLU,MACF1,PON2,SPON1,SLC1A3,FGFR3 |
8.349e-05 | -9.39 | multicellular organismal process | biological process | GO:0032501 | 6177 | 30 | 18204 | 49 |
ARHGAP24,LSAMP,PTGDS,APOE,CTNND2,PTPRZ1,NTM,BMPR1B,SLC4A4,FGFR3,NFIA,ABLIM1,MEIS2,DTNA,PCDH9,CLU,MSI2,SLC1A3,TRPS1,CPE,CDH20,SLC1A2,PREX2,AQP4,QKI,NDRG2,CTNNA2,GPM6A,RYR3,GLI3 |
8.544e-05 | -9.37 | striated_muscle | COSMIC cancer mutations | striated_muscle | 4228 | 25 | 16828 | 49 |
SORBS1,PREX2,NFIA,TRPS1,PARD3B,NHSL1,CDH20,PAMR1,COL5A3,FGFR3,GLI3,CLU,MAML2,PON2,APOE,RYR3,CTNND2,SPARCL1,AQP4,NPAS3,GLIS3,SPON1,SLC1A3,PTPRZ1,MACF1 |
8.642e-05 | -9.36 | embryonal | COSMIC cancer mutations | embryonal | 2659 | 19 | 16828 | 49 |
PARD3B,NFIA,SPARCL1,PREX2,RYR3,SORBS1,CTNND2,NPAS3,AQP4,FGFR3,GLI3,PTPRZ1,SPON1,COL5A3,GLIS3,APOE,MACF1,MAML2,PON2 |
8.642e-05 | -9.36 | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma-embryonal | 2659 | 19 | 16828 | 49 |
APOE,PON2,MAML2,MACF1,PTPRZ1,GLI3,FGFR3,SPON1,GLIS3,COL5A3,NPAS3,AQP4,PARD3B,SPARCL1,NFIA,PREX2,CTNND2,SORBS1,RYR3 |
8.887e-05 | -9.33 | anatomical structure development | biological process | GO:0048856 | 5207 | 27 | 18204 | 49 |
SLC1A3,TRPS1,CPE,CDH20,CLU,MSI2,CTNNA2,SPARCL1,GPM6A,GLI3,SLC1A2,NDRG2,QKI,PREX2,LSAMP,CTNND2,APOE,PTPRZ1,COL5A3,ARHGAP24,ABLIM1,MEIS2,PCDH9,NTM,BMPR1B,FGFR3,NFIA |
1.027e-04 | -9.18 | collagen-containing extracellular matrix | cellular component | GO:0062023 | 428 | 7 | 19108 | 49 |
CLU,APOE,PTPRZ1,SPON1,SPARCL1,COL5A3,GPC5 |
1.034e-04 | -9.18 | negative regulation of amide metabolic process | biological process | GO:0034249 | 34 | 3 | 18204 | 49 |
APOE,CLU,SPON1 |
1.057e-04 | -9.15 | L-aspartate import across plasma membrane | biological process | GO:0140009 | 6 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
1.057e-04 | -9.15 | D-amino acid transport | biological process | GO:0042940 | 6 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
1.064e-04 | -9.15 | GLI-like | interpro domains | IPR043359 | 6 | 2 | 18521 | 50 |
GLIS3,GLI3 |
1.080e-04 | -9.13 | autonomic_ganglia | COSMIC cancer mutations | autonomic_ganglia | 4005 | 24 | 16828 | 49 |
NHSL1,NFIA,TRPS1,PARD3B,GPM6A,PREX2,MAML2,PCDH9,AMZ2,GLI3,FGFR3,COL5A3,FBXL7,ACSS1,AQP4,SLC4A4,NPAS3,RYR3,CTNND2,SLC1A2,PITPNC1,MACF1,PTPRZ1,GLIS3 |
1.112e-04 | -9.10 | neuron differentiation | biological process | GO:0030182 | 1081 | 11 | 18204 | 49 |
GPM6A,CTNNA2,GLI3,BMPR1B,NTM,PREX2,NFIA,APOE,CTNND2,SLC1A3,PTPRZ1 |
1.139e-04 | -9.08 | plasma membrane | cellular component | GO:0005886 | 5538 | 27 | 19108 | 49 |
PARD3B,AQP4,CTNNA2,ATP13A4,GPC5,BMPR1B,LSAMP,FGFR3,SLC4A4,GPM6A,MACF1,CTNND2,DTNA,RYR3,NKAIN3,CDH20,PTPRZ1,PREX2,APOE,CST3,PCDH9,PON2,SORBS1,CPE,NTM,SLC1A2,SLC1A3 |
1.287e-04 | -8.96 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-mantle_cell_lymphoma | 2737 | 19 | 16828 | 49 |
PCDH9,SPON1,NKAIN3,SLC1A3,GLI3,FBXL7,MAML2,GPC5,TRPS1,PARD3B,GPM6A,RYR3,SLC1A2,CTNND2,LSAMP,PREX2,ARHGAP24,CPE,MEIS2 |
1.399e-04 | -8.87 | endoplasmic reticulum lumen | cellular component | GO:0005788 | 312 | 6 | 19108 | 49 |
COL5A3,SPON1,SPARCL1,APOE,CLU,CST3 |
1.462e-04 | -8.83 | ductolobular_carcinoma | COSMIC cancer mutations | ductolobular_carcinoma | 1619 | 14 | 16828 | 49 |
MACF1,ABLIM1,DTNA,FGFR3,GLI3,NDRG2,PTPRZ1,CDH20,CPE,QKI,PARD3B,PREX2,CTNND2,SORBS1 |
1.462e-04 | -8.83 | breast-carcinoma-ductolobular_carcinoma | COSMIC cancer mutations | breast-carcinoma-ductolobular_carcinoma | 1619 | 14 | 16828 | 49 |
PARD3B,PREX2,CTNND2,SORBS1,CDH20,CPE,QKI,GLI3,FGFR3,NDRG2,PTPRZ1,MACF1,ABLIM1,DTNA |
1.469e-04 | -8.83 | HUNK (hormonally up-regulated Neu-associated kinase) | protein interactions | 30811 | 104 | 4 | 19454 | 50 |
SORBS1,SPARCL1,CLU,ABLIM1 |
1.487e-04 | -8.81 | Na:dicarbo_symporter_sf | interpro domains | IPR036458 | 7 | 2 | 18521 | 50 |
SLC1A3,SLC1A2 |
1.487e-04 | -8.81 | Na-dicarboxylate_symporter | interpro domains | IPR001991 | 7 | 2 | 18521 | 50 |
SLC1A2,SLC1A3 |
1.487e-04 | -8.81 | Na-dicarboxylate_symporter_CS | interpro domains | IPR018107 | 7 | 2 | 18521 | 50 |
SLC1A3,SLC1A2 |
1.565e-04 | -8.76 | cellular response to alkaloid | biological process | GO:0071312 | 39 | 3 | 18204 | 49 |
RYR3,SLC1A2,SLC1A3 |
1.610e-04 | -8.73 | SDF | pfam domains | PF00375 | 7 | 2 | 17795 | 50 |
SLC1A3,SLC1A2 |
1.687e-04 | -8.69 | developmental process | biological process | GO:0032502 | 5716 | 28 | 18204 | 49 |
SLC1A3,TRPS1,CPE,CDH20,CLU,MSI2,CTNNA2,SPARCL1,GPM6A,GLI3,SLC1A2,QKI,NDRG2,PREX2,LSAMP,CTNND2,APOE,PTPRZ1,COL5A3,ARHGAP24,ABLIM1,NHSL1,MEIS2,PCDH9,NTM,BMPR1B,FGFR3,NFIA |
1.712e-04 | -8.67 | cell morphogenesis involved in neuron differentiation | biological process | GO:0048667 | 443 | 7 | 18204 | 49 |
PREX2,BMPR1B,PTPRZ1,GLI3,CTNNA2,SLC1A3,CTNND2 |
1.776e-04 | -8.64 | CTNNA1 (catenin alpha 1) | protein interactions | 1495 | 325 | 6 | 19454 | 50 |
DTNA,ABLIM1,MACF1,CTNNA2,SORBS1,NHSL1 |
1.841e-04 | -8.60 | beta-catenin binding | molecular function | GO:0008013 | 107 | 4 | 18094 | 48 |
CDH20,CTNND2,CTNNA2,GLI3 |
1.874e-04 | -8.58 | bone-tibia-other-chondroblastoma | COSMIC cancer mutations | bone-tibia-other-chondroblastoma | 98 | 4 | 16828 | 49 |
NKAIN3,CTNND2,GPM6A,LSAMP |
1.879e-04 | -8.58 | Sodium:dicarboxylate symporter | gene3d domains | 1.10.3860.10 | 7 | 2 | 14470 | 44 |
SLC1A2,SLC1A3 |
1.967e-04 | -8.53 | protein import | biological process | GO:0017038 | 8 | 2 | 18204 | 49 |
CLU,APOE |
2.035e-04 | -8.50 | cell projection | cellular component | GO:0042995 | 2398 | 16 | 19108 | 49 |
ARHGAP24,APOE,AQP4,NDRG2,CTNNA2,ABLIM1,PCDH9,CLU,BMPR1B,GPM6A,MACF1,DTNA,CTNND2,SLC1A2,GLI3,SLC1A3 |
2.040e-04 | -8.50 | generation of neurons | biological process | GO:0048699 | 1158 | 11 | 18204 | 49 |
GPM6A,CTNNA2,GLI3,BMPR1B,NTM,PREX2,NFIA,APOE,CTNND2,SLC1A3,PTPRZ1 |
2.304e-04 | -8.38 | KLB (klotho beta) | protein interactions | 152831 | 9 | 2 | 19454 | 50 |
FGFR3,ARHGAP24 |
2.304e-04 | -8.38 | LSAMP (limbic system associated membrane protein) | protein interactions | 4045 | 9 | 2 | 19454 | 50 |
NTM,LSAMP |
2.304e-04 | -8.38 | NEGR1 (neuronal growth regulator 1) | protein interactions | 257194 | 9 | 2 | 19454 | 50 |
LSAMP,NTM |
2.409e-04 | -8.33 | NA_DICARBOXYL_SYMP_1 | prosite domains | PS00713 | 7 | 2 | 12186 | 42 |
SLC1A2,SLC1A3 |
2.409e-04 | -8.33 | NA_DICARBOXYL_SYMP_2 | prosite domains | PS00714 | 7 | 2 | 12186 | 42 |
SLC1A2,SLC1A3 |
2.888e-04 | -8.15 | EDTRNSPORT | prints domains | PR00173 | 7 | 2 | 5227 | 20 |
SLC1A2,SLC1A3 |
2.894e-04 | -8.15 | autonomic_ganglia-neuroblastoma | COSMIC cancer mutations | autonomic_ganglia-neuroblastoma | 3970 | 23 | 16828 | 49 |
NPAS3,SLC4A4,AQP4,PARD3B,TRPS1,NFIA,PREX2,SLC1A2,CTNND2,GPM6A,RYR3,PITPNC1,MACF1,MAML2,PTPRZ1,GLI3,FGFR3,AMZ2,PCDH9,ACSS1,GLIS3,FBXL7,COL5A3 |
2.905e-04 | -8.14 | neuroblastoma | COSMIC cancer mutations | neuroblastoma | 3971 | 23 | 16828 | 49 |
MAML2,COL5A3,ACSS1,FBXL7,FGFR3,GLI3,PCDH9,AMZ2,PREX2,GPM6A,PARD3B,NFIA,TRPS1,MACF1,PITPNC1,GLIS3,PTPRZ1,NPAS3,AQP4,SLC4A4,RYR3,SLC1A2,CTNND2 |
2.909e-04 | -8.14 | nodular | COSMIC cancer mutations | nodular | 1515 | 13 | 16828 | 49 |
SPARCL1,PREX2,CTNND2,CDH20,NPAS3,SLC4A4,ATP13A4,CPE,PTPRZ1,FGFR3,GLIS3,MACF1,ABLIM1 |
2.911e-04 | -8.14 | regulation of amyloid-beta formation | biological process | GO:1902003 | 48 | 3 | 18204 | 49 |
APOE,CLU,SPON1 |
2.984e-04 | -8.12 | glial cell differentiation | biological process | GO:0010001 | 219 | 5 | 18204 | 49 |
CLU,QKI,NFIA,PTPRZ1,GLI3 |
3.013e-04 | -8.11 | neuron projection morphogenesis | biological process | GO:0048812 | 486 | 7 | 18204 | 49 |
GPM6A,CTNND2,CTNNA2,GLI3,PTPRZ1,BMPR1B,PREX2 |
3.121e-04 | -8.07 | cell-cell junction | cellular component | GO:0005911 | 513 | 7 | 19108 | 49 |
PCDH9,CDH20,CTNNA2,CTNND2,PARD3B,ARHGAP24,SORBS1 |
3.150e-04 | -8.06 | cellular response to cocaine | biological process | GO:0071314 | 10 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
3.162e-04 | -8.06 | PAX9 (paired box 9) | protein interactions | 5083 | 127 | 4 | 19454 | 50 |
QKI,TRPS1,NFIA,ARHGAP24 |
3.205e-04 | -8.05 | plasma membrane bounded cell projection morphogenesis | biological process | GO:0120039 | 491 | 7 | 18204 | 49 |
PTPRZ1,PREX2,GLI3,CTNNA2,CTNND2,GPM6A,BMPR1B |
3.234e-04 | -8.04 | upper_aerodigestive_tract-mouth-carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma | 6426 | 31 | 16828 | 49 |
FGFR3,GLI3,AMZ2,FBXL7,ACSS1,COL5A3,APOE,MAML2,CLU,ABLIM1,PARD3B,TRPS1,PREX2,SORBS1,GPM6A,CDH20,PAMR1,NHSL1,NDRG2,SLC1A3,SPON1,PITPNC1,MACF1,GPC5,CTNND2,SLC1A2,RYR3,NTM,NPAS3,SLC4A4,QKI |
3.407e-04 | -7.98 | cell projection morphogenesis | biological process | GO:0048858 | 496 | 7 | 18204 | 49 |
BMPR1B,PREX2,GPM6A,CTNND2,CTNNA2,GLI3,PTPRZ1 |
3.844e-04 | -7.86 | L-glutamate import across plasma membrane | biological process | GO:0098712 | 11 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
3.844e-04 | -7.86 | L-aspartate transmembrane transport | biological process | GO:0070778 | 11 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
3.906e-04 | -7.85 | regulation of chondrocyte differentiation | biological process | GO:0032330 | 53 | 3 | 18204 | 49 |
BMPR1B,TRPS1,GLI3 |
4.023e-04 | -7.82 | CSTL1 (cystatin like 1) | protein interactions | 128817 | 56 | 3 | 19454 | 50 |
CLU,APOE,CPE |
4.129e-04 | -7.79 | plasma membrane bounded cell projection | cellular component | GO:0120025 | 2285 | 15 | 19108 | 49 |
APOE,AQP4,NDRG2,CTNNA2,CLU,PCDH9,ABLIM1,BMPR1B,GPM6A,DTNA,CTNND2,MACF1,SLC1A2,GLI3,SLC1A3 |
4.203e-04 | -7.77 | TREM2 (triggering receptor expressed on myeloid cells 2) | protein interactions | 54209 | 12 | 2 | 19454 | 50 |
CLU,APOE |
4.357e-04 | -7.74 | regulation of amyloid precursor protein catabolic process | biological process | GO:1902991 | 55 | 3 | 18204 | 49 |
APOE,SPON1,CLU |
4.466e-04 | -7.71 | neuron projection | cellular component | GO:0043005 | 1331 | 11 | 19108 | 49 |
APOE,PCDH9,CLU,NDRG2,CTNNA2,GPM6A,BMPR1B,SLC1A3,DTNA,CTNND2,SLC1A2 |
4.513e-04 | -7.70 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-myelodysplastic_syndrome | 1174 | 11 | 16828 | 49 |
FGFR3,NKAIN3,NFIA,FBXL7,LSAMP,PREX2,COL5A3,SLC1A2,BMPR1B,RYR3,NPAS3 |
4.513e-04 | -7.70 | myelodysplastic_syndrome | COSMIC cancer mutations | myelodysplastic_syndrome | 1174 | 11 | 16828 | 49 |
RYR3,SLC1A2,LSAMP,PREX2,NFIA,NPAS3,BMPR1B,COL5A3,FBXL7,NKAIN3,FGFR3 |
4.796e-04 | -7.64 | neuron projection development | biological process | GO:0031175 | 693 | 8 | 18204 | 49 |
PREX2,BMPR1B,GLI3,PTPRZ1,CTNND2,APOE,GPM6A,CTNNA2 |
5.187e-04 | -7.56 | cell junction organization | biological process | GO:0034330 | 532 | 7 | 18204 | 49 |
SPARCL1,APOE,GPM6A,SORBS1,CTNND2,CDH20,NFIA |
5.199e-04 | -7.56 | CTNNB1 (catenin beta 1) | protein interactions | 1499 | 926 | 9 | 19454 | 50 |
NHSL1,SORBS1,PTPRZ1,CTNND2,CTNNA2,PARD3B,ARHGAP24,DTNA,APOE |
5.225e-04 | -7.56 | extracellular matrix | cellular component | GO:0031012 | 559 | 7 | 19108 | 49 |
SPARCL1,SPON1,GPC5,COL5A3,CLU,PTPRZ1,APOE |
5.281e-04 | -7.55 | external encapsulating structure | cellular component | GO:0030312 | 560 | 7 | 19108 | 49 |
APOE,PTPRZ1,CLU,COL5A3,GPC5,SPON1,SPARCL1 |
5.432e-04 | -7.52 | negative regulation of amyloid fibril formation | biological process | GO:1905907 | 13 | 2 | 18204 | 49 |
APOE,CLU |
5.776e-04 | -7.46 | C9 (complement C9) | protein interactions | 735 | 14 | 2 | 19454 | 50 |
CLU,APOE |
5.776e-04 | -7.46 | PLXNA4 (plexin A4) | protein interactions | 91584 | 14 | 2 | 19454 | 50 |
GPM6A,CLU |
5.776e-04 | -7.46 | CTSO (cathepsin O) | protein interactions | 1519 | 14 | 2 | 19454 | 50 |
CST3,AMZ2 |
6.145e-04 | -7.39 | L-glutamate transmembrane transporter activity | molecular function | GO:0005313 | 14 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
6.239e-04 | -7.38 | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-nasopharyngeal_carcinoma | 1425 | 12 | 16828 | 49 |
SLC4A4,CLU,QKI,ATP13A4,PITPNC1,NHSL1,SLC1A2,CTNND2,PREX2,AMZ2,NFIA,FGFR3 |
6.239e-04 | -7.38 | nasopharyngeal_carcinoma | COSMIC cancer mutations | nasopharyngeal_carcinoma | 1425 | 12 | 16828 | 49 |
FGFR3,NFIA,AMZ2,PREX2,SLC1A2,CTNND2,NHSL1,PITPNC1,ATP13A4,CLU,QKI,SLC4A4 |
6.654e-04 | -7.32 | RNASE13 (ribonuclease A family member 13 (inactive)) | protein interactions | 440163 | 15 | 2 | 19454 | 50 |
CLU,CPE |
6.803e-04 | -7.29 | dendrite morphogenesis | biological process | GO:0048813 | 64 | 3 | 18204 | 49 |
CTNND2,CTNNA2,PREX2 |
7.592e-04 | -7.18 | CNTNAP2 (contactin associated protein 2) | protein interactions | 26047 | 16 | 2 | 19454 | 50 |
CPE,MACF1 |
8.133e-04 | -7.11 | carcinoid-endocrine_tumour | COSMIC cancer mutations | carcinoid-endocrine_tumour | 7752 | 34 | 16828 | 49 |
COL5A3,ACSS1,FBXL7,PCDH9,NKAIN3,FGFR3,GLI3,CLU,ABLIM1,MAML2,PON2,APOE,GPM6A,PREX2,TRPS1,NHSL1,CDH20,PAMR1,BMPR1B,GLIS3,SPON1,SLC1A3,PTPRZ1,MACF1,RYR3,CTNND2,SLC1A2,LSAMP,GPC5,ATP13A4,QKI,CPE,SLC4A4,MEIS2 |
8.340e-04 | -7.09 | plasma_cell_myeloma | COSMIC cancer mutations | plasma_cell_myeloma | 1263 | 11 | 16828 | 49 |
MACF1,ATP13A4,ABLIM1,NTM,PAMR1,GPM6A,RYR3,CTNND2,GLI3,FGFR3,TRPS1 |
8.340e-04 | -7.09 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-plasma_cell_myeloma | 1263 | 11 | 16828 | 49 |
MACF1,ABLIM1,ATP13A4,NTM,PAMR1,CTNND2,GPM6A,RYR3,FGFR3,GLI3,TRPS1 |
8.403e-04 | -7.08 | gliogenesis | biological process | GO:0042063 | 275 | 5 | 18204 | 49 |
CLU,PTPRZ1,NFIA,QKI,GLI3 |
8.422e-04 | -7.08 | chondroblastoma | COSMIC cancer mutations | chondroblastoma | 534 | 7 | 16828 | 49 |
RYR3,GPM6A,CTNND2,LSAMP,GPC5,PCDH9,NKAIN3 |
8.516e-04 | -7.07 | spindle | COSMIC cancer mutations | spindle | 386 | 6 | 16828 | 49 |
PREX2,MACF1,CTNND2,CPE,FGFR3,PCDH9 |
8.681e-04 | -7.05 | lymphoid_neoplasm | COSMIC cancer mutations | lymphoid_neoplasm | 12233 | 45 | 16828 | 49 |
TRPS1,NFIA,PARD3B,SORBS1,GPM6A,PREX2,CDH20,PAMR1,MSI2,NHSL1,ARHGAP24,NKAIN3,AMZ2,PCDH9,GLI3,FGFR3,ACSS1,FBXL7,COL5A3,DTNA,CLU,ABLIM1,PON2,MAML2,SPARCL1,GPC5,CTNND2,SLC1A2,RYR3,LSAMP,NTM,SLC4A4,QKI,ATP13A4,CPE,AQP4,MEIS2,NPAS3,SLC1A3,SPON1,PTPRZ1,BMPR1B,GLIS3,PITPNC1,MACF1 |
9.407e-04 | -6.97 | regulation of amyloid fibril formation | biological process | GO:1905906 | 17 | 2 | 18204 | 49 |
CLU,APOE |
9.407e-04 | -6.97 | reverse cholesterol transport | biological process | GO:0043691 | 17 | 2 | 18204 | 49 |
CLU,APOE |
9.985e-04 | -6.91 | regulation of cartilage development | biological process | GO:0061035 | 73 | 3 | 18204 | 49 |
BMPR1B,TRPS1,GLI3 |
9.998e-04 | -6.91 | skin-trunk-malignant_melanoma-nodular | COSMIC cancer mutations | skin-trunk-malignant_melanoma-nodular | 1291 | 11 | 16828 | 49 |
PREX2,GLIS3,CTNND2,PTPRZ1,SPARCL1,MACF1,NPAS3,CPE,ATP13A4,ABLIM1,CDH20 |
1.022e-03 | -6.89 | Htt (huntingtin) | protein interactions | 15194 | 77 | 3 | 19454 | 50 |
LSAMP,NTM,GPM6A |
1.026e-03 | -6.88 | acidic amino acid transmembrane transporter activity | molecular function | GO:0015172 | 18 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
1.069e-03 | -6.84 | oesophagus-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-carcinoma-squamous_cell_carcinoma | 6486 | 30 | 16828 | 49 |
ABLIM1,MAML2,FBXL7,COL5A3,PCDH9,FGFR3,GLI3,ARHGAP24,SORBS1,GPM6A,PREX2,TRPS1,PARD3B,MACF1,PITPNC1,BMPR1B,GLIS3,SPON1,PTPRZ1,NDRG2,SLC4A4,AQP4,CPE,ATP13A4,MEIS2,NPAS3,CTNND2,RYR3,SPARCL1,GPC5 |
1.071e-03 | -6.84 | astrocyte projection | cellular component | GO:0097449 | 19 | 2 | 19108 | 49 |
AQP4,SLC1A2 |
1.077e-03 | -6.83 | RIT2 (Ras like without CAAX 2) | protein interactions | 6014 | 19 | 2 | 19454 | 50 |
ARHGAP24,DTNA |
1.158e-03 | -6.76 | superficial_spreading | COSMIC cancer mutations | superficial_spreading | 1110 | 10 | 16828 | 49 |
SORBS1,CTNND2,COL5A3,PREX2,FGFR3,GLI3,SLC4A4,ATP13A4,MACF1,NTM |
1.179e-03 | -6.74 | regulation of amyloid-beta clearance | biological process | GO:1900221 | 19 | 2 | 18204 | 49 |
CLU,APOE |
1.194e-03 | -6.73 | PDZD2 (PDZ domain containing 2) | protein interactions | 23037 | 20 | 2 | 19454 | 50 |
CTNND2,CST3 |
1.196e-03 | -6.73 | cartilage development | biological process | GO:0051216 | 173 | 4 | 18204 | 49 |
BMPR1B,GLI3,FGFR3,NFIA |
1.247e-03 | -6.69 | solute:sodium symporter activity | molecular function | GO:0015370 | 80 | 3 | 18094 | 48 |
SLC1A2,SLC1A3,SLC4A4 |
1.261e-03 | -6.68 | behavior | biological process | GO:0007610 | 619 | 7 | 18204 | 49 |
GLI3,PTPRZ1,MEIS2,APOE,SLC1A3,PREX2,SLC1A2 |
1.265e-03 | -6.67 | mouth | COSMIC cancer mutations | mouth | 9004 | 37 | 16828 | 49 |
GPC5,LSAMP,RYR3,CTNND2,SLC1A2,NTM,NPAS3,ATP13A4,QKI,SLC4A4,PTPRZ1,NDRG2,SPON1,SLC1A3,PITPNC1,MACF1,PARD3B,TRPS1,PREX2,GPM6A,SORBS1,NHSL1,PAMR1,CDH20,FGFR3,GLI3,CST3,PCDH9,AMZ2,COL5A3,ACSS1,FBXL7,APOE,MAML2,ABLIM1,CLU,DTNA |
1.307e-03 | -6.64 | positive regulation of chondrocyte differentiation | biological process | GO:0032332 | 20 | 2 | 18204 | 49 |
BMPR1B,GLI3 |
1.307e-03 | -6.64 | aspartate transmembrane transport | biological process | GO:0015810 | 20 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
1.318e-03 | -6.63 | TENM1 (teneurin transmembrane protein 1) | protein interactions | 10178 | 21 | 2 | 19454 | 50 |
SORBS1,MACF1 |
1.349e-03 | -6.61 | regulation of amide metabolic process | biological process | GO:0034248 | 81 | 3 | 18204 | 49 |
APOE,SPON1,CLU |
1.398e-03 | -6.57 | pancreas-carcinoid-endocrine_tumour | COSMIC cancer mutations | pancreas-carcinoid-endocrine_tumour | 7250 | 32 | 16828 | 49 |
GPM6A,PREX2,NHSL1,PAMR1,CDH20,PCDH9,NKAIN3,FGFR3,GLI3,COL5A3,ACSS1,FBXL7,APOE,CLU,ABLIM1,MAML2,PON2,GPC5,RYR3,CTNND2,SLC1A2,LSAMP,QKI,ATP13A4,CPE,SLC4A4,MEIS2,SPON1,SLC1A3,BMPR1B,GLIS3,MACF1 |
1.550e-03 | -6.47 | chondrocyte differentiation | biological process | GO:0002062 | 85 | 3 | 18204 | 49 |
BMPR1B,GLI3,FGFR3 |
1.550e-03 | -6.47 | oligodendrocyte differentiation | biological process | GO:0048709 | 85 | 3 | 18204 | 49 |
CLU,PTPRZ1,GLI3 |
1.570e-03 | -6.46 | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-mouth-carcinoma-squamous_cell_carcinoma | 6953 | 31 | 16828 | 49 |
GLI3,FGFR3,CST3,PCDH9,FBXL7,ACSS1,MAML2,DTNA,ABLIM1,PARD3B,TRPS1,PREX2,SORBS1,GPM6A,PAMR1,CDH20,NHSL1,PTPRZ1,NDRG2,SPON1,PITPNC1,MACF1,GPC5,LSAMP,CTNND2,SLC1A2,RYR3,NTM,SLC4A4,QKI,ATP13A4 |
1.582e-03 | -6.45 | TIMM10B (translocase of inner mitochondrial membrane 10B) | protein interactions | 26515 | 23 | 2 | 19454 | 50 |
MSI2,MEIS2 |
1.582e-03 | -6.45 | Rbm38 (RNA binding motif protein 38) | protein interactions | 56190 | 23 | 2 | 19454 | 50 |
QKI,MSI2 |
1.603e-03 | -6.44 | transport across blood-brain barrier | biological process | GO:0150104 | 86 | 3 | 18204 | 49 |
SLC1A3,SLC1A2,SLC4A4 |
1.603e-03 | -6.44 | vascular transport | biological process | GO:0010232 | 86 | 3 | 18204 | 49 |
SLC4A4,SLC1A2,SLC1A3 |
1.636e-03 | -6.42 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm | 7307 | 32 | 16828 | 49 |
PON2,MAML2,CLU,ABLIM1,FBXL7,ACSS1,COL5A3,GLI3,NKAIN3,PCDH9,CDH20,PAMR1,NHSL1,PREX2,GPM6A,PARD3B,MACF1,GLIS3,BMPR1B,PTPRZ1,SLC1A3,SPON1,MEIS2,ATP13A4,CPE,QKI,LSAMP,SLC1A2,CTNND2,RYR3,SPARCL1,GPC5 |
1.683e-03 | -6.39 | amino acid:sodium symporter activity | molecular function | GO:0005283 | 23 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
1.696e-03 | -6.38 | amyloid-beta binding | molecular function | GO:0001540 | 89 | 3 | 18094 | 48 |
CST3,CLU,APOE |
1.715e-03 | -6.37 | human chr17q24.2 | chromosome location | human chr17q24.2 | 32 | 2 | 26134 | 50 |
PITPNC1,AMZ2 |
1.748e-03 | -6.35 | parathyroid-carcinoma | COSMIC cancer mutations | parathyroid-carcinoma | 300 | 5 | 16828 | 49 |
MACF1,RYR3,GPC5,PAMR1,TRPS1 |
1.758e-03 | -6.34 | lung-right_lower_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_lower_lobe-carcinoma-adenocarcinoma | 5692 | 27 | 16828 | 49 |
MACF1,SPON1,SLC1A3,PTPRZ1,NTM,ATP13A4,SLC4A4,NPAS3,MEIS2,GPC5,RYR3,CTNND2,LSAMP,CLU,DTNA,MAML2,NKAIN3,CST3,GLI3,COL5A3,FBXL7,CDH20,PAMR1,TRPS1,PARD3B,GPM6A,SORBS1 |
1.758e-03 | -6.34 | right_lower_lobe | COSMIC cancer mutations | right_lower_lobe | 5692 | 27 | 16828 | 49 |
ATP13A4,SLC4A4,NPAS3,MEIS2,NTM,RYR3,CTNND2,LSAMP,GPC5,MACF1,SPON1,SLC1A3,PTPRZ1,CDH20,PAMR1,GPM6A,SORBS1,TRPS1,PARD3B,CLU,DTNA,MAML2,COL5A3,FBXL7,NKAIN3,GLI3,CST3 |
1.832e-03 | -6.30 | low-density lipoprotein particle receptor binding | molecular function | GO:0050750 | 24 | 2 | 18094 | 48 |
CLU,APOE |
1.912e-03 | -6.26 | SOX2 (SRY-box transcription factor 2) | protein interactions | 6657 | 1342 | 10 | 19454 | 50 |
NFIA,CLU,LSAMP,QKI,MEIS2,TRPS1,GLIS3,GLI3,MACF1,MSI2 |
1.913e-03 | -6.26 | human chr15q13.3-q14 | chromosome location | human chr15q13.3-q14 | 1 | 1 | 26134 | 50 |
RYR3 |
1.913e-03 | -6.26 | human chr4q21.23-q21.3 | chromosome location | human chr4q21.23-q21.3 | 1 | 1 | 26134 | 50 |
ARHGAP24 |
1.928e-03 | -6.25 | anchoring junction | cellular component | GO:0070161 | 902 | 8 | 19108 | 49 |
CDH20,PCDH9,CTNNA2,CTNND2,FGFR3,ARHGAP24,PARD3B,SORBS1 |
1.960e-03 | -6.23 | synapse organization | biological process | GO:0050808 | 333 | 5 | 18204 | 49 |
NFIA,CTNND2,GPM6A,APOE,SPARCL1 |
2.013e-03 | -6.21 | high-density lipoprotein particle | cellular component | GO:0034364 | 26 | 2 | 19108 | 49 |
APOE,CLU |
2.021e-03 | -6.20 | skin-face-malignant_melanoma-lentigo_maligna | COSMIC cancer mutations | skin-face-malignant_melanoma-lentigo_maligna | 23 | 2 | 16828 | 49 |
FGFR3,PREX2 |
2.023e-03 | -6.20 | CYP2C18 (cytochrome P450 family 2 subfamily C member 18) | protein interactions | 1562 | 26 | 2 | 19454 | 50 |
AMZ2,APOE |
2.047e-03 | -6.19 | positive regulation of amyloid precursor protein catabolic process | biological process | GO:1902993 | 25 | 2 | 18204 | 49 |
CLU,SPON1 |
2.047e-03 | -6.19 | L-glutamate transmembrane transport | biological process | GO:0015813 | 25 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
2.118e-03 | -6.16 | regulation of Wnt signaling pathway | biological process | GO:0030111 | 339 | 5 | 18204 | 49 |
GPC5,CTNND2,MACF1,APOE,GLI3 |
2.152e-03 | -6.14 | extrinsic component of plasma membrane | cellular component | GO:0019897 | 100 | 3 | 19108 | 49 |
DTNA,CTNNA2,CDH20 |
2.181e-03 | -6.13 | KCNJ12 (potassium inwardly rectifying channel subfamily J member 12) | protein interactions | 3768 | 27 | 2 | 19454 | 50 |
DTNA,ABLIM1 |
2.181e-03 | -6.13 | HPCAL4 (hippocalcin like 4) | protein interactions | 51440 | 27 | 2 | 19454 | 50 |
GPM6A,AQP4 |
2.181e-03 | -6.13 | MBNL2 (muscleblind like splicing regulator 2) | protein interactions | 10150 | 27 | 2 | 19454 | 50 |
MSI2,QKI |
2.181e-03 | -6.13 | Glutamate Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-210500 | 24 | 2 | 10285 | 30 |
SLC1A2,SLC1A3 |
2.214e-03 | -6.11 | C4-dicarboxylate transport | biological process | GO:0015740 | 26 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
2.247e-03 | -6.10 | PROKAR_LIPOPROTEIN | prosite domains | PS51257 | 76 | 3 | 12186 | 42 |
CPE,APOE,GLIS3 |
2.304e-03 | -6.07 | oesophagus-carcinoma | COSMIC cancer mutations | oesophagus-carcinoma | 4269 | 22 | 16828 | 49 |
SLC4A4,PTGDS,ATP13A4,NTM,CDH20,NHSL1,PREX2,SORBS1,CTNND2,GPM6A,RYR3,PARD3B,TRPS1,NFIA,MACF1,ACSS1,FBXL7,COL5A3,PTPRZ1,GLI3,FGFR3,PCDH9 |
2.398e-03 | -6.03 | bone morphogenesis | biological process | GO:0060349 | 99 | 3 | 18204 | 49 |
FGFR3,GLI3,BMPR1B |
2.412e-03 | -6.03 | haematopoietic_and_lymphoid_tissue-spleen-lymphoid_neoplasm-marginal_zone_lymphoma | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-spleen-lymphoid_neoplasm-marginal_zone_lymphoma | 323 | 5 | 16828 | 49 |
SORBS1,MEIS2,PARD3B,PTPRZ1,NTM |
2.447e-03 | -6.01 | bone | COSMIC cancer mutations | bone | 8157 | 34 | 16828 | 49 |
SLC4A4,QKI,CPE,ATP13A4,NPAS3,SPARCL1,GPC5,CTNND2,RYR3,LSAMP,MACF1,SLC1A3,SPON1,PTPRZ1,NDRG2,GLIS3,PAMR1,PTGDS,TRPS1,PARD3B,SORBS1,GPM6A,PREX2,DTNA,ABLIM1,PON2,MAML2,NKAIN3,PCDH9,FGFR3,CST3,GLI3,ACSS1,COL5A3 |
2.467e-03 | -6.00 | response to alkaloid | biological process | GO:0043279 | 100 | 3 | 18204 | 49 |
SLC1A2,RYR3,SLC1A3 |
2.476e-03 | -6.00 | parathyroid | COSMIC cancer mutations | parathyroid | 476 | 6 | 16828 | 49 |
GPC5,PAMR1,TRPS1,MACF1,RYR3,GPM6A |
2.564e-03 | -5.97 | perinuclear endoplasmic reticulum lumen | cellular component | GO:0099020 | 1 | 1 | 19108 | 49 |
CLU |
2.566e-03 | -5.97 | positive regulation of oligodendrocyte differentiation | biological process | GO:0048714 | 28 | 2 | 18204 | 49 |
PTPRZ1,QKI |
2.566e-03 | -5.97 | glial cell proliferation | biological process | GO:0014009 | 28 | 2 | 18204 | 49 |
NFIA,CLU |
2.570e-03 | -5.96 | ZNF75D (zinc finger protein 75D) | protein interactions | 7626 | 1 | 1 | 19454 | 50 |
ARHGAP24 |
2.570e-03 | -5.96 | ZNF880 (zinc finger protein 880) | protein interactions | 400713 | 1 | 1 | 19454 | 50 |
ARHGAP24 |
2.570e-03 | -5.96 | ZNF780B (zinc finger protein 780B) | protein interactions | 163131 | 1 | 1 | 19454 | 50 |
ARHGAP24 |
2.570e-03 | -5.96 | Isl1 (ISL1 transcription factor, LIM/homeodomain) | protein interactions | 16392 | 1 | 1 | 19454 | 50 |
GLIS3 |
2.570e-03 | -5.96 | Hipk3 (homeodomain interacting protein kinase 3) | protein interactions | 15259 | 1 | 1 | 19454 | 50 |
GLIS3 |
2.570e-03 | -5.96 | Sh2b1 (SH2B adaptor protein 1) | protein interactions | 20399 | 1 | 1 | 19454 | 50 |
FGFR3 |
2.570e-03 | -5.96 | 1700006A11Rik (RIKEN cDNA 1700006A11 gene) | protein interactions | 71824 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.570e-03 | -5.96 | Lztr1 (leucine-zipper-like transcriptional regulator, 1) | protein interactions | 66863 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.570e-03 | -5.96 | ZNF781 (zinc finger protein 781) | protein interactions | 163115 | 1 | 1 | 19454 | 50 |
ARHGAP24 |
2.570e-03 | -5.96 | Agtrap (angiotensin II, type I receptor-associated protein) | protein interactions | 11610 | 1 | 1 | 19454 | 50 |
PITPNC1 |
2.570e-03 | -5.96 | fgf3.L (fibroblast growth factor 3 L homeolog) | protein interactions | 373669 | 1 | 1 | 19454 | 50 |
FGFR3 |
2.570e-03 | -5.96 | Dcaf7 (DDB1 and CUL4 associated factor 7) | protein interactions | 71833 | 1 | 1 | 19454 | 50 |
BMPR1B |
2.570e-03 | -5.96 | ZNF729 (zinc finger protein 729) | protein interactions | 100287226 | 1 | 1 | 19454 | 50 |
ARHGAP24 |
2.653e-03 | -5.93 | internal N(7)-methylguanine-containing RNA reader activity | molecular function | GO:0160089 | 1 | 1 | 18094 | 48 |
QKI |
2.653e-03 | -5.93 | metal chelating activity | molecular function | GO:0046911 | 1 | 1 | 18094 | 48 |
APOE |
2.671e-03 | -5.93 | human chr20p11.21 | chromosome location | human chr20p11.21 | 40 | 2 | 26134 | 50 |
CST3,ACSS1 |
2.673e-03 | -5.92 | amino acid:monoatomic cation symporter activity | molecular function | GO:0005416 | 29 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
2.673e-03 | -5.92 | lipoprotein particle receptor binding | molecular function | GO:0070325 | 29 | 2 | 18094 | 48 |
CLU,APOE |
2.681e-03 | -5.92 | marginal_zone_lymphoma | COSMIC cancer mutations | marginal_zone_lymphoma | 331 | 5 | 16828 | 49 |
MEIS2,SORBS1,PARD3B,NTM,PTPRZ1 |
2.692e-03 | -5.92 | intermediate-density lipoprotein particle clearance | biological process | GO:0071831 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | lateral semicircular canal development | biological process | GO:0060875 | 1 | 1 | 18204 | 49 |
GLI3 |
2.692e-03 | -5.92 | sagittal suture morphogenesis | biological process | GO:0060367 | 1 | 1 | 18204 | 49 |
GLI3 |
2.692e-03 | -5.92 | lambdoid suture morphogenesis | biological process | GO:0060366 | 1 | 1 | 18204 | 49 |
GLI3 |
2.692e-03 | -5.92 | positive regulation of transport across blood-brain barrier | biological process | GO:0150201 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | regulation of lipid transport across blood-brain barrier | biological process | GO:1903000 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | regulation of heparan sulfate proteoglycan binding | biological process | GO:1905858 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | subpallium cell proliferation in forebrain | biological process | GO:0022012 | 1 | 1 | 18204 | 49 |
GLI3 |
2.692e-03 | -5.92 | lateral ganglionic eminence cell proliferation | biological process | GO:0022018 | 1 | 1 | 18204 | 49 |
GLI3 |
2.692e-03 | -5.92 | positive regulation of neurofibrillary tangle assembly | biological process | GO:1902998 | 1 | 1 | 18204 | 49 |
CLU |
2.692e-03 | -5.92 | negative regulation of collagen catabolic process | biological process | GO:0010711 | 1 | 1 | 18204 | 49 |
CST3 |
2.692e-03 | -5.92 | anterior semicircular canal development | biological process | GO:0060873 | 1 | 1 | 18204 | 49 |
GLI3 |
2.692e-03 | -5.92 | regulation of neuronal signal transduction | biological process | GO:1902847 | 1 | 1 | 18204 | 49 |
CLU |
2.692e-03 | -5.92 | negative regulation of elastin catabolic process | biological process | GO:0060311 | 1 | 1 | 18204 | 49 |
CST3 |
2.692e-03 | -5.92 | regulation of transport across blood-brain barrier | biological process | GO:0150200 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | positive regulation of lipid transport across blood-brain barrier | biological process | GO:1903002 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | regulation of cellular response to very-low-density lipoprotein particle stimulus | biological process | GO:1905890 | 1 | 1 | 18204 | 49 |
APOE |
2.692e-03 | -5.92 | positive regulation of heparan sulfate proteoglycan binding | biological process | GO:1905860 | 1 | 1 | 18204 | 49 |
APOE |
2.700e-03 | -5.91 | TRPS1 | interpro domains | IPR028440 | 1 | 1 | 18521 | 50 |
TRPS1 |
2.700e-03 | -5.91 | SORBS1_SH3 | interpro domains | IPR035606 | 1 | 1 | 18521 | 50 |
SORBS1 |
2.700e-03 | -5.91 | Clusterin_CS | interpro domains | IPR033986 | 1 | 1 | 18521 | 50 |
CLU |
2.700e-03 | -5.91 | STAR_dimer | interpro domains | IPR032377 | 1 | 1 | 18521 | 50 |
QKI |
2.700e-03 | -5.91 | Quaking_NLS | interpro domains | IPR032367 | 1 | 1 | 18521 | 50 |
QKI |
2.700e-03 | -5.91 | SPARC-like_p1 | interpro domains | IPR016359 | 1 | 1 | 18521 | 50 |
SPARCL1 |
2.700e-03 | -5.91 | SORBS1_SH3_2 | interpro domains | IPR035611 | 1 | 1 | 18521 | 50 |
SORBS1 |
2.700e-03 | -5.91 | Rex2_DEP_1 | interpro domains | IPR037367 | 1 | 1 | 18521 | 50 |
PREX2 |
2.700e-03 | -5.91 | Clusterin | interpro domains | IPR016016 | 1 | 1 | 18521 | 50 |
CLU |
2.700e-03 | -5.91 | SORBS1_SH3_1 | interpro domains | IPR035610 | 1 | 1 | 18521 | 50 |
SORBS1 |
2.700e-03 | -5.91 | M14_CPE_CPD | interpro domains | IPR034232 | 1 | 1 | 18521 | 50 |
CPE |
2.700e-03 | -5.91 | MAML2_TAD | interpro domains | IPR048452 | 1 | 1 | 18521 | 50 |
MAML2 |
2.709e-03 | -5.91 | large_intestine-caecum-carcinoma-adenocarcinoma | COSMIC cancer mutations | large_intestine-caecum-carcinoma-adenocarcinoma | 14236 | 48 | 16828 | 49 |
PCDH9,NKAIN3,AMZ2,GLI3,FGFR3,DTNA,PON2,APOE,PREX2,PARD3B,CDH20,ARHGAP24,GLIS3,SPON1,SLC1A3,NDRG2,PTPRZ1,MACF1,PITPNC1,CTNND2,GPC5,QKI,ATP13A4,SLC4A4,MEIS2,NPAS3,NTM,COL5A3,FBXL7,ACSS1,CST3,ABLIM1,CLU,MAML2,GPM6A,SORBS1,NFIA,TRPS1,PTGDS,NHSL1,PAMR1,BMPR1B,RYR3,SLC1A2,LSAMP,SPARCL1,AQP4,CPE |
2.809e-03 | -5.87 | caecum | COSMIC cancer mutations | caecum | 14248 | 48 | 16828 | 49 |
GLIS3,SLC1A3,SPON1,PTPRZ1,NDRG2,MACF1,PITPNC1,CTNND2,GPC5,SLC4A4,QKI,ATP13A4,NPAS3,MEIS2,NTM,AMZ2,NKAIN3,PCDH9,GLI3,FGFR3,DTNA,PON2,APOE,PREX2,PARD3B,CDH20,ARHGAP24,BMPR1B,SLC1A2,RYR3,LSAMP,SPARCL1,AQP4,CPE,ACSS1,FBXL7,COL5A3,CST3,CLU,ABLIM1,MAML2,SORBS1,GPM6A,TRPS1,NFIA,PTGDS,PAMR1,NHSL1 |
2.810e-03 | -5.87 | Peptidase_M54 | pfam domains | PF07998 | 1 | 1 | 17795 | 50 |
AMZ2 |
2.810e-03 | -5.87 | FGFR3_TM | pfam domains | PF21165 | 1 | 1 | 17795 | 50 |
FGFR3 |
2.810e-03 | -5.87 | STAR_dimer | pfam domains | PF16544 | 1 | 1 | 17795 | 50 |
QKI |
2.810e-03 | -5.87 | Quaking_NLS | pfam domains | PF16551 | 1 | 1 | 17795 | 50 |
QKI |
2.810e-03 | -5.87 | MAML2_TAD | pfam domains | PF20804 | 1 | 1 | 17795 | 50 |
MAML2 |
2.857e-03 | -5.86 | cell body | cellular component | GO:0044297 | 556 | 6 | 19108 | 49 |
BMPR1B,CTNND2,SLC1A2,SLC1A3,GPM6A,APOE |
2.857e-03 | -5.86 | catenin complex | cellular component | GO:0016342 | 31 | 2 | 19108 | 49 |
CTNNA2,CDH20 |
2.862e-03 | -5.86 | ACTB (actin beta) | protein interactions | 60 | 958 | 8 | 19454 | 50 |
ABLIM1,ARHGAP24,MACF1,APOE,DTNA,NHSL1,MEIS2,SORBS1 |
2.917e-03 | -5.84 | t(4;14) translocations of FGFR3 | REACTOME pathways | R-HSA-2033515 | 1 | 1 | 10285 | 30 |
FGFR3 |
2.942e-03 | -5.83 | L-glutamate import | biological process | GO:0051938 | 30 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
2.942e-03 | -5.83 | neurotransmitter uptake | biological process | GO:0001504 | 30 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
3.041e-03 | -5.80 | - | gene3d domains | 6.10.250.1740 | 1 | 1 | 14470 | 44 |
FGFR3 |
3.041e-03 | -5.80 | - | gene3d domains | 1.20.5.4010 | 1 | 1 | 14470 | 44 |
QKI |
3.055e-03 | -5.79 | CDH1 (cadherin 1) | protein interactions | 999 | 757 | 7 | 19454 | 50 |
NDRG2,CTNND2,CTNNA2,ABLIM1,MACF1,NHSL1,SORBS1 |
3.072e-03 | -5.79 | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-pharynx-carcinoma-squamous_cell_carcinoma | 1485 | 11 | 16828 | 49 |
SORBS1,RYR3,PREX2,PCDH9,GPC5,PTPRZ1,FGFR3,PARD3B,DTNA,MACF1,NPAS3 |
3.219e-03 | -5.74 | skin-leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-leg-malignant_melanoma-superficial_spreading | 210 | 4 | 16828 | 49 |
SLC4A4,ATP13A4,COL5A3,NTM |
3.224e-03 | -5.74 | human chr11p13 | chromosome location | human chr11p13 | 44 | 2 | 26134 | 50 |
SLC1A2,PAMR1 |
3.249e-03 | -5.73 | VLDLR (very low density lipoprotein receptor) | protein interactions | 7436 | 33 | 2 | 19454 | 50 |
CLU,APOE |
3.249e-03 | -5.73 | KATNAL1 (katanin catalytic subunit A1 like 1) | protein interactions | 84056 | 33 | 2 | 19454 | 50 |
PITPNC1,ARHGAP24 |
3.253e-03 | -5.73 | intestinal_adenocarcinoma | COSMIC cancer mutations | intestinal_adenocarcinoma | 7225 | 31 | 16828 | 49 |
PITPNC1,MACF1,SPON1,PTPRZ1,NTM,AQP4,ATP13A4,QKI,SLC4A4,MEIS2,NPAS3,RYR3,CTNND2,SLC1A2,LSAMP,CLU,MAML2,PCDH9,FGFR3,CST3,GLI3,COL5A3,FBXL7,ACSS1,NHSL1,CDH20,ARHGAP24,NFIA,TRPS1,PARD3B,PREX2 |
3.253e-03 | -5.73 | stomach-carcinoma-intestinal_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-intestinal_adenocarcinoma | 7225 | 31 | 16828 | 49 |
COL5A3,FBXL7,ACSS1,PCDH9,GLI3,CST3,FGFR3,CLU,MAML2,PREX2,NFIA,TRPS1,PARD3B,NHSL1,CDH20,ARHGAP24,SPON1,PTPRZ1,MACF1,PITPNC1,RYR3,CTNND2,SLC1A2,LSAMP,AQP4,QKI,ATP13A4,SLC4A4,NPAS3,MEIS2,NTM |
3.261e-03 | -5.73 | plasma membrane bounded cell projection organization | biological process | GO:0120036 | 1152 | 9 | 18204 | 49 |
PREX2,BMPR1B,PTPRZ1,GLI3,CTNNA2,ABLIM1,CTNND2,GPM6A,APOE |
3.344e-03 | -5.70 | positive regulation of cartilage development | biological process | GO:0061036 | 32 | 2 | 18204 | 49 |
GLI3,BMPR1B |
3.344e-03 | -5.70 | transepithelial transport | biological process | GO:0070633 | 32 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
3.353e-03 | -5.70 | HNRNPL (heterogeneous nuclear ribonucleoprotein L) | protein interactions | 3191 | 1958 | 12 | 19454 | 50 |
NFIA,FGFR3,QKI,TRPS1,ABLIM1,BMPR1B,PON2,DTNA,ARHGAP24,MACF1,MSI2,PARD3B |
3.430e-03 | -5.68 | skin-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-malignant_melanoma-acral_lentiginous | 30 | 2 | 16828 | 49 |
PREX2,FGFR3 |
3.430e-03 | -5.68 | lentigo_maligna | COSMIC cancer mutations | lentigo_maligna | 30 | 2 | 16828 | 49 |
PREX2,FGFR3 |
3.447e-03 | -5.67 | CLUSTERIN_2 | prosite domains | PS00493 | 1 | 1 | 12186 | 42 |
CLU |
3.447e-03 | -5.67 | CLUSTERIN_1 | prosite domains | PS00492 | 1 | 1 | 12186 | 42 |
CLU |
3.465e-03 | -5.67 | CEACAM8 (CEA cell adhesion molecule 8) | protein interactions | 1088 | 118 | 3 | 19454 | 50 |
CPE,APOE,CLU |
3.476e-03 | -5.66 | connective tissue development | biological process | GO:0061448 | 232 | 4 | 18204 | 49 |
GLI3,FGFR3,NFIA,BMPR1B |
3.482e-03 | -5.66 | cell adhesion molecule binding | molecular function | GO:0050839 | 560 | 6 | 18094 | 48 |
CDH20,CPE,CTNNA2,PTPRZ1,CTNND2,MACF1 |
3.486e-03 | -5.66 | dendrite development | biological process | GO:0016358 | 113 | 3 | 18204 | 49 |
CTNNA2,CTNND2,PREX2 |
3.504e-03 | -5.65 | eye development | biological process | GO:0001654 | 381 | 5 | 18204 | 49 |
GPM6A,BMPR1B,MEIS2,NFIA,GLI3 |
3.548e-03 | -5.64 | HLA-DPA1 (major histocompatibility complex, class II, DP alpha 1) | protein interactions | 3113 | 119 | 3 | 19454 | 50 |
CLU,PCDH9,APOE |
3.602e-03 | -5.63 | DELLA | smart domains | SM01129 | 1 | 1 | 9717 | 35 |
MACF1 |
3.615e-03 | -5.62 | trunk | COSMIC cancer mutations | trunk | 3554 | 19 | 16828 | 49 |
ABLIM1,MAML2,MACF1,SLC1A3,PCDH9,PTPRZ1,FGFR3,GLIS3,CDH20,ATP13A4,CPE,MEIS2,NPAS3,SPARCL1,TRPS1,CTNND2,RYR3,PREX2,LSAMP |
3.624e-03 | -5.62 | Transport of inorganic cations/anions and amino acids/oligopeptides | REACTOME pathways | R-HSA-425393 | 107 | 3 | 10285 | 30 |
SLC4A4,SLC1A3,SLC1A2 |
3.663e-03 | -5.61 | fatty acid biosynthetic process | biological process | GO:0006633 | 115 | 3 | 18204 | 49 |
PTGDS,ACSS1,QKI |
3.663e-03 | -5.61 | visual system development | biological process | GO:0150063 | 385 | 5 | 18204 | 49 |
NFIA,GLI3,MEIS2,BMPR1B,GPM6A |
3.680e-03 | -5.60 | synapse | cellular component | GO:0045202 | 1473 | 10 | 19108 | 49 |
GPM6A,APOE,SPARCL1,SLC1A3,PTPRZ1,CLU,DTNA,CTNND2,QKI,SLC1A2 |
3.688e-03 | -5.60 | solute:monoatomic cation symporter activity | molecular function | GO:0015294 | 117 | 3 | 18094 | 48 |
SLC4A4,SLC1A2,SLC1A3 |
3.826e-03 | -5.57 | AQUAPORIN4 | prints domains | PR02016 | 1 | 1 | 5227 | 20 |
AQP4 |
3.839e-03 | -5.56 | lipoprotein particle | cellular component | GO:1990777 | 36 | 2 | 19108 | 49 |
CLU,APOE |
3.839e-03 | -5.56 | plasma lipoprotein particle | cellular component | GO:0034358 | 36 | 2 | 19108 | 49 |
APOE,CLU |
3.878e-03 | -5.55 | organic acid:sodium symporter activity | molecular function | GO:0005343 | 35 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
3.912e-03 | -5.54 | sensory system development | biological process | GO:0048880 | 391 | 5 | 18204 | 49 |
MEIS2,BMPR1B,GPM6A,NFIA,GLI3 |
3.978e-03 | -5.53 | eye-uveal_tract-malignant_melanoma-spindle | COSMIC cancer mutations | eye-uveal_tract-malignant_melanoma-spindle | 363 | 5 | 16828 | 49 |
CPE,CTNND2,PREX2,MACF1,PCDH9 |
3.990e-03 | -5.52 | neuron fate specification | biological process | GO:0048665 | 35 | 2 | 18204 | 49 |
GLI3,NFIA |
4.052e-03 | -5.51 | glial cell projection | cellular component | GO:0097386 | 37 | 2 | 19108 | 49 |
SLC1A2,AQP4 |
4.071e-03 | -5.50 | HPCA (hippocalcin) | protein interactions | 3208 | 37 | 2 | 19454 | 50 |
CST3,GPM6A |
4.094e-03 | -5.50 | transporter activity | molecular function | GO:0005215 | 1211 | 9 | 18094 | 48 |
GPM6A,SLC1A2,SLC4A4,ATP13A4,AQP4,PITPNC1,APOE,SLC1A3,RYR3 |
4.099e-03 | -5.50 | proteoglycan binding | molecular function | GO:0043394 | 36 | 2 | 18094 | 48 |
COL5A3,APOE |
4.258e-03 | -5.46 | EPB41L4A (erythrocyte membrane protein band 4.1 like 4A) | protein interactions | 64097 | 127 | 3 | 19454 | 50 |
ABLIM1,MACF1,DTNA |
4.275e-03 | -5.45 | cell projection organization | biological process | GO:0030030 | 1200 | 9 | 18204 | 49 |
BMPR1B,PREX2,ABLIM1,CTNNA2,CTNND2,GPM6A,APOE,PTPRZ1,GLI3 |
4.281e-03 | -5.45 | positive regulation of neurogenesis | biological process | GO:0050769 | 246 | 4 | 18204 | 49 |
QKI,PTPRZ1,GLI3,MACF1 |
4.290e-03 | -5.45 | MMP3 (matrix metallopeptidase 3) | protein interactions | 4314 | 38 | 2 | 19454 | 50 |
APOE,CLU |
4.290e-03 | -5.45 | Pcbp1 (poly(rC) binding protein 1) | protein interactions | 23983 | 38 | 2 | 19454 | 50 |
QKI,MSI2 |
4.391e-03 | -5.43 | central_nervous_system-parietal_lobe-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-parietal_lobe-glioma-astrocytoma_Grade_I | 34 | 2 | 16828 | 49 |
QKI,FGFR3 |
4.448e-03 | -5.42 | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_III | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-oligoastrocytoma_Grade_III | 114 | 3 | 16828 | 49 |
PREX2,SLC1A2,RYR3 |
4.451e-03 | -5.41 | positive regulation of glucose import | biological process | GO:0046326 | 37 | 2 | 18204 | 49 |
SLC1A2,SORBS1 |
4.491e-03 | -5.41 | intracellular chemical homeostasis | biological process | GO:0055082 | 581 | 6 | 18204 | 49 |
SLC4A4,AQP4,ATP13A4,APOE,RYR3,SLC1A3 |
4.493e-03 | -5.41 | protein-lipid complex | cellular component | GO:0032994 | 39 | 2 | 19108 | 49 |
CLU,APOE |
4.496e-03 | -5.40 | skin-face-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-face-carcinoma-squamous_cell_carcinoma | 2036 | 13 | 16828 | 49 |
PTPRZ1,FGFR3,PCDH9,MACF1,ABLIM1,TRPS1,GPC5,LSAMP,PREX2,GPM6A,ARHGAP24,MSI2,AQP4 |
4.691e-03 | -5.36 | amino acid import across plasma membrane | biological process | GO:0089718 | 38 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
4.783e-03 | -5.34 | lung-carcinoma-small_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-small_cell_carcinoma | 9908 | 38 | 16828 | 49 |
ARHGAP24,PAMR1,CDH20,MSI2,PARD3B,NFIA,TRPS1,PREX2,GPM6A,SORBS1,MAML2,ABLIM1,CLU,DTNA,GLI3,FGFR3,CST3,PCDH9,NKAIN3,COL5A3,FBXL7,NTM,NPAS3,MEIS2,CPE,ATP13A4,QKI,SLC4A4,GPC5,SPARCL1,RYR3,CTNND2,PITPNC1,MACF1,PTPRZ1,NDRG2,SPON1,BMPR1B |
4.840e-03 | -5.33 | small_cell_carcinoma | COSMIC cancer mutations | small_cell_carcinoma | 9913 | 38 | 16828 | 49 |
CDH20,PAMR1,MSI2,ARHGAP24,TRPS1,NFIA,PARD3B,SORBS1,GPM6A,PREX2,DTNA,CLU,ABLIM1,MAML2,NKAIN3,PCDH9,FGFR3,GLI3,CST3,FBXL7,COL5A3,NTM,SLC4A4,QKI,CPE,ATP13A4,MEIS2,NPAS3,SPARCL1,GPC5,CTNND2,RYR3,PITPNC1,MACF1,SPON1,NDRG2,PTPRZ1,BMPR1B |
4.912e-03 | -5.32 | central_nervous_system-thalamus-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-thalamus-glioma-astrocytoma_Grade_I | 36 | 2 | 16828 | 49 |
FGFR3,QKI |
4.918e-03 | -5.31 | cell differentiation | biological process | GO:0030154 | 3645 | 18 | 18204 | 49 |
GLI3,GPM6A,NHSL1,CTNNA2,PREX2,NFIA,QKI,FGFR3,NDRG2,BMPR1B,NTM,PTPRZ1,APOE,CTNND2,SLC1A3,ARHGAP24,MSI2,CLU |
4.936e-03 | -5.31 | positive regulation of nitric oxide biosynthetic process | biological process | GO:0045429 | 39 | 2 | 18204 | 49 |
CLU,APOE |
4.945e-03 | -5.31 | NUFIP1 (nuclear FMR1 interacting protein 1) | protein interactions | 26747 | 134 | 3 | 19454 | 50 |
NTM,GPM6A,CPE |
4.963e-03 | -5.31 | cellular developmental process | biological process | GO:0048869 | 3648 | 18 | 18204 | 49 |
MSI2,ARHGAP24,CLU,PTPRZ1,APOE,CTNND2,SLC1A3,PREX2,QKI,NFIA,FGFR3,NDRG2,BMPR1B,NTM,GLI3,GPM6A,NHSL1,CTNNA2 |
5.090e-03 | -5.28 | cation binding | molecular function | GO:0043169 | 4341 | 20 | 18094 | 48 |
SLC1A3,APOE,ATP13A4,SPARCL1,TRPS1,DTNA,PON2,RYR3,PAMR1,BMPR1B,GLI3,MACF1,CPE,ACSS1,PCDH9,SPON1,ABLIM1,SLC1A2,AMZ2,GLIS3 |
5.122e-03 | -5.27 | discoidal high-density lipoprotein particle | cellular component | GO:0034365 | 2 | 1 | 19108 | 49 |
APOE |
5.122e-03 | -5.27 | chylomicron remnant | cellular component | GO:0034360 | 2 | 1 | 19108 | 49 |
APOE |
5.123e-03 | -5.27 | cell development | biological process | GO:0048468 | 2236 | 13 | 18204 | 49 |
MSI2,CLU,PTPRZ1,APOE,CTNND2,SLC1A3,PREX2,QKI,BMPR1B,NTM,GLI3,GPM6A,CTNNA2 |
5.127e-03 | -5.27 | EF-hand-dom_pair | interpro domains | IPR011992 | 258 | 4 | 18521 | 50 |
RYR3,MACF1,SPARCL1,DTNA |
5.134e-03 | -5.27 | Irf7 (interferon regulatory factor 7) | protein interactions | 54123 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Klhl1 (kelch-like 1) | protein interactions | 93688 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Ppp3cc (protein phosphatase 3, catalytic subunit, gamma isoform) | protein interactions | 19057 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Fkbp1b (FK506 binding protein 1b) | protein interactions | 14226 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | ZNF680 (zinc finger protein 680) | protein interactions | 340252 | 2 | 1 | 19454 | 50 |
ARHGAP24 |
5.134e-03 | -5.27 | Bmpr2 (bone morphogenetic protein receptor type 2) | protein interactions | 12168 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Fkbp1a (FK506 binding protein 1a) | protein interactions | 14225 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Kdm4c (lysine (K)-specific demethylase 4C) | protein interactions | 76804 | 2 | 1 | 19454 | 50 |
GLIS3 |
5.134e-03 | -5.27 | Bcr (BCR activator of RhoGEF and GTPase) | protein interactions | 110279 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Mknk2 (MAP kinase-interacting serine/threonine kinase 2) | protein interactions | 17347 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Sh3kbp1 (SH3-domain kinase binding protein 1) | protein interactions | 58194 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | Fbxo34 (F-box protein 34) | protein interactions | 78938 | 2 | 1 | 19454 | 50 |
BMPR1B |
5.134e-03 | -5.27 | ZNF658B (zinc finger protein 658B (pseudogene)) | protein interactions | 401509 | 2 | 1 | 19454 | 50 |
ARHGAP24 |
5.134e-03 | -5.27 | Zmym2 (zinc finger, MYM-type 2) | protein interactions | 76007 | 2 | 1 | 19454 | 50 |
GLIS3 |
5.184e-03 | -5.26 | central_nervous_system-third_ventricle-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-third_ventricle-glioma-astrocytoma_Grade_I | 37 | 2 | 16828 | 49 |
QKI,FGFR3 |
5.187e-03 | -5.26 | positive regulation of nitric oxide metabolic process | biological process | GO:1904407 | 40 | 2 | 18204 | 49 |
APOE,CLU |
5.198e-03 | -5.26 | RDX (radixin) | protein interactions | 5962 | 272 | 4 | 19454 | 50 |
FGFR3,MACF1,ABLIM1,ARHGAP24 |
5.251e-03 | -5.25 | oligoastrocytoma_Grade_II | COSMIC cancer mutations | oligoastrocytoma_Grade_II | 121 | 3 | 16828 | 49 |
FGFR3,CDH20,DTNA |
5.376e-03 | -5.23 | larynx development | biological process | GO:0120224 | 2 | 1 | 18204 | 49 |
GLI3 |
5.376e-03 | -5.23 | regulation of neurofibrillary tangle assembly | biological process | GO:1902996 | 2 | 1 | 18204 | 49 |
CLU |
5.376e-03 | -5.23 | larynx morphogenesis | biological process | GO:0120223 | 2 | 1 | 18204 | 49 |
GLI3 |
5.376e-03 | -5.23 | propionate biosynthetic process | biological process | GO:0019542 | 2 | 1 | 18204 | 49 |
ACSS1 |
5.376e-03 | -5.23 | fibroblast growth factor receptor apoptotic signaling pathway | biological process | GO:1902178 | 2 | 1 | 18204 | 49 |
FGFR3 |
5.376e-03 | -5.23 | acetyl-CoA biosynthetic process from acetate | biological process | GO:0019427 | 2 | 1 | 18204 | 49 |
ACSS1 |
5.376e-03 | -5.23 | regulation of elastin catabolic process | biological process | GO:0060310 | 2 | 1 | 18204 | 49 |
CST3 |
5.376e-03 | -5.23 | lipid transport involved in lipid storage | biological process | GO:0010877 | 2 | 1 | 18204 | 49 |
APOE |
5.376e-03 | -5.23 | negative regulation of blood vessel remodeling | biological process | GO:0060313 | 2 | 1 | 18204 | 49 |
CST3 |
5.376e-03 | -5.23 | negative regulation of 3'-UTR-mediated mRNA stabilization | biological process | GO:1905869 | 2 | 1 | 18204 | 49 |
QKI |
5.376e-03 | -5.23 | mammary gland specification | biological process | GO:0060594 | 2 | 1 | 18204 | 49 |
GLI3 |
5.376e-03 | -5.23 | myofibroblast contraction | biological process | GO:1990764 | 2 | 1 | 18204 | 49 |
QKI |
5.376e-03 | -5.23 | smoothened signaling pathway involved in spinal cord motor neuron cell fate specification | biological process | GO:0021776 | 2 | 1 | 18204 | 49 |
GLI3 |
5.376e-03 | -5.23 | acetate biosynthetic process | biological process | GO:0019413 | 2 | 1 | 18204 | 49 |
ACSS1 |
5.392e-03 | -5.22 | Pept_M54_archaemetzincn | interpro domains | IPR012962 | 2 | 1 | 18521 | 50 |
AMZ2 |
5.392e-03 | -5.22 | MSI_RRM2 | interpro domains | IPR034126 | 2 | 1 | 18521 | 50 |
MSI2 |
5.392e-03 | -5.22 | Osteonectin_CS | interpro domains | IPR001999 | 2 | 1 | 18521 | 50 |
SPARCL1 |
5.392e-03 | -5.22 | Distrobrevin | interpro domains | IPR017432 | 2 | 1 | 18521 | 50 |
DTNA |
5.392e-03 | -5.22 | Clusterin_N | interpro domains | IPR016014 | 2 | 1 | 18521 | 50 |
CLU |
5.392e-03 | -5.22 | Spondin_N_sf | interpro domains | IPR038678 | 2 | 1 | 18521 | 50 |
SPON1 |
5.392e-03 | -5.22 | Clusterin_C | interpro domains | IPR016015 | 2 | 1 | 18521 | 50 |
CLU |
5.392e-03 | -5.22 | Alpha_CARP_receptor-type | interpro domains | IPR041887 | 2 | 1 | 18521 | 50 |
PTPRZ1 |
5.392e-03 | -5.22 | Paraoxonase2 | interpro domains | IPR008364 | 2 | 1 | 18521 | 50 |
PON2 |
5.392e-03 | -5.22 | Ac_CoA_lig | interpro domains | IPR011904 | 2 | 1 | 18521 | 50 |
ACSS1 |
5.392e-03 | -5.22 | Clusterin-like | interpro domains | IPR000753 | 2 | 1 | 18521 | 50 |
CLU |
5.392e-03 | -5.22 | Par3/HAL_N | interpro domains | IPR021922 | 2 | 1 | 18521 | 50 |
PARD3B |
5.392e-03 | -5.22 | Spondin_N | interpro domains | IPR009465 | 2 | 1 | 18521 | 50 |
SPON1 |
5.432e-03 | -5.22 | Ig_I-set | interpro domains | IPR013098 | 132 | 3 | 18521 | 50 |
FGFR3,NTM,LSAMP |
5.461e-03 | -5.21 | central_nervous_system-brainstem-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-brainstem-glioma-astrocytoma_Grade_I | 38 | 2 | 16828 | 49 |
QKI,FGFR3 |
5.545e-03 | -5.19 | neutral L-amino acid transmembrane transporter activity | molecular function | GO:0015175 | 42 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
5.565e-03 | -5.19 | regulation of canonical Wnt signaling pathway | biological process | GO:0060828 | 265 | 4 | 18204 | 49 |
CTNND2,APOE,GPC5,GLI3 |
5.612e-03 | -5.18 | Spond_N | pfam domains | PF06468 | 2 | 1 | 17795 | 50 |
SPON1 |
5.612e-03 | -5.18 | Clusterin | pfam domains | PF01093 | 2 | 1 | 17795 | 50 |
CLU |
5.612e-03 | -5.18 | Reeler | pfam domains | PF02014 | 2 | 1 | 17795 | 50 |
SPON1 |
5.612e-03 | -5.18 | Par3_HAL_N_term | pfam domains | PF12053 | 2 | 1 | 17795 | 50 |
PARD3B |
5.696e-03 | -5.17 | UPK2 (uroplakin 2) | protein interactions | 7379 | 141 | 3 | 19454 | 50 |
CTNNA2,PON2,PCDH9 |
5.721e-03 | -5.16 | intracellular monoatomic cation homeostasis | biological process | GO:0030003 | 428 | 5 | 18204 | 49 |
SLC1A3,APOE,RYR3,SLC4A4,ATP13A4 |
5.767e-03 | -5.16 | sarcolemma | cellular component | GO:0042383 | 142 | 3 | 19108 | 49 |
AQP4,RYR3,DTNA |
5.802e-03 | -5.15 | mast_cell_neoplasm | COSMIC cancer mutations | mast_cell_neoplasm | 248 | 4 | 16828 | 49 |
NPAS3,PCDH9,NFIA,GPC5 |
5.802e-03 | -5.15 | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-haematopoietic_neoplasm-mast_cell_neoplasm | 248 | 4 | 16828 | 49 |
NFIA,GPC5,PCDH9,NPAS3 |
5.806e-03 | -5.15 | tau protein binding | molecular function | GO:0048156 | 43 | 2 | 18094 | 48 |
CLU,APOE |
5.885e-03 | -5.14 | central_nervous_system-brain-glioma-oligodendroglioma_Grade_III | COSMIC cancer mutations | central_nervous_system-brain-glioma-oligodendroglioma_Grade_III | 249 | 4 | 16828 | 49 |
MACF1,GLIS3,FGFR3,PTPRZ1 |
5.890e-03 | -5.13 | response to wounding | biological process | GO:0009611 | 431 | 5 | 18204 | 49 |
NFIA,ARHGAP24,SLC1A3,MACF1,SLC1A2 |
5.935e-03 | -5.13 | active monoatomic ion transmembrane transporter activity | molecular function | GO:0022853 | 274 | 4 | 18094 | 48 |
SLC4A4,ATP13A4,SLC1A2,SLC1A3 |
6.018e-03 | -5.11 | carboxylic acid biosynthetic process | biological process | GO:0046394 | 271 | 4 | 18204 | 49 |
PTGDS,SLC1A3,ACSS1,QKI |
6.064e-03 | -5.11 | I-set | pfam domains | PF07679 | 132 | 3 | 17795 | 50 |
FGFR3,LSAMP,NTM |
6.073e-03 | -5.10 | F-spondin domain | gene3d domains | 2.60.40.2130 | 2 | 1 | 14470 | 44 |
SPON1 |
6.073e-03 | -5.10 | Vinculin, Vh2 four-helix bundle | gene3d domains | 1.20.120.810 | 2 | 1 | 14470 | 44 |
CTNNA2 |
6.073e-03 | -5.10 | - | gene3d domains | 6.20.350.10 | 2 | 1 | 14470 | 44 |
RYR3 |
6.098e-03 | -5.10 | scalp | COSMIC cancer mutations | scalp | 2110 | 13 | 16828 | 49 |
PTPRZ1,FGFR3,COL5A3,MACF1,TRPS1,NFIA,GPC5,SORBS1,LSAMP,PREX2,NTM,SLC4A4,ATP13A4 |
6.107e-03 | -5.10 | axon | cellular component | GO:0030424 | 650 | 6 | 19108 | 49 |
GPM6A,PCDH9,DTNA,NDRG2,SLC1A2,CTNNA2 |
6.141e-03 | -5.09 | metal ion transmembrane transporter activity | molecular function | GO:0046873 | 442 | 5 | 18094 | 48 |
SLC4A4,GPM6A,SLC1A2,SLC1A3,RYR3 |
6.159e-03 | -5.09 | monoatomic cation transmembrane transporter activity | molecular function | GO:0008324 | 630 | 6 | 18094 | 48 |
RYR3,SLC1A3,SLC1A2,ATP13A4,GPM6A,SLC4A4 |
6.174e-03 | -5.09 | vascular process in circulatory system | biological process | GO:0003018 | 273 | 4 | 18204 | 49 |
SLC1A3,APOE,SLC1A2,SLC4A4 |
6.238e-03 | -5.08 | intracellular monoatomic ion homeostasis | biological process | GO:0006873 | 437 | 5 | 18204 | 49 |
APOE,RYR3,SLC1A3,SLC4A4,ATP13A4 |
6.247e-03 | -5.08 | positive regulation of glucose transmembrane transport | biological process | GO:0010828 | 44 | 2 | 18204 | 49 |
SORBS1,SLC1A2 |
6.254e-03 | -5.07 | organic acid biosynthetic process | biological process | GO:0016053 | 274 | 4 | 18204 | 49 |
ACSS1,QKI,PTGDS,SLC1A3 |
6.272e-03 | -5.07 | DSCR9 (Down syndrome critical region 9) | protein interactions | 257203 | 146 | 3 | 19454 | 50 |
SPARCL1,CLU,MACF1 |
6.493e-03 | -5.04 | spleen | COSMIC cancer mutations | spleen | 408 | 5 | 16828 | 49 |
PARD3B,NTM,PTPRZ1,MEIS2,SORBS1 |
6.500e-03 | -5.04 | CNTN1 (contactin 1) | protein interactions | 1272 | 47 | 2 | 19454 | 50 |
PTPRZ1,GPM6A |
6.527e-03 | -5.03 | acidic amino acid transport | biological process | GO:0015800 | 45 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
6.588e-03 | -5.02 | monoatomic anion transmembrane transport | biological process | GO:0098656 | 142 | 3 | 18204 | 49 |
SLC1A2,SLC1A3,SLC4A4 |
6.588e-03 | -5.02 | positive regulation of small molecule metabolic process | biological process | GO:0062013 | 142 | 3 | 18204 | 49 |
APOE,SORBS1,SLC4A4 |
6.760e-03 | -5.00 | pseudomyxoma_peritonei | COSMIC cancer mutations | pseudomyxoma_peritonei | 585 | 6 | 16828 | 49 |
FGFR3,TRPS1,MEIS2,COL5A3,MACF1,FBXL7 |
6.760e-03 | -5.00 | peritoneum-appendix-other-pseudomyxoma_peritonei | COSMIC cancer mutations | peritoneum-appendix-other-pseudomyxoma_peritonei | 585 | 6 | 16828 | 49 |
MEIS2,MACF1,TRPS1,FGFR3,FBXL7,COL5A3 |
6.812e-03 | -4.99 | positive regulation of glial cell differentiation | biological process | GO:0045687 | 46 | 2 | 18204 | 49 |
QKI,PTPRZ1 |
6.812e-03 | -4.99 | regulation of oligodendrocyte differentiation | biological process | GO:0048713 | 46 | 2 | 18204 | 49 |
PTPRZ1,QKI |
6.815e-03 | -4.99 | appendix | COSMIC cancer mutations | appendix | 586 | 6 | 16828 | 49 |
FBXL7,MACF1,MEIS2,COL5A3,FGFR3,TRPS1 |
6.841e-03 | -4.98 | face | COSMIC cancer mutations | face | 2139 | 13 | 16828 | 49 |
ABLIM1,AQP4,MACF1,MSI2,ARHGAP24,GPM6A,LSAMP,PREX2,TRPS1,PCDH9,GPC5,PTPRZ1,FGFR3 |
6.870e-03 | -4.98 | uveal_tract | COSMIC cancer mutations | uveal_tract | 587 | 6 | 16828 | 49 |
FGFR3,PCDH9,PREX2,MACF1,CTNND2,CPE |
6.870e-03 | -4.98 | peritoneum | COSMIC cancer mutations | peritoneum | 587 | 6 | 16828 | 49 |
TRPS1,FGFR3,FBXL7,COL5A3,MACF1,MEIS2 |
6.882e-03 | -4.98 | OSTEONECTIN_2 | prosite domains | PS00613 | 2 | 1 | 12186 | 42 |
SPARCL1 |
6.882e-03 | -4.98 | SPONDIN | prosite domains | PS51020 | 2 | 1 | 12186 | 42 |
SPON1 |
6.882e-03 | -4.98 | OSTEONECTIN_1 | prosite domains | PS00612 | 2 | 1 | 12186 | 42 |
SPARCL1 |
6.997e-03 | -4.96 | Wnt signaling pathway | biological process | GO:0016055 | 283 | 4 | 18204 | 49 |
CPE,NDRG2,MACF1,CTNND2 |
7.049e-03 | -4.95 | HBZ (hemoglobin subunit zeta) | protein interactions | 3050 | 49 | 2 | 19454 | 50 |
ARHGAP24,FGFR3 |
7.087e-03 | -4.95 | symporter activity | molecular function | GO:0015293 | 148 | 3 | 18094 | 48 |
SLC4A4,SLC1A3,SLC1A2 |
7.119e-03 | -4.94 | oligoastrocytoma_Grade_III | COSMIC cancer mutations | oligoastrocytoma_Grade_III | 263 | 4 | 16828 | 49 |
FGFR3,PREX2,RYR3,SLC1A2 |
7.191e-03 | -4.93 | CLa | smart domains | SM00035 | 2 | 1 | 9717 | 35 |
CLU |
7.191e-03 | -4.93 | CLb | smart domains | SM00030 | 2 | 1 | 9717 | 35 |
CLU |
7.211e-03 | -4.93 | Retinoid metabolism and transport | REACTOME pathways | R-HSA-975634 | 44 | 2 | 10285 | 30 |
APOE,GPC5 |
7.263e-03 | -4.92 | NMT1 (N-myristoyltransferase 1) | protein interactions | 4836 | 154 | 3 | 19454 | 50 |
ARHGAP24,ABLIM1,DTNA |
7.266e-03 | -4.92 | soft_tissue-striated_muscle-rhabdomyosarcoma | COSMIC cancer mutations | soft_tissue-striated_muscle-rhabdomyosarcoma | 594 | 6 | 16828 | 49 |
MACF1,TRPS1,SPON1,CTNND2,COL5A3,PREX2 |
7.272e-03 | -4.92 | Ig_3 | pfam domains | PF13927 | 141 | 3 | 17795 | 50 |
NTM,LSAMP,FGFR3 |
7.306e-03 | -4.92 | Statin Pathway | WikiPathways | WP430 | 33 | 2 | 5310 | 21 |
ACSS1,APOE |
7.404e-03 | -4.91 | large_intestine-adenoma | COSMIC cancer mutations | large_intestine-adenoma | 266 | 4 | 16828 | 49 |
RYR3,GLI3,APOE,CDH20 |
7.493e-03 | -4.89 | cell surface | cellular component | GO:0009986 | 896 | 7 | 19108 | 49 |
CLU,SLC1A3,SLC1A2,GPC5,AQP4,SLC4A4,FGFR3 |
7.592e-03 | -4.88 | third_ventricle | COSMIC cancer mutations | third_ventricle | 45 | 2 | 16828 | 49 |
FGFR3,QKI |
7.617e-03 | -4.88 | Ndc80 (NDC80 kinetochore complex component) | protein interactions | 67052 | 51 | 2 | 19454 | 50 |
MACF1,NHSL1 |
7.617e-03 | -4.88 | LINGO1 (leucine rich repeat and Ig domain containing 1) | protein interactions | 84894 | 51 | 2 | 19454 | 50 |
NTM,PON2 |
7.631e-03 | -4.88 | human chr8q23.3 | chromosome location | human chr8q23.3 | 4 | 1 | 26134 | 50 |
TRPS1 |
7.639e-03 | -4.87 | PARAOXONASE2 | prints domains | PR01787 | 2 | 1 | 5227 | 20 |
PON2 |
7.691e-03 | -4.87 | Atg16l1 (autophagy related 16 like 1) | protein interactions | 77040 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Smad6 (SMAD family member 6) | protein interactions | 17130 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | IL34 (interleukin 34) | protein interactions | 146433 | 3 | 1 | 19454 | 50 |
PTPRZ1 |
7.691e-03 | -4.87 | ZNF257 (zinc finger protein 257) | protein interactions | 113835 | 3 | 1 | 19454 | 50 |
ARHGAP24 |
7.691e-03 | -4.87 | QRFPR (pyroglutamylated RFamide peptide receptor) | protein interactions | 84109 | 3 | 1 | 19454 | 50 |
NTM |
7.691e-03 | -4.87 | ZNF506 (zinc finger protein 506) | protein interactions | 440515 | 3 | 1 | 19454 | 50 |
ARHGAP24 |
7.691e-03 | -4.87 | Hk2 (hexokinase 2) | protein interactions | 25059 | 3 | 1 | 19454 | 50 |
PTGDS |
7.691e-03 | -4.87 | Lep (leptin) | protein interactions | 16846 | 3 | 1 | 19454 | 50 |
CLU |
7.691e-03 | -4.87 | BCO1 (beta-carotene oxygenase 1) | protein interactions | 53630 | 3 | 1 | 19454 | 50 |
ABLIM1 |
7.691e-03 | -4.87 | Chn1 (chimerin 1) | protein interactions | 108699 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | PIGL (phosphatidylinositol glycan anchor biosynthesis class L) | protein interactions | 9487 | 3 | 1 | 19454 | 50 |
MEIS2 |
7.691e-03 | -4.87 | Shh (sonic hedgehog) | protein interactions | 20423 | 3 | 1 | 19454 | 50 |
GLI3 |
7.691e-03 | -4.87 | Fbxw5 (F-box and WD-40 domain protein 5) | protein interactions | 30839 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | ZNF540 (zinc finger protein 540) | protein interactions | 163255 | 3 | 1 | 19454 | 50 |
ARHGAP24 |
7.691e-03 | -4.87 | ZNF682 (zinc finger protein 682) | protein interactions | 91120 | 3 | 1 | 19454 | 50 |
ARHGAP24 |
7.691e-03 | -4.87 | Rap2a (RAS related protein 2a) | protein interactions | 76108 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | ZNF716 (zinc finger protein 716) | protein interactions | 441234 | 3 | 1 | 19454 | 50 |
ARHGAP24 |
7.691e-03 | -4.87 | Spop (speckle-type BTB/POZ protein) | protein interactions | 20747 | 3 | 1 | 19454 | 50 |
GLIS3 |
7.691e-03 | -4.87 | Plekhb1 (pleckstrin homology domain containing, family B (evectins) member 1) | protein interactions | 27276 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Stk35 (serine/threonine kinase 35) | protein interactions | 67333 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.691e-03 | -4.87 | Usp45 (ubiquitin specific petidase 45) | protein interactions | 77593 | 3 | 1 | 19454 | 50 |
BMPR1B |
7.700e-03 | -4.87 | astrocytoma_Grade_I | COSMIC cancer mutations | astrocytoma_Grade_I | 139 | 3 | 16828 | 49 |
QKI,FGFR3,GPC5 |
7.750e-03 | -4.86 | diffuse_adenocarcinoma | COSMIC cancer mutations | diffuse_adenocarcinoma | 4383 | 21 | 16828 | 49 |
PON2,MACF1,DTNA,CLU,ABLIM1,PTPRZ1,FGFR3,GLI3,SLC1A3,SPON1,PCDH9,ACSS1,GLIS3,NHSL1,MEIS2,QKI,TRPS1,PREX2,CTNND2,RYR3,GPM6A |
7.750e-03 | -4.86 | stomach-carcinoma-diffuse_adenocarcinoma | COSMIC cancer mutations | stomach-carcinoma-diffuse_adenocarcinoma | 4383 | 21 | 16828 | 49 |
RYR3,GPM6A,CTNND2,PREX2,TRPS1,QKI,MEIS2,NHSL1,ACSS1,GLIS3,PCDH9,SPON1,SLC1A3,FGFR3,GLI3,PTPRZ1,CLU,ABLIM1,DTNA,MACF1,PON2 |
7.761e-03 | -4.86 | C20 prostanoid biosynthesis | BIOCYC pathways | META_PWY66-374 | 7 | 1 | 902 | 1 |
PTGDS |
7.761e-03 | -4.86 | C20 prostanoid biosynthesis | BIOCYC pathways | HUMAN_PWY66-374 | 7 | 1 | 902 | 1 |
PTGDS |
7.928e-03 | -4.84 | TYRO3 (TYRO3 protein tyrosine kinase) | protein interactions | 7301 | 159 | 3 | 19454 | 50 |
SLC1A3,CLU,APOE |
7.938e-03 | -4.84 | lactonohydrolase activity | molecular function | GO:0046573 | 3 | 1 | 18094 | 48 |
PON2 |
7.938e-03 | -4.84 | acyl-L-homoserine-lactone lactonohydrolase activity | molecular function | GO:0102007 | 3 | 1 | 18094 | 48 |
PON2 |
7.938e-03 | -4.84 | cysteine transmembrane transporter activity | molecular function | GO:0033229 | 3 | 1 | 18094 | 48 |
SLC1A2 |
7.938e-03 | -4.84 | prostaglandin-D synthase activity | molecular function | GO:0004667 | 3 | 1 | 18094 | 48 |
PTGDS |
7.984e-03 | -4.83 | eye | COSMIC cancer mutations | eye | 606 | 6 | 16828 | 49 |
PCDH9,FGFR3,CTNND2,PREX2,CPE,MACF1 |
8.029e-03 | -4.82 | stomach-adenocarcinoma | COSMIC cancer mutations | stomach-adenocarcinoma | 4101 | 20 | 16828 | 49 |
SLC4A4,QKI,ATP13A4,MEIS2,CDH20,PAMR1,CTNND2,SLC1A2,PREX2,TRPS1,GPC5,PARD3B,ABLIM1,PON2,MACF1,ACSS1,COL5A3,PCDH9,GLI3,FGFR3 |
8.054e-03 | -4.82 | cysteine transport | biological process | GO:0042883 | 3 | 1 | 18204 | 49 |
SLC1A2 |
8.054e-03 | -4.82 | immune complex clearance | biological process | GO:0002434 | 3 | 1 | 18204 | 49 |
CLU |
8.054e-03 | -4.82 | acetate metabolic process | biological process | GO:0006083 | 3 | 1 | 18204 | 49 |
ACSS1 |
8.054e-03 | -4.82 | regulation of platelet-derived growth factor production | biological process | GO:0090361 | 3 | 1 | 18204 | 49 |
NDRG2 |
8.054e-03 | -4.82 | smoothened signaling pathway involved in ventral spinal cord interneuron specification | biological process | GO:0021775 | 3 | 1 | 18204 | 49 |
GLI3 |
8.054e-03 | -4.82 | radial glia guided migration of Purkinje cell | biological process | GO:0021942 | 3 | 1 | 18204 | 49 |
CTNNA2 |
8.054e-03 | -4.82 | cysteine transmembrane transport | biological process | GO:1903712 | 3 | 1 | 18204 | 49 |
SLC1A2 |
8.054e-03 | -4.82 | positive regulation of low-density lipoprotein particle receptor catabolic process | biological process | GO:0032805 | 3 | 1 | 18204 | 49 |
APOE |
8.054e-03 | -4.82 | smoothened signaling pathway involved in ventral spinal cord patterning | biological process | GO:0021910 | 3 | 1 | 18204 | 49 |
GLI3 |
8.054e-03 | -4.82 | protein targeting to lysosome involved in chaperone-mediated autophagy | biological process | GO:0061740 | 3 | 1 | 18204 | 49 |
CLU |
8.054e-03 | -4.82 | very-low-density lipoprotein particle clearance | biological process | GO:0034447 | 3 | 1 | 18204 | 49 |
APOE |
8.054e-03 | -4.82 | nose morphogenesis | biological process | GO:0043585 | 3 | 1 | 18204 | 49 |
GLI3 |
8.078e-03 | -4.82 | Arylesterase | interpro domains | IPR002640 | 3 | 1 | 18521 | 50 |
PON2 |
8.078e-03 | -4.82 | Mastermind-like_N | interpro domains | IPR019082 | 3 | 1 | 18521 | 50 |
MAML2 |
8.078e-03 | -4.82 | Ryanodine_rcpt | interpro domains | IPR003032 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | MAML1-3 | interpro domains | IPR046369 | 3 | 1 | 18521 | 50 |
MAML2 |
8.078e-03 | -4.82 | SoHo_dom | interpro domains | IPR003127 | 3 | 1 | 18521 | 50 |
SORBS1 |
8.078e-03 | -4.82 | MAML_N_sf | interpro domains | IPR046370 | 3 | 1 | 18521 | 50 |
MAML2 |
8.078e-03 | -4.82 | SPRY3_RyR | interpro domains | IPR035762 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Myelin_PLP_CS | interpro domains | IPR018237 | 3 | 1 | 18521 | 50 |
GPM6A |
8.078e-03 | -4.82 | Ryanrecept_TM4-6 | interpro domains | IPR009460 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Vinculin_CS | interpro domains | IPR000633 | 3 | 1 | 18521 | 50 |
CTNNA2 |
8.078e-03 | -4.82 | Ryan_recept | interpro domains | IPR013333 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Myelin_PLP | interpro domains | IPR001614 | 3 | 1 | 18521 | 50 |
GPM6A |
8.078e-03 | -4.82 | SPRY2_RyR | interpro domains | IPR035764 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | RYDR_Jsol | interpro domains | IPR048581 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | SPRY1_RyR | interpro domains | IPR035761 | 3 | 1 | 18521 | 50 |
RYR3 |
8.078e-03 | -4.82 | Reeler_sf | interpro domains | IPR042307 | 3 | 1 | 18521 | 50 |
SPON1 |
8.078e-03 | -4.82 | Reeler_dom | interpro domains | IPR002861 | 3 | 1 | 18521 | 50 |
SPON1 |
8.124e-03 | -4.81 | neuronal cell body | cellular component | GO:0043025 | 489 | 5 | 19108 | 49 |
APOE,GPM6A,SLC1A3,CTNND2,BMPR1B |
8.172e-03 | -4.81 | positive regulation of nervous system development | biological process | GO:0051962 | 296 | 4 | 18204 | 49 |
QKI,PTPRZ1,GLI3,MACF1 |
8.406e-03 | -4.78 | RYDR_Jsol | pfam domains | PF21119 | 3 | 1 | 17795 | 50 |
RYR3 |
8.406e-03 | -4.78 | SR_plectin_7 | pfam domains | PF21097 | 3 | 1 | 17795 | 50 |
MACF1 |
8.406e-03 | -4.78 | RR_TM4-6 | pfam domains | PF06459 | 3 | 1 | 17795 | 50 |
RYR3 |
8.406e-03 | -4.78 | Myelin_PLP | pfam domains | PF01275 | 3 | 1 | 17795 | 50 |
GPM6A |
8.406e-03 | -4.78 | MamL-1 | pfam domains | PF09596 | 3 | 1 | 17795 | 50 |
MAML2 |
8.406e-03 | -4.78 | Arylesterase | pfam domains | PF01731 | 3 | 1 | 17795 | 50 |
PON2 |
8.406e-03 | -4.78 | RyR | pfam domains | PF02026 | 3 | 1 | 17795 | 50 |
RYR3 |
8.406e-03 | -4.78 | Sorb | pfam domains | PF02208 | 3 | 1 | 17795 | 50 |
SORBS1 |
8.476e-03 | -4.77 | sodium ion transmembrane transporter activity | molecular function | GO:0015081 | 158 | 3 | 18094 | 48 |
SLC4A4,SLC1A3,SLC1A2 |
8.519e-03 | -4.77 | extracellular region | cellular component | GO:0005576 | 4350 | 19 | 19108 | 49 |
PTPRZ1,COL5A3,NTM,SPON1,SLC4A4,FGFR3,GPM6A,LSAMP,CPE,PTGDS,PAMR1,PON2,CST3,CLU,GPC5,NDRG2,APOE,AQP4,SPARCL1 |
8.525e-03 | -4.76 | retina development in camera-type eye | biological process | GO:0060041 | 156 | 3 | 18204 | 49 |
BMPR1B,GPM6A,NFIA |
8.573e-03 | -4.76 | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | upper_aerodigestive_tract-larynx-carcinoma-squamous_cell_carcinoma | 1946 | 12 | 16828 | 49 |
MAML2,MACF1,COL5A3,BMPR1B,FGFR3,GLI3,PCDH9,NPAS3,SLC4A4,RYR3,GPM6A,PARD3B |
8.641e-03 | -4.75 | larynx | COSMIC cancer mutations | larynx | 1948 | 12 | 16828 | 49 |
PARD3B,GPM6A,RYR3,NPAS3,SLC4A4,FGFR3,GLI3,PCDH9,COL5A3,BMPR1B,MAML2,MACF1 |
8.710e-03 | -4.74 | growth cone | cellular component | GO:0030426 | 165 | 3 | 19108 | 49 |
PCDH9,GPM6A,NDRG2 |
8.711e-03 | -4.74 | skin-trunk-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-trunk-other-seborrhoeic_keratosis | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | lentigo | COSMIC cancer mutations | lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-leg-lentigo | COSMIC cancer mutations | skin-leg-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-forearm-lentigo | COSMIC cancer mutations | skin-forearm-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | urinary_tract-bladder-papilloma | COSMIC cancer mutations | urinary_tract-bladder-papilloma | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-face-lentigo | COSMIC cancer mutations | skin-face-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-trunk-lentigo | COSMIC cancer mutations | skin-trunk-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-hand-lentigo | COSMIC cancer mutations | skin-hand-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-leg-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-leg-other-seborrhoeic_keratosis | 3 | 1 | 16828 | 49 |
FGFR3 |
8.711e-03 | -4.74 | skin-lentigo | COSMIC cancer mutations | skin-lentigo | 3 | 1 | 16828 | 49 |
FGFR3 |
8.726e-03 | -4.74 | GLI proteins bind promoters of Hh responsive genes to promote transcription | REACTOME pathways | R-HSA-5635851 | 3 | 1 | 10285 | 30 |
GLI3 |
8.962e-03 | -4.71 | neutral amino acid transport | biological process | GO:0015804 | 53 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
8.979e-03 | -4.71 | monoatomic anion transport | biological process | GO:0006820 | 159 | 3 | 18204 | 49 |
SLC4A4,SLC1A3,SLC1A2 |
9.087e-03 | -4.70 | metal ion binding | molecular function | GO:0046872 | 4239 | 19 | 18094 | 48 |
RYR3,PON2,DTNA,TRPS1,ATP13A4,SPARCL1,APOE,SLC1A3,GLI3,MACF1,BMPR1B,PAMR1,ABLIM1,SPON1,PCDH9,CPE,GLIS3,AMZ2,SLC1A2 |
9.095e-03 | -4.70 | - | gene3d domains | 6.10.250.970 | 3 | 1 | 14470 | 44 |
MAML2 |
9.095e-03 | -4.70 | - | gene3d domains | 6.10.250.2510 | 3 | 1 | 14470 | 44 |
CTNNA2 |
9.095e-03 | -4.70 | Reeler domain | gene3d domains | 2.60.40.4060 | 3 | 1 | 14470 | 44 |
SPON1 |
9.095e-03 | -4.70 | - | gene3d domains | 1.10.490.160 | 3 | 1 | 14470 | 44 |
RYR3 |
9.142e-03 | -4.69 | cervix-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | cervix-carcinoma-squamous_cell_carcinoma | 11789 | 42 | 16828 | 49 |
ARHGAP24,NHSL1,CDH20,PAMR1,PREX2,GPM6A,SORBS1,PARD3B,NFIA,TRPS1,MAML2,PON2,ABLIM1,DTNA,COL5A3,ACSS1,FBXL7,FGFR3,GLI3,CST3,PCDH9,AMZ2,NPAS3,MEIS2,ATP13A4,CPE,QKI,SLC4A4,NTM,LSAMP,RYR3,CTNND2,SLC1A2,GPC5,SPARCL1,MACF1,PITPNC1,GLIS3,BMPR1B,PTPRZ1,SPON1,SLC1A3 |
9.191e-03 | -4.69 | EF-hand | gene3d domains | 1.10.238.10 | 272 | 4 | 14470 | 44 |
SPARCL1,MACF1,RYR3,DTNA |
9.227e-03 | -4.69 | cervix | COSMIC cancer mutations | cervix | 11793 | 42 | 16828 | 49 |
ABLIM1,DTNA,MAML2,PON2,PCDH9,AMZ2,FGFR3,CST3,GLI3,COL5A3,FBXL7,ACSS1,NHSL1,CDH20,PAMR1,ARHGAP24,NFIA,TRPS1,PARD3B,GPM6A,SORBS1,PREX2,PITPNC1,MACF1,SPON1,SLC1A3,PTPRZ1,BMPR1B,GLIS3,NTM,ATP13A4,QKI,CPE,SLC4A4,NPAS3,MEIS2,GPC5,SPARCL1,RYR3,CTNND2,SLC1A2,LSAMP |
9.290e-03 | -4.68 | negative regulation of supramolecular fiber organization | biological process | GO:1902904 | 161 | 3 | 18204 | 49 |
CLU,CTNNA2,APOE |
9.446e-03 | -4.66 | site of polarized growth | cellular component | GO:0030427 | 170 | 3 | 19108 | 49 |
GPM6A,PCDH9,NDRG2 |
9.513e-03 | -4.66 | NNT (nicotinamide nucleotide transhydrogenase) | protein interactions | 23530 | 170 | 3 | 19454 | 50 |
ARHGAP24,PON2,APOE |
9.597e-03 | -4.65 | Neurotransmitter Release Cycle | REACTOME pathways | R-HSA-112310 | 51 | 2 | 10285 | 30 |
SLC1A2,SLC1A3 |
9.613e-03 | -4.64 | Amyotrophic lateral sclerosis (ALS) | WikiPathways | WP2447 | 38 | 2 | 5310 | 21 |
CST3,SLC1A2 |
9.625e-03 | -4.64 | intermembrane lipid transfer | biological process | GO:0120009 | 55 | 2 | 18204 | 49 |
APOE,PITPNC1 |
9.625e-03 | -4.64 | response to cocaine | biological process | GO:0042220 | 55 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
9.665e-03 | -4.64 | TLX1 (T cell leukemia homeobox 1) | protein interactions | 3195 | 171 | 3 | 19454 | 50 |
NFIA,MEIS2,TRPS1 |
9.687e-03 | -4.64 | lipid transfer activity | molecular function | GO:0120013 | 56 | 2 | 18094 | 48 |
PITPNC1,APOE |
9.929e-03 | -4.61 | monocarboxylic acid biosynthetic process | biological process | GO:0072330 | 165 | 3 | 18204 | 49 |
ACSS1,QKI,PTGDS |
1.005e-02 | -4.60 | organic substance transport | biological process | GO:0071702 | 1881 | 11 | 18204 | 49 |
ATP13A4,CPE,GLI3,SLC1A3,MACF1,PITPNC1,APOE,QKI,CLU,SLC4A4,SLC1A2 |
1.008e-02 | -4.60 | cellular homeostasis | biological process | GO:0019725 | 689 | 6 | 18204 | 49 |
SLC1A3,APOE,RYR3,AQP4,SLC4A4,ATP13A4 |
1.009e-02 | -4.60 | HBA1 (hemoglobin subunit alpha 1) | protein interactions | 3039 | 59 | 2 | 19454 | 50 |
CLU,ARHGAP24 |
1.009e-02 | -4.60 | VEGFA (vascular endothelial growth factor A) | protein interactions | 7422 | 59 | 2 | 19454 | 50 |
CLU,PTPRZ1 |
1.022e-02 | -4.58 | extrinsic component of membrane | cellular component | GO:0019898 | 175 | 3 | 19108 | 49 |
CTNNA2,DTNA,CDH20 |
1.022e-02 | -4.58 | GLI-SUFU complex | cellular component | GO:1990788 | 4 | 1 | 19108 | 49 |
GLI3 |
1.022e-02 | -4.58 | intermediate-density lipoprotein particle | cellular component | GO:0034363 | 4 | 1 | 19108 | 49 |
APOE |
1.022e-02 | -4.58 | collagen type V trimer | cellular component | GO:0005588 | 4 | 1 | 19108 | 49 |
COL5A3 |
1.024e-02 | -4.58 | Dnaja1 (DnaJ heat shock protein family (Hsp40) member A1) | protein interactions | 15502 | 4 | 1 | 19454 | 50 |
GLIS3 |
1.024e-02 | -4.58 | CCDC126 (coiled-coil domain containing 126) | protein interactions | 90693 | 4 | 1 | 19454 | 50 |
GPM6A |
1.024e-02 | -4.58 | Ctbp2 (C-terminal binding protein 2) | protein interactions | 13017 | 4 | 1 | 19454 | 50 |
TRPS1 |
1.024e-02 | -4.58 | ZNF879 (zinc finger protein 879) | protein interactions | 345462 | 4 | 1 | 19454 | 50 |
ARHGAP24 |
1.024e-02 | -4.58 | Ilkap (integrin-linked kinase-associated serine/threonine phosphatase 2C) | protein interactions | 67444 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Rhebl1 (Ras homolog enriched in brain like 1) | protein interactions | 69159 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Arhgef6 (Rac/Cdc42 guanine nucleotide exchange factor 6) | protein interactions | 73341 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | ZNF615 (zinc finger protein 615) | protein interactions | 284370 | 4 | 1 | 19454 | 50 |
ARHGAP24 |
1.024e-02 | -4.58 | ZNF749 (zinc finger protein 749) | protein interactions | 388567 | 4 | 1 | 19454 | 50 |
ARHGAP24 |
1.024e-02 | -4.58 | Cdk14 (cyclin dependent kinase 14) | protein interactions | 18647 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Srgap1 (SLIT-ROBO Rho GTPase activating protein 1) | protein interactions | 117600 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Nkiras1 (NFKB inhibitor interacting Ras-like protein 1) | protein interactions | 69721 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Naa20 (N(alpha)-acetyltransferase 20, NatB catalytic subunit) | protein interactions | 67877 | 4 | 1 | 19454 | 50 |
BMPR1B |
1.024e-02 | -4.58 | Sufu (SUFU negative regulator of hedgehog signaling) | protein interactions | 24069 | 4 | 1 | 19454 | 50 |
GLI3 |
1.030e-02 | -4.58 | VINCULIN_1 | prosite domains | PS00663 | 3 | 1 | 12186 | 42 |
CTNNA2 |
1.030e-02 | -4.58 | SOHO | prosite domains | PS50831 | 3 | 1 | 12186 | 42 |
SORBS1 |
1.030e-02 | -4.58 | MYELIN_PLP_2 | prosite domains | PS01004 | 3 | 1 | 12186 | 42 |
GPM6A |
1.030e-02 | -4.58 | REELIN | prosite domains | PS51019 | 3 | 1 | 12186 | 42 |
SPON1 |
1.030e-02 | -4.58 | MYELIN_PLP_1 | prosite domains | PS00575 | 3 | 1 | 12186 | 42 |
GPM6A |
1.031e-02 | -4.57 | visual behavior | biological process | GO:0007632 | 57 | 2 | 18204 | 49 |
SLC1A2,MEIS2 |
1.034e-02 | -4.57 | Metabolism of fat-soluble vitamins | REACTOME pathways | R-HSA-6806667 | 53 | 2 | 10285 | 30 |
GPC5,APOE |
1.042e-02 | -4.56 | SNTB1 (syntrophin beta 1) | protein interactions | 6641 | 60 | 2 | 19454 | 50 |
DTNA,FGFR3 |
1.057e-02 | -4.55 | acetate-CoA ligase activity | molecular function | GO:0003987 | 4 | 1 | 18094 | 48 |
ACSS1 |
1.057e-02 | -4.55 | very-low-density lipoprotein particle receptor binding | molecular function | GO:0070326 | 4 | 1 | 18094 | 48 |
APOE |
1.057e-02 | -4.55 | ryanodine-sensitive calcium-release channel activity | molecular function | GO:0005219 | 4 | 1 | 18094 | 48 |
RYR3 |
1.057e-02 | -4.55 | mediator complex binding | molecular function | GO:0036033 | 4 | 1 | 18094 | 48 |
GLI3 |
1.057e-02 | -4.55 | propionate-CoA ligase activity | molecular function | GO:0050218 | 4 | 1 | 18094 | 48 |
ACSS1 |
1.057e-02 | -4.55 | short-chain fatty acid-CoA ligase activity | molecular function | GO:0031955 | 4 | 1 | 18094 | 48 |
ACSS1 |
1.061e-02 | -4.55 | GATA3 (GATA binding protein 3) | protein interactions | 2625 | 177 | 3 | 19454 | 50 |
QKI,TRPS1,NFIA |
1.072e-02 | -4.54 | regulation of phospholipid efflux | biological process | GO:1902994 | 4 | 1 | 18204 | 49 |
APOE |
1.072e-02 | -4.54 | frontal suture morphogenesis | biological process | GO:0060364 | 4 | 1 | 18204 | 49 |
GLI3 |
1.072e-02 | -4.54 | response to caloric restriction | biological process | GO:0061771 | 4 | 1 | 18204 | 49 |
APOE |
1.072e-02 | -4.54 | positive regulation of cardiac muscle myoblast proliferation | biological process | GO:0110024 | 4 | 1 | 18204 | 49 |
MEIS2 |
1.072e-02 | -4.54 | smoothened signaling pathway involved in dorsal/ventral neural tube patterning | biological process | GO:0060831 | 4 | 1 | 18204 | 49 |
GLI3 |
1.072e-02 | -4.54 | ovarian cumulus expansion | biological process | GO:0001550 | 4 | 1 | 18204 | 49 |
BMPR1B |
1.072e-02 | -4.54 | NMDA glutamate receptor clustering | biological process | GO:0097114 | 4 | 1 | 18204 | 49 |
APOE |
1.072e-02 | -4.54 | negative regulation of germ cell proliferation | biological process | GO:1905937 | 4 | 1 | 18204 | 49 |
PTGDS |
1.072e-02 | -4.54 | positive regulation of inclusion body assembly | biological process | GO:0090261 | 4 | 1 | 18204 | 49 |
CLU |
1.072e-02 | -4.54 | regulation of collagen catabolic process | biological process | GO:0010710 | 4 | 1 | 18204 | 49 |
CST3 |
1.072e-02 | -4.54 | negative regulation of male germ cell proliferation | biological process | GO:2000255 | 4 | 1 | 18204 | 49 |
PTGDS |
1.072e-02 | -4.54 | protein localization to secretory granule | biological process | GO:0033366 | 4 | 1 | 18204 | 49 |
CPE |
1.072e-02 | -4.54 | positive regulation of phospholipid efflux | biological process | GO:1902995 | 4 | 1 | 18204 | 49 |
APOE |
1.072e-02 | -4.54 | short-chain fatty acid biosynthetic process | biological process | GO:0051790 | 4 | 1 | 18204 | 49 |
ACSS1 |
1.076e-02 | -4.53 | CTF/NFI_DNA-bd-dom | interpro domains | IPR020604 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | ApoA_E | interpro domains | IPR000074 | 4 | 1 | 18521 | 50 |
APOE |
1.076e-02 | -4.53 | Alpha_catenin | interpro domains | IPR001033 | 4 | 1 | 18521 | 50 |
CTNNA2 |
1.076e-02 | -4.53 | CTF/NFI | interpro domains | IPR000647 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | CTF/NFI_DNA-bd_CS | interpro domains | IPR019739 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | P5B-type_ATPase | interpro domains | IPR047821 | 4 | 1 | 18521 | 50 |
ATP13A4 |
1.076e-02 | -4.53 | PKNOX/Meis_N | interpro domains | IPR032453 | 4 | 1 | 18521 | 50 |
MEIS2 |
1.076e-02 | -4.53 | NHS-like | interpro domains | IPR024845 | 4 | 1 | 18521 | 50 |
NHSL1 |
1.076e-02 | -4.53 | Desmoplakin_Spectrin-like | interpro domains | IPR041573 | 4 | 1 | 18521 | 50 |
MACF1 |
1.076e-02 | -4.53 | AbLIM_anchor | interpro domains | IPR032402 | 4 | 1 | 18521 | 50 |
ABLIM1 |
1.076e-02 | -4.53 | Na/K-Atpase_Interacting | interpro domains | IPR008516 | 4 | 1 | 18521 | 50 |
NKAIN3 |
1.076e-02 | -4.53 | CTF/NFI_DNA-bd_N | interpro domains | IPR019548 | 4 | 1 | 18521 | 50 |
NFIA |
1.076e-02 | -4.53 | NDRG | interpro domains | IPR004142 | 4 | 1 | 18521 | 50 |
NDRG2 |
1.076e-02 | -4.53 | ACAS_N | interpro domains | IPR032387 | 4 | 1 | 18521 | 50 |
ACSS1 |
1.076e-02 | -4.53 | P5A-ATPase_N | interpro domains | IPR047819 | 4 | 1 | 18521 | 50 |
ATP13A4 |
1.076e-02 | -4.53 | FGF_rcpt_fam | interpro domains | IPR016248 | 4 | 1 | 18521 | 50 |
FGFR3 |
1.076e-02 | -4.53 | PCN-like_spectrin-like_rpt | interpro domains | IPR049538 | 4 | 1 | 18521 | 50 |
MACF1 |
1.077e-02 | -4.53 | MamL-1 | smart domains | SM01275 | 3 | 1 | 9717 | 35 |
MAML2 |
1.077e-02 | -4.53 | Sorb | smart domains | SM00459 | 3 | 1 | 9717 | 35 |
SORBS1 |
1.077e-02 | -4.53 | PLP | smart domains | SM00002 | 3 | 1 | 9717 | 35 |
GPM6A |
1.082e-02 | -4.53 | skeletal system development | biological process | GO:0001501 | 500 | 5 | 18204 | 49 |
TRPS1,BMPR1B,NFIA,FGFR3,GLI3 |
1.098e-02 | -4.51 | bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-tibia-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 649 | 6 | 16828 | 49 |
ABLIM1,QKI,MACF1,ACSS1,PREX2,FGFR3 |
1.098e-02 | -4.51 | primitive_neuroectodermal_tumour-medulloblastoma | COSMIC cancer mutations | primitive_neuroectodermal_tumour-medulloblastoma | 15350 | 49 | 16828 | 49 |
PITPNC1,MACF1,NDRG2,PTPRZ1,SPON1,SLC1A3,GLIS3,NTM,NPAS3,MEIS2,QKI,ATP13A4,SLC4A4,GPC5,CTNND2,APOE,PON2,DTNA,FGFR3,GLI3,PCDH9,AMZ2,NKAIN3,ARHGAP24,CDH20,PARD3B,PREX2,BMPR1B,AQP4,CPE,SPARCL1,LSAMP,RYR3,SLC1A2,MAML2,CLU,ABLIM1,CST3,COL5A3,FBXL7,ACSS1,NHSL1,PAMR1,MSI2,PTGDS,NFIA,TRPS1,GPM6A,SORBS1 |
1.101e-02 | -4.51 | endochondral bone morphogenesis | biological process | GO:0060350 | 59 | 2 | 18204 | 49 |
BMPR1B,FGFR3 |
1.104e-02 | -4.51 | EZR (ezrin) | protein interactions | 7430 | 526 | 5 | 19454 | 50 |
ABLIM1,ARHGAP24,MACF1,DTNA,SORBS1 |
1.107e-02 | -4.50 | inorganic molecular entity transmembrane transporter activity | molecular function | GO:0015318 | 714 | 6 | 18094 | 48 |
RYR3,SLC4A4,SLC1A3,AQP4,GPM6A,SLC1A2 |
1.118e-02 | -4.49 | parietal_lobe | COSMIC cancer mutations | parietal_lobe | 55 | 2 | 16828 | 49 |
FGFR3,QKI |
1.119e-02 | -4.49 | ACAS_N | pfam domains | PF16177 | 4 | 1 | 17795 | 50 |
ACSS1 |
1.119e-02 | -4.49 | Spectrin_2 | pfam domains | PF18373 | 4 | 1 | 17795 | 50 |
MACF1 |
1.119e-02 | -4.49 | AbLIM_anchor | pfam domains | PF16182 | 4 | 1 | 17795 | 50 |
ABLIM1 |
1.119e-02 | -4.49 | Ndr | pfam domains | PF03096 | 4 | 1 | 17795 | 50 |
NDRG2 |
1.119e-02 | -4.49 | Spectrin_3 | pfam domains | PF21019 | 4 | 1 | 17795 | 50 |
MACF1 |
1.119e-02 | -4.49 | Apolipoprotein | pfam domains | PF01442 | 4 | 1 | 17795 | 50 |
APOE |
1.119e-02 | -4.49 | Spectrin_4 | pfam domains | PF21020 | 4 | 1 | 17795 | 50 |
MACF1 |
1.119e-02 | -4.49 | NfI_DNAbd_pre-N | pfam domains | PF10524 | 4 | 1 | 17795 | 50 |
NFIA |
1.119e-02 | -4.49 | P5-ATPase | pfam domains | PF12409 | 4 | 1 | 17795 | 50 |
ATP13A4 |
1.119e-02 | -4.49 | CTF_NFI | pfam domains | PF00859 | 4 | 1 | 17795 | 50 |
NFIA |
1.119e-02 | -4.49 | NKAIN | pfam domains | PF05640 | 4 | 1 | 17795 | 50 |
NKAIN3 |
1.119e-02 | -4.49 | NHS | pfam domains | PF15273 | 4 | 1 | 17795 | 50 |
NHSL1 |
1.119e-02 | -4.49 | Meis_PKNOX_N | pfam domains | PF16493 | 4 | 1 | 17795 | 50 |
MEIS2 |
1.121e-02 | -4.49 | YWHAB (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein beta) | protein interactions | 7529 | 965 | 7 | 19454 | 50 |
PARD3B,MACF1,ABLIM1,SORBS1,PITPNC1,NHSL1,FGFR3 |
1.126e-02 | -4.49 | monoatomic cation homeostasis | biological process | GO:0055080 | 505 | 5 | 18204 | 49 |
SLC4A4,ATP13A4,APOE,RYR3,SLC1A3 |
1.128e-02 | -4.48 | regulation of cell size | biological process | GO:0008361 | 173 | 3 | 18204 | 49 |
APOE,MACF1,AQP4 |
1.137e-02 | -4.48 | regulation of glucose import | biological process | GO:0046324 | 60 | 2 | 18204 | 49 |
SORBS1,SLC1A2 |
1.137e-02 | -4.48 | protein homotetramerization | biological process | GO:0051289 | 60 | 2 | 18204 | 49 |
AQP4,RYR3 |
1.143e-02 | -4.47 | human chr14q13.1 | chromosome location | human chr14q13.1 | 6 | 1 | 26134 | 50 |
NPAS3 |
1.143e-02 | -4.47 | human chr4q34.2 | chromosome location | human chr4q34.2 | 6 | 1 | 26134 | 50 |
GPM6A |
1.144e-02 | -4.47 | MYELINPLP | prints domains | PR00214 | 3 | 1 | 5227 | 20 |
GPM6A |
1.144e-02 | -4.47 | RYANODINER | prints domains | PR00795 | 3 | 1 | 5227 | 20 |
RYR3 |
1.144e-02 | -4.47 | PGNDSYNTHASE | prints domains | PR01254 | 3 | 1 | 5227 | 20 |
PTGDS |
1.144e-02 | -4.47 | PARAOXONASE | prints domains | PR01785 | 3 | 1 | 5227 | 20 |
PON2 |
1.153e-02 | -4.46 | response to endogenous stimulus | biological process | GO:0009719 | 1402 | 9 | 18204 | 49 |
SLC1A2,BMPR1B,NFIA,FGFR3,PTGDS,SLC1A3,SORBS1,MEIS2,RYR3 |
1.156e-02 | -4.46 | oligodendroglioma_Grade_III | COSMIC cancer mutations | oligodendroglioma_Grade_III | 303 | 4 | 16828 | 49 |
FGFR3,PTPRZ1,MACF1,GLIS3 |
1.160e-02 | -4.46 | urinary_tract-bladder-other-normal | COSMIC cancer mutations | urinary_tract-bladder-other-normal | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | inverted | COSMIC cancer mutations | inverted | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | skin-face-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-face-malignant_melanoma-superficial_spreading | 4 | 1 | 16828 | 49 |
PREX2 |
1.160e-02 | -4.46 | skin-lower_leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-lower_leg-malignant_melanoma-nodular | 4 | 1 | 16828 | 49 |
PREX2 |
1.160e-02 | -4.46 | urinary_tract-bladder-papilloma-inverted | COSMIC cancer mutations | urinary_tract-bladder-papilloma-inverted | 4 | 1 | 16828 | 49 |
FGFR3 |
1.160e-02 | -4.46 | skin-benign_melanocytic_nevus-junctional | COSMIC cancer mutations | skin-benign_melanocytic_nevus-junctional | 4 | 1 | 16828 | 49 |
FGFR3 |
1.179e-02 | -4.44 | COL1A2 (collagen type I alpha 2 chain) | protein interactions | 1278 | 64 | 2 | 19454 | 50 |
COL5A3,ARHGAP24 |
1.179e-02 | -4.44 | SYNC (syncoilin, intermediate filament protein) | protein interactions | 81493 | 64 | 2 | 19454 | 50 |
MAML2,DTNA |
1.179e-02 | -4.44 | VSX1 (visual system homeobox 1) | protein interactions | 30813 | 64 | 2 | 19454 | 50 |
TRPS1,NFIA |
1.179e-02 | -4.44 | EVA1C (eva-1 homolog C) | protein interactions | 59271 | 64 | 2 | 19454 | 50 |
BMPR1B,PCDH9 |
1.184e-02 | -4.44 | cadherin binding | molecular function | GO:0045296 | 335 | 4 | 18094 | 48 |
MACF1,CTNNA2,CTNND2,CDH20 |
1.190e-02 | -4.43 | biliary_tract-gallbladder-carcinoma-adenocarcinoma | COSMIC cancer mutations | biliary_tract-gallbladder-carcinoma-adenocarcinoma | 2821 | 15 | 16828 | 49 |
SLC4A4,NHSL1,CTNND2,RYR3,PREX2,TRPS1,SPARCL1,CLU,MACF1,PITPNC1,COL5A3,NKAIN3,PCDH9,PTPRZ1,FGFR3 |
1.190e-02 | -4.43 | gallbladder | COSMIC cancer mutations | gallbladder | 2821 | 15 | 16828 | 49 |
NHSL1,SLC4A4,SPARCL1,TRPS1,CTNND2,RYR3,PREX2,PITPNC1,CLU,MACF1,NKAIN3,PCDH9,PTPRZ1,FGFR3,COL5A3 |
1.211e-02 | -4.41 | - | gene3d domains | 1.20.58.1060 | 4 | 1 | 14470 | 44 |
MACF1 |
1.213e-02 | -4.41 | Transmembrane transport of small molecules | REACTOME pathways | R-HSA-382551 | 677 | 6 | 10285 | 30 |
AQP4,ATP13A4,SLC1A2,RYR3,SLC4A4,SLC1A3 |
1.218e-02 | -4.41 | monoatomic ion homeostasis | biological process | GO:0050801 | 515 | 5 | 18204 | 49 |
ATP13A4,SLC4A4,SLC1A3,RYR3,APOE |
1.230e-02 | -4.40 | KLF5 (KLF transcription factor 5) | protein interactions | 688 | 187 | 3 | 19454 | 50 |
TRPS1,CLU,NFIA |
1.245e-02 | -4.39 | camera-type eye development | biological process | GO:0043010 | 335 | 4 | 18204 | 49 |
BMPR1B,GPM6A,GLI3,NFIA |
1.249e-02 | -4.38 | regulation of nitric oxide biosynthetic process | biological process | GO:0045428 | 63 | 2 | 18204 | 49 |
APOE,CLU |
1.250e-02 | -4.38 | MICB (MHC class I polypeptide-related sequence B) | protein interactions | 4277 | 66 | 2 | 19454 | 50 |
APOE,CLU |
1.250e-02 | -4.38 | MAML1 (mastermind like transcriptional coactivator 1) | protein interactions | 9794 | 66 | 2 | 19454 | 50 |
NFIA,MAML2 |
1.250e-02 | -4.38 | ORM1 (orosomucoid 1) | protein interactions | 5004 | 66 | 2 | 19454 | 50 |
CLU,PTGDS |
1.250e-02 | -4.38 | KATNA1 (katanin catalytic subunit A1) | protein interactions | 11104 | 66 | 2 | 19454 | 50 |
ARHGAP24,CLU |
1.265e-02 | -4.37 | brain development | biological process | GO:0007420 | 724 | 6 | 18204 | 49 |
SLC1A2,NDRG2,CTNNA2,MEIS2,GLI3,PCDH9 |
1.269e-02 | -4.37 | Arachidonic acid metabolism | REACTOME pathways | R-HSA-2142753 | 59 | 2 | 10285 | 30 |
PON2,PTGDS |
1.276e-02 | -4.36 | neurofibrillary tangle | cellular component | GO:0097418 | 5 | 1 | 19108 | 49 |
CLU |
1.279e-02 | -4.36 | EPPIN (epididymal peptidase inhibitor) | protein interactions | 57119 | 5 | 1 | 19454 | 50 |
CLU |
1.279e-02 | -4.36 | Rhoj (ras homolog family member J) | protein interactions | 80837 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | TRPM6 (transient receptor potential cation channel subfamily M member 6) | protein interactions | 140803 | 5 | 1 | 19454 | 50 |
ARHGAP24 |
1.279e-02 | -4.36 | POU2F3 (POU class 2 homeobox 3) | protein interactions | 25833 | 5 | 1 | 19454 | 50 |
ARHGAP24 |
1.279e-02 | -4.36 | ZNF93 (zinc finger protein 93) | protein interactions | 81931 | 5 | 1 | 19454 | 50 |
ARHGAP24 |
1.279e-02 | -4.36 | Rab38 (RAB38, member RAS oncogene family) | protein interactions | 72433 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | ZNF571 (zinc finger protein 571) | protein interactions | 51276 | 5 | 1 | 19454 | 50 |
ARHGAP24 |
1.279e-02 | -4.36 | Rras2 (related RAS viral (r-ras) oncogene 2) | protein interactions | 66922 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Hk3 (hexokinase 3) | protein interactions | 25060 | 5 | 1 | 19454 | 50 |
PTGDS |
1.279e-02 | -4.36 | ADCYAP1R1 (ADCYAP receptor type I) | protein interactions | 117 | 5 | 1 | 19454 | 50 |
CLU |
1.279e-02 | -4.36 | Rab6b (RAB6B, member RAS oncogene family) | protein interactions | 270192 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | Rhobtb1 (Rho-related BTB domain containing 1) | protein interactions | 69288 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | TRH (thyrotropin releasing hormone) | protein interactions | 7200 | 5 | 1 | 19454 | 50 |
CPE |
1.279e-02 | -4.36 | Wwp2 (WW domain containing E3 ubiquitin protein ligase 2) | protein interactions | 66894 | 5 | 1 | 19454 | 50 |
GLIS3 |
1.279e-02 | -4.36 | SLC10A3 (solute carrier family 10 member 3) | protein interactions | 8273 | 5 | 1 | 19454 | 50 |
SORBS1 |
1.279e-02 | -4.36 | ZNF836 (zinc finger protein 836) | protein interactions | 162962 | 5 | 1 | 19454 | 50 |
ARHGAP24 |
1.279e-02 | -4.36 | Cdk4 (cyclin dependent kinase 4) | protein interactions | 12567 | 5 | 1 | 19454 | 50 |
BMPR1B |
1.279e-02 | -4.36 | PTGER2 (prostaglandin E receptor 2) | protein interactions | 5732 | 5 | 1 | 19454 | 50 |
PTGDS |
1.287e-02 | -4.35 | cranial nerve development | biological process | GO:0021545 | 64 | 2 | 18204 | 49 |
SLC1A3,GLI3 |
1.310e-02 | -4.34 | medullomyoblastoma | COSMIC cancer mutations | medullomyoblastoma | 485 | 5 | 16828 | 49 |
PCDH9,ATP13A4,RYR3,SLC4A4,LSAMP |
1.310e-02 | -4.34 | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-medullomyoblastoma | COSMIC cancer mutations | central_nervous_system-brain-primitive_neuroectodermal_tumour-medulloblastoma-medullomyoblastoma | 485 | 5 | 16828 | 49 |
RYR3,ATP13A4,SLC4A4,LSAMP,PCDH9 |
1.311e-02 | -4.33 | Signaling by BRAF and RAF fusions | REACTOME pathways | R-HSA-6802952 | 60 | 2 | 10285 | 30 |
MACF1,QKI |
1.317e-02 | -4.33 | upper_leg | COSMIC cancer mutations | upper_leg | 880 | 7 | 16828 | 49 |
PAMR1,FGFR3,PCDH9,NFIA,PREX2,ACSS1,GLIS3 |
1.320e-02 | -4.33 | fibroblast growth factor receptor activity | molecular function | GO:0005007 | 5 | 1 | 18094 | 48 |
FGFR3 |
1.320e-02 | -4.33 | transforming growth factor beta receptor activity, type I | molecular function | GO:0005025 | 5 | 1 | 18094 | 48 |
BMPR1B |
1.325e-02 | -4.32 | regulation of nitric oxide metabolic process | biological process | GO:0080164 | 65 | 2 | 18204 | 49 |
APOE,CLU |
1.327e-02 | -4.32 | L-amino acid transmembrane transporter activity | molecular function | GO:0015179 | 66 | 2 | 18094 | 48 |
SLC1A2,SLC1A3 |
1.332e-02 | -4.32 | human chr13q21.32 | chromosome location | human chr13q21.32 | 7 | 1 | 26134 | 50 |
PCDH9 |
1.332e-02 | -4.32 | human chr8q13.2 | chromosome location | human chr8q13.2 | 7 | 1 | 26134 | 50 |
PREX2 |
1.339e-02 | -4.31 | PHIP (pleckstrin homology domain interacting protein) | protein interactions | 55023 | 193 | 3 | 19454 | 50 |
CLU,GLI3,TRPS1 |
1.339e-02 | -4.31 | propionate metabolic process | biological process | GO:0019541 | 5 | 1 | 18204 | 49 |
ACSS1 |
1.339e-02 | -4.31 | AMPA glutamate receptor clustering | biological process | GO:0097113 | 5 | 1 | 18204 | 49 |
APOE |
1.339e-02 | -4.31 | positive regulation of dendritic spine maintenance | biological process | GO:1902952 | 5 | 1 | 18204 | 49 |
APOE |
1.339e-02 | -4.31 | central nervous system myelin maintenance | biological process | GO:0032286 | 5 | 1 | 18204 | 49 |
CLU |
1.339e-02 | -4.31 | glutamate receptor clustering | biological process | GO:0097688 | 5 | 1 | 18204 | 49 |
APOE |
1.339e-02 | -4.31 | negative regulation of Rac protein signal transduction | biological process | GO:0035021 | 5 | 1 | 18204 | 49 |
ARHGAP24 |
1.339e-02 | -4.31 | negative regulation of chondrocyte proliferation | biological process | GO:1902731 | 5 | 1 | 18204 | 49 |
BMPR1B |
1.339e-02 | -4.31 | chylomicron remnant clearance | biological process | GO:0034382 | 5 | 1 | 18204 | 49 |
APOE |
1.343e-02 | -4.31 | PI_transfer | interpro domains | IPR001666 | 5 | 1 | 18521 | 50 |
PITPNC1 |
1.343e-02 | -4.31 | Vinculin/catenin | interpro domains | IPR006077 | 5 | 1 | 18521 | 50 |
CTNNA2 |
1.343e-02 | -4.31 | Protocadherin | interpro domains | IPR013585 | 5 | 1 | 18521 | 50 |
PCDH9 |
1.343e-02 | -4.31 | Na/HCO3_transpt | interpro domains | IPR003024 | 5 | 1 | 18521 | 50 |
SLC4A4 |
1.343e-02 | -4.31 | P-type_TPase_V | interpro domains | IPR006544 | 5 | 1 | 18521 | 50 |
ATP13A4 |
1.343e-02 | -4.31 | Follistatin/Osteonectin_EGF | interpro domains | IPR015369 | 5 | 1 | 18521 | 50 |
SPARCL1 |
1.343e-02 | -4.31 | BBP-like | interpro domains | IPR045071 | 5 | 1 | 18521 | 50 |
QKI |
1.356e-02 | -4.30 | arm | COSMIC cancer mutations | arm | 1331 | 9 | 16828 | 49 |
NTM,SLC4A4,MACF1,NPAS3,TRPS1,PARD3B,FGFR3,SORBS1,COL5A3 |
1.364e-02 | -4.29 | L-alpha-amino acid transmembrane transport | biological process | GO:1902475 | 66 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
1.367e-02 | -4.29 | neoplasm | COSMIC cancer mutations | neoplasm | 14787 | 48 | 16828 | 49 |
SPON1,SLC1A3,NDRG2,PTPRZ1,GLIS3,MACF1,GPC5,CTNND2,NTM,QKI,ATP13A4,SLC4A4,MEIS2,NPAS3,PCDH9,NKAIN3,AMZ2,GLI3,FGFR3,APOE,DTNA,PON2,PARD3B,PREX2,CDH20,ARHGAP24,BMPR1B,SPARCL1,RYR3,SLC1A2,LSAMP,AQP4,CPE,CST3,COL5A3,FBXL7,ACSS1,CLU,ABLIM1,MAML2,NFIA,TRPS1,GPM6A,SORBS1,NHSL1,PAMR1,MSI2,PTGDS |
1.372e-02 | -4.29 | CTF_NFI_1 | prosite domains | PS00349 | 4 | 1 | 12186 | 42 |
NFIA |
1.372e-02 | -4.29 | CTF_NFI_2 | prosite domains | PS51080 | 4 | 1 | 12186 | 42 |
NFIA |
1.375e-02 | -4.29 | right_upper_lobe | COSMIC cancer mutations | right_upper_lobe | 10376 | 38 | 16828 | 49 |
CDH20,PAMR1,ARHGAP24,GPM6A,SORBS1,PREX2,NFIA,TRPS1,PARD3B,ABLIM1,DTNA,PON2,APOE,COL5A3,FBXL7,PCDH9,NKAIN3,FGFR3,GLI3,CPE,ATP13A4,SLC4A4,NPAS3,MEIS2,NTM,RYR3,CTNND2,SLC1A2,LSAMP,GPC5,MACF1,PITPNC1,BMPR1B,GLIS3,SPON1,SLC1A3,PTPRZ1,NDRG2 |
1.375e-02 | -4.29 | lung-right_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-right_upper_lobe-carcinoma-adenocarcinoma | 10376 | 38 | 16828 | 49 |
PON2,DTNA,ABLIM1,APOE,FBXL7,COL5A3,GLI3,FGFR3,NKAIN3,PCDH9,ARHGAP24,CDH20,PAMR1,PREX2,SORBS1,GPM6A,PARD3B,TRPS1,NFIA,MACF1,PITPNC1,GLIS3,BMPR1B,PTPRZ1,NDRG2,SLC1A3,SPON1,MEIS2,NPAS3,SLC4A4,CPE,ATP13A4,NTM,LSAMP,CTNND2,SLC1A2,RYR3,GPC5 |
1.397e-02 | -4.27 | FOLN | pfam domains | PF09289 | 5 | 1 | 17795 | 50 |
SPARCL1 |
1.397e-02 | -4.27 | IP_trans | pfam domains | PF02121 | 5 | 1 | 17795 | 50 |
PITPNC1 |
1.397e-02 | -4.27 | Vinculin | pfam domains | PF01044 | 5 | 1 | 17795 | 50 |
CTNNA2 |
1.397e-02 | -4.27 | Protocadherin | pfam domains | PF08374 | 5 | 1 | 17795 | 50 |
PCDH9 |
1.399e-02 | -4.27 | PCDH20 (protocadherin 20) | protein interactions | 64881 | 70 | 2 | 19454 | 50 |
PON2,CTNNA2 |
1.400e-02 | -4.27 | adenoma | COSMIC cancer mutations | adenoma | 2873 | 15 | 16828 | 49 |
APOE,MACF1,PTPRZ1,FGFR3,GLI3,PCDH9,ACSS1,COL5A3,BMPR1B,CDH20,NPAS3,GPC5,CTNND2,RYR3,GPM6A |
1.403e-02 | -4.27 | monoatomic ion transmembrane transporter activity | molecular function | GO:0015075 | 752 | 6 | 18094 | 48 |
ATP13A4,SLC4A4,SLC1A3,RYR3,GPM6A,SLC1A2 |
1.404e-02 | -4.27 | cholesterol transport | biological process | GO:0030301 | 67 | 2 | 18204 | 49 |
CLU,APOE |
1.404e-02 | -4.27 | collagen binding | molecular function | GO:0005518 | 68 | 2 | 18094 | 48 |
COL5A3,SPARCL1 |
1.410e-02 | -4.26 | protein processing | biological process | GO:0016485 | 188 | 3 | 18204 | 49 |
SPON1,CPE,GLI3 |
1.418e-02 | -4.26 | hepatocellular_carcinoma | COSMIC cancer mutations | hepatocellular_carcinoma | 14800 | 48 | 16828 | 49 |
ATP13A4,QKI,SLC4A4,MEIS2,NPAS3,NTM,CTNND2,GPC5,MACF1,PITPNC1,GLIS3,SPON1,SLC1A3,NDRG2,PTPRZ1,CDH20,ARHGAP24,PREX2,PARD3B,DTNA,PON2,APOE,PCDH9,AMZ2,NKAIN3,FGFR3,GLI3,AQP4,CPE,RYR3,SLC1A2,LSAMP,SPARCL1,BMPR1B,PTGDS,NHSL1,PAMR1,GPM6A,SORBS1,NFIA,TRPS1,CLU,ABLIM1,MAML2,COL5A3,ACSS1,FBXL7,CST3 |
1.418e-02 | -4.26 | liver-carcinoma-hepatocellular_carcinoma | COSMIC cancer mutations | liver-carcinoma-hepatocellular_carcinoma | 14800 | 48 | 16828 | 49 |
PTGDS,NHSL1,PAMR1,GPM6A,SORBS1,NFIA,TRPS1,MAML2,ABLIM1,CLU,COL5A3,ACSS1,FBXL7,CST3,CPE,AQP4,LSAMP,RYR3,SLC1A2,SPARCL1,BMPR1B,ARHGAP24,CDH20,PREX2,PARD3B,PON2,DTNA,APOE,FGFR3,GLI3,PCDH9,NKAIN3,AMZ2,MEIS2,NPAS3,QKI,ATP13A4,SLC4A4,NTM,CTNND2,GPC5,MACF1,PITPNC1,GLIS3,PTPRZ1,NDRG2,SPON1,SLC1A3 |
1.433e-02 | -4.25 | VAC14 (VAC14 component of PIKFYVE complex) | protein interactions | 55697 | 198 | 3 | 19454 | 50 |
QKI,ACSS1,ARHGAP24 |
1.448e-02 | -4.24 | skin-other-lichenoid_keratosis | COSMIC cancer mutations | skin-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-face-other-nevus_sebaceous | COSMIC cancer mutations | skin-face-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-upper_leg-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_leg-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-shoulder-other-nevus_sebaceous | COSMIC cancer mutations | skin-shoulder-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-scalp-other-nevus_sebaceous | COSMIC cancer mutations | skin-scalp-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-chest-other-lichenoid_keratosis | COSMIC cancer mutations | skin-chest-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | syringocystadenoma_papilliferum | COSMIC cancer mutations | syringocystadenoma_papilliferum | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-breast-other-nevus_sebaceous | COSMIC cancer mutations | skin-breast-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_back-other-lichenoid_keratosis | COSMIC cancer mutations | skin-lower_back-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_leg-other-lichenoid_keratosis | COSMIC cancer mutations | skin-lower_leg-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-shoulder-other-lichenoid_keratosis | COSMIC cancer mutations | skin-shoulder-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-adnexal_tumour-syringocystadenoma_papilliferum | COSMIC cancer mutations | skin-adnexal_tumour-syringocystadenoma_papilliferum | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-upper_arm-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_arm-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-forearm-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-forearm-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-forearm-other-lichenoid_keratosis | COSMIC cancer mutations | skin-forearm-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | monoclonal_gammopathy_of_undetermined_significance | COSMIC cancer mutations | monoclonal_gammopathy_of_undetermined_significance | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-neck-other-lichenoid_keratosis | COSMIC cancer mutations | skin-neck-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-breast-other-lichenoid_keratosis | COSMIC cancer mutations | skin-breast-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-flank-other-lichenoid_keratosis | COSMIC cancer mutations | skin-flank-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_back-other-nevus_sebaceous | COSMIC cancer mutations | skin-lower_back-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-monoclonal_gammopathy_of_undetermined_significance | COSMIC cancer mutations | haematopoietic_and_lymphoid_tissue-lymphoid_neoplasm-monoclonal_gammopathy_of_undetermined_significance | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-neck-other-nevus_sebaceous | COSMIC cancer mutations | skin-neck-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-arm-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-arm-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | lichenoid_keratosis | COSMIC cancer mutations | lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-ear-other-nevus_sebaceous | COSMIC cancer mutations | skin-ear-other-nevus_sebaceous | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-lower_leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-lower_leg-malignant_melanoma-superficial_spreading | 5 | 1 | 16828 | 49 |
PREX2 |
1.448e-02 | -4.24 | skin-upper_back-other-lichenoid_keratosis | COSMIC cancer mutations | skin-upper_back-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-hand-other-lichenoid_keratosis | COSMIC cancer mutations | skin-hand-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-hip-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-hip-other-seborrhoeic_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.448e-02 | -4.24 | skin-face-other-lichenoid_keratosis | COSMIC cancer mutations | skin-face-other-lichenoid_keratosis | 5 | 1 | 16828 | 49 |
FGFR3 |
1.476e-02 | -4.22 | PPP3CC (protein phosphatase 3 catalytic subunit gamma) | protein interactions | 5533 | 72 | 2 | 19454 | 50 |
BMPR1B,PARD3B |
1.508e-02 | -4.19 | upper_back | COSMIC cancer mutations | upper_back | 328 | 4 | 16828 | 49 |
MACF1,GPC5,PARD3B,FGFR3 |
1.511e-02 | -4.19 | Apolipoprotein | gene3d domains | 1.20.120.20 | 5 | 1 | 14470 | 44 |
APOE |
1.521e-02 | -4.19 | plasma membrane region | cellular component | GO:0098590 | 1278 | 8 | 19108 | 49 |
SLC4A4,GPM6A,AQP4,SORBS1,PARD3B,SLC1A3,MACF1,SLC1A2 |
1.522e-02 | -4.19 | ALPHACATENIN | prints domains | PR00805 | 4 | 1 | 5227 | 20 |
CTNNA2 |
1.526e-02 | -4.18 | negative regulation of smooth muscle cell proliferation | biological process | GO:0048662 | 70 | 2 | 18204 | 49 |
NDRG2,APOE |
1.527e-02 | -4.18 | Ethanol Degradation | SMPDB pathways | SMP0000449 | 7 | 1 | 1369 | 3 |
ACSS1 |
1.529e-02 | -4.18 | multivesicular body, internal vesicle | cellular component | GO:0097487 | 6 | 1 | 19108 | 49 |
APOE |
1.532e-02 | -4.18 | FGF6 (fibroblast growth factor 6) | protein interactions | 2251 | 6 | 1 | 19454 | 50 |
FGFR3 |
1.532e-02 | -4.18 | Map2k3 (mitogen-activated protein kinase kinase 3) | protein interactions | 26397 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | PBP2 (Pbp2p) | protein interactions | 852533 | 6 | 1 | 19454 | 50 |
QKI |
1.532e-02 | -4.18 | LCAT (lecithin-cholesterol acyltransferase) | protein interactions | 3931 | 6 | 1 | 19454 | 50 |
APOE |
1.532e-02 | -4.18 | ZNF311 (zinc finger protein 311) | protein interactions | 282890 | 6 | 1 | 19454 | 50 |
ARHGAP24 |
1.532e-02 | -4.18 | Itch (itchy, E3 ubiquitin protein ligase) | protein interactions | 16396 | 6 | 1 | 19454 | 50 |
GLIS3 |
1.532e-02 | -4.18 | Tiam2 (T cell lymphoma invasion and metastasis 2) | protein interactions | 24001 | 6 | 1 | 19454 | 50 |
DTNA |
1.532e-02 | -4.18 | FGF23 (fibroblast growth factor 23) | protein interactions | 8074 | 6 | 1 | 19454 | 50 |
FGFR3 |
1.532e-02 | -4.18 | FGF18 (fibroblast growth factor 18) | protein interactions | 8817 | 6 | 1 | 19454 | 50 |
FGFR3 |
1.532e-02 | -4.18 | SLC12A5 (solute carrier family 12 member 5) | protein interactions | 57468 | 6 | 1 | 19454 | 50 |
GPM6A |
1.532e-02 | -4.18 | DRP2 (dystrophin related protein 2) | protein interactions | 1821 | 6 | 1 | 19454 | 50 |
DTNA |
1.532e-02 | -4.18 | Taok2 (TAO kinase 2) | protein interactions | 381921 | 6 | 1 | 19454 | 50 |
CLU |
1.532e-02 | -4.18 | GDF6 (growth differentiation factor 6) | protein interactions | 392255 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | DAZ4 (deleted in azoospermia 4) | protein interactions | 57135 | 6 | 1 | 19454 | 50 |
QKI |
1.532e-02 | -4.18 | Rhod (ras homolog family member D) | protein interactions | 11854 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | CYRIA (CYFIP related Rac1 interactor A) | protein interactions | 81553 | 6 | 1 | 19454 | 50 |
GPM6A |
1.532e-02 | -4.18 | Fancl (Fanconi anemia, complementation group L) | protein interactions | 67030 | 6 | 1 | 19454 | 50 |
BMPR1B |
1.532e-02 | -4.18 | Zbtb2 (zinc finger and BTB domain containing 2) | protein interactions | 381990 | 6 | 1 | 19454 | 50 |
SORBS1 |
1.532e-02 | -4.18 | FXYD7 (FXYD domain containing ion transport regulator 7) | protein interactions | 53822 | 6 | 1 | 19454 | 50 |
APOE |
1.533e-02 | -4.18 | protein homooligomerization | biological process | GO:0051260 | 194 | 3 | 18204 | 49 |
AQP4,SLC1A2,RYR3 |
1.535e-02 | -4.18 | cell-cell adhesion | biological process | GO:0098609 | 546 | 5 | 18204 | 49 |
PCDH9,CDH20,CTNNA2,SPARCL1,CTNND2 |
1.552e-02 | -4.17 | CASK (calcium/calmodulin dependent serine protein kinase) | protein interactions | 8573 | 204 | 3 | 19454 | 50 |
PARD3B,DTNA,ABLIM1 |
1.554e-02 | -4.16 | bone development | biological process | GO:0060348 | 195 | 3 | 18204 | 49 |
GLI3,FGFR3,BMPR1B |
1.554e-02 | -4.16 | CACNA2D1 (calcium voltage-gated channel auxiliary subunit alpha2delta 1) | protein interactions | 781 | 74 | 2 | 19454 | 50 |
PON2,GPM6A |
1.581e-02 | -4.15 | calcium-induced calcium release activity | molecular function | GO:0048763 | 6 | 1 | 18094 | 48 |
RYR3 |
1.581e-02 | -4.15 | arylesterase activity | molecular function | GO:0004064 | 6 | 1 | 18094 | 48 |
PON2 |
1.581e-02 | -4.15 | sodium:bicarbonate symporter activity | molecular function | GO:0008510 | 6 | 1 | 18094 | 48 |
SLC4A4 |
1.581e-02 | -4.15 | phosphatidylcholine-sterol O-acyltransferase activator activity | molecular function | GO:0060228 | 6 | 1 | 18094 | 48 |
APOE |
1.590e-02 | -4.14 | animal organ morphogenesis | biological process | GO:0009887 | 988 | 7 | 18204 | 49 |
FGFR3,CPE,GLI3,ABLIM1,CTNNA2,MEIS2,BMPR1B |
1.600e-02 | -4.13 | other | COSMIC cancer mutations | other | 14843 | 48 | 16828 | 49 |
MAML2,ABLIM1,CLU,COL5A3,ACSS1,FBXL7,CST3,PTGDS,NHSL1,MSI2,PAMR1,GPM6A,SORBS1,NFIA,TRPS1,BMPR1B,AQP4,CPE,LSAMP,RYR3,SLC1A2,SPARCL1,PON2,DTNA,APOE,FGFR3,GLI3,PCDH9,AMZ2,NKAIN3,ARHGAP24,CDH20,PREX2,PARD3B,MACF1,GLIS3,PTPRZ1,NDRG2,SPON1,SLC1A3,NPAS3,MEIS2,QKI,ATP13A4,SLC4A4,NTM,CTNND2,GPC5 |
1.604e-02 | -4.13 | regulation of low-density lipoprotein particle receptor catabolic process | biological process | GO:0032803 | 6 | 1 | 18204 | 49 |
APOE |
1.604e-02 | -4.13 | protein targeting to vacuole involved in autophagy | biological process | GO:0071211 | 6 | 1 | 18204 | 49 |
CLU |
1.604e-02 | -4.13 | optic nerve morphogenesis | biological process | GO:0021631 | 6 | 1 | 18204 | 49 |
GLI3 |
1.604e-02 | -4.13 | intracellular water homeostasis | biological process | GO:0009992 | 6 | 1 | 18204 | 49 |
AQP4 |
1.604e-02 | -4.13 | gamma-aminobutyric acid biosynthetic process | biological process | GO:0009449 | 6 | 1 | 18204 | 49 |
SLC1A3 |
1.604e-02 | -4.13 | negative regulation of extracellular matrix disassembly | biological process | GO:0010716 | 6 | 1 | 18204 | 49 |
CST3 |
1.604e-02 | -4.13 | fused antrum stage | biological process | GO:0048165 | 6 | 1 | 18204 | 49 |
BMPR1B |
1.604e-02 | -4.13 | vascular associated smooth muscle cell proliferation | biological process | GO:1990874 | 6 | 1 | 18204 | 49 |
NDRG2 |
1.604e-02 | -4.13 | mammary gland formation | biological process | GO:0060592 | 6 | 1 | 18204 | 49 |
GLI3 |
1.604e-02 | -4.13 | triglyceride-rich lipoprotein particle clearance | biological process | GO:0071830 | 6 | 1 | 18204 | 49 |
APOE |
1.609e-02 | -4.13 | RyR/IP3R_RIH_dom_sf | interpro domains | IPR035910 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | Desmoplakin_SH3 | interpro domains | IPR041615 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | RIH_assoc-dom | interpro domains | IPR013662 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | TSP1_spondin_dom | interpro domains | IPR044004 | 6 | 1 | 18521 | 50 |
SPON1 |
1.609e-02 | -4.13 | Ryanodine_IP3_receptor | interpro domains | IPR015925 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | Glypican_CS | interpro domains | IPR019803 | 6 | 1 | 18521 | 50 |
GPC5 |
1.609e-02 | -4.13 | EF-hand_dom_typ1 | interpro domains | IPR015153 | 6 | 1 | 18521 | 50 |
DTNA |
1.609e-02 | -4.13 | Glypican | interpro domains | IPR001863 | 6 | 1 | 18521 | 50 |
GPC5 |
1.609e-02 | -4.13 | GAR_dom | interpro domains | IPR003108 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | Ins145_P3_rcpt | interpro domains | IPR014821 | 6 | 1 | 18521 | 50 |
RYR3 |
1.609e-02 | -4.13 | EF-hand_dom_typ2 | interpro domains | IPR015154 | 6 | 1 | 18521 | 50 |
DTNA |
1.609e-02 | -4.13 | GAR_dom_sf | interpro domains | IPR036534 | 6 | 1 | 18521 | 50 |
MACF1 |
1.609e-02 | -4.13 | RIH_dom | interpro domains | IPR000699 | 6 | 1 | 18521 | 50 |
RYR3 |
1.616e-02 | -4.13 | bone-femur-other-chondroblastoma | COSMIC cancer mutations | bone-femur-other-chondroblastoma | 183 | 3 | 16828 | 49 |
GPC5,PCDH9,RYR3 |
1.627e-02 | -4.12 | protein-containing complex binding | molecular function | GO:0044877 | 1772 | 10 | 18094 | 48 |
COL5A3,MACF1,GLI3,PTPRZ1,CTNNA2,ABLIM1,NFIA,SPARCL1,CLU,APOE |
1.629e-02 | -4.12 | MKRN2 (makorin ring finger protein 2) | protein interactions | 23609 | 380 | 4 | 19454 | 50 |
BMPR1B,FGFR3,GLI3,MACF1 |
1.633e-02 | -4.11 | RYK (receptor like tyrosine kinase) | protein interactions | 6259 | 208 | 3 | 19454 | 50 |
PCDH9,CLU,CTNNA2 |
1.633e-02 | -4.11 | BCL2L1 (BCL2 like 1) | protein interactions | 598 | 208 | 3 | 19454 | 50 |
RYR3,CLU,ABLIM1 |
1.634e-02 | -4.11 | system process | biological process | GO:0003008 | 2015 | 11 | 18204 | 49 |
DTNA,MEIS2,RYR3,ABLIM1,CTNNA2,AQP4,SLC4A4,SLC1A2,PTPRZ1,APOE,SLC1A3 |
1.635e-02 | -4.11 | MIR200A (microRNA 200a) | protein interactions | 406983 | 76 | 2 | 19454 | 50 |
QKI,MSI2 |
1.652e-02 | -4.10 | neuron fate commitment | biological process | GO:0048663 | 73 | 2 | 18204 | 49 |
NFIA,GLI3 |
1.652e-02 | -4.10 | peptide metabolic process | biological process | GO:0006518 | 73 | 2 | 18204 | 49 |
SLC1A2,CPE |
1.673e-02 | -4.09 | axonogenesis | biological process | GO:0007409 | 366 | 4 | 18204 | 49 |
GLI3,PTPRZ1,BMPR1B,CTNNA2 |
1.674e-02 | -4.09 | EF-hand_3 | pfam domains | PF09069 | 6 | 1 | 17795 | 50 |
DTNA |
1.674e-02 | -4.09 | EF-hand_2 | pfam domains | PF09068 | 6 | 1 | 17795 | 50 |
DTNA |
1.674e-02 | -4.09 | RIH_assoc | pfam domains | PF08454 | 6 | 1 | 17795 | 50 |
RYR3 |
1.674e-02 | -4.09 | Plectin | pfam domains | PF00681 | 6 | 1 | 17795 | 50 |
MACF1 |
1.674e-02 | -4.09 | SH3_10 | pfam domains | PF17902 | 6 | 1 | 17795 | 50 |
MACF1 |
1.674e-02 | -4.09 | Ins145_P3_rec | pfam domains | PF08709 | 6 | 1 | 17795 | 50 |
RYR3 |
1.674e-02 | -4.09 | Glypican | pfam domains | PF01153 | 6 | 1 | 17795 | 50 |
GPC5 |
1.674e-02 | -4.09 | GAS2 | pfam domains | PF02187 | 6 | 1 | 17795 | 50 |
MACF1 |
1.674e-02 | -4.09 | TSP1_spondin | pfam domains | PF19028 | 6 | 1 | 17795 | 50 |
SPON1 |
1.674e-02 | -4.09 | RYDR_ITPR | pfam domains | PF01365 | 6 | 1 | 17795 | 50 |
RYR3 |
1.675e-02 | -4.09 | skin-head_neck-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-head_neck-malignant_melanoma-superficial_spreading | 923 | 7 | 16828 | 49 |
GLI3,PREX2,COL5A3,SORBS1,CTNND2,MACF1,ATP13A4 |
1.675e-02 | -4.09 | ABI1 (abl interactor 1) | protein interactions | 10006 | 210 | 3 | 19454 | 50 |
SORBS1,SLC1A3,NHSL1 |
1.695e-02 | -4.08 | positive regulation of gliogenesis | biological process | GO:0014015 | 74 | 2 | 18204 | 49 |
PTPRZ1,QKI |
1.695e-02 | -4.08 | sterol transport | biological process | GO:0015918 | 74 | 2 | 18204 | 49 |
APOE,CLU |
1.706e-02 | -4.07 | intracellular calcium ion homeostasis | biological process | GO:0006874 | 202 | 3 | 18204 | 49 |
RYR3,APOE,ATP13A4 |
1.709e-02 | -4.07 | human chr4q22.3 | chromosome location | human chr4q22.3 | 9 | 1 | 26134 | 50 |
BMPR1B |
1.710e-02 | -4.07 | head development | biological process | GO:0060322 | 774 | 6 | 18204 | 49 |
NDRG2,SLC1A2,PCDH9,GLI3,MEIS2,CTNNA2 |
1.715e-02 | -4.07 | extremity | COSMIC cancer mutations | extremity | 1876 | 11 | 16828 | 49 |
ATP13A4,PITPNC1,CDH20,ACSS1,FBXL7,PREX2,COL5A3,RYR3,PTPRZ1,FGFR3,PCDH9 |
1.717e-02 | -4.06 | LRP8 (LDL receptor related protein 8) | protein interactions | 7804 | 78 | 2 | 19454 | 50 |
CLU,APOE |
1.717e-02 | -4.06 | MIR34C (microRNA 34c) | protein interactions | 407042 | 78 | 2 | 19454 | 50 |
QKI,MSI2 |
1.735e-02 | -4.05 | kidney-carcinoma-collecting_duct_carcinoma | COSMIC cancer mutations | kidney-carcinoma-collecting_duct_carcinoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-in_situ_epithelial_neoplasm-actinic_keratosis | COSMIC cancer mutations | skin-in_situ_epithelial_neoplasm-actinic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-epidermal_nevus | COSMIC cancer mutations | skin-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-arm-epidermal_nevus | COSMIC cancer mutations | skin-arm-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-upper_leg-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-upper_leg-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-benign_melanocytic_nevus-lentiginous_nevus | COSMIC cancer mutations | skin-benign_melanocytic_nevus-lentiginous_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-adnexal_tumour-trichoblastoma | COSMIC cancer mutations | skin-adnexal_tumour-trichoblastoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | autonomic_ganglia-paraganglioma-benign | COSMIC cancer mutations | autonomic_ganglia-paraganglioma-benign | 6 | 1 | 16828 | 49 |
NHSL1 |
1.735e-02 | -4.05 | skin-face-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-face-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | collecting_duct_carcinoma | COSMIC cancer mutations | collecting_duct_carcinoma | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | lentiginous_nevus | COSMIC cancer mutations | lentiginous_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-lower_back-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-lower_back-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-in_situ_epithelial_neoplasm-Bowen_disease | COSMIC cancer mutations | skin-in_situ_epithelial_neoplasm-Bowen_disease | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-head_neck-epidermal_nevus | COSMIC cancer mutations | skin-head_neck-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-trunk-epidermal_nevus | COSMIC cancer mutations | skin-trunk-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-forearm-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-forearm-malignant_melanoma-superficial_spreading | 6 | 1 | 16828 | 49 |
PREX2 |
1.735e-02 | -4.05 | skin-abdomen-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-abdomen-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-back-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-back-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-flank-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-flank-other-seborrhoeic_keratosis | 6 | 1 | 16828 | 49 |
FGFR3 |
1.735e-02 | -4.05 | skin-head_neck-malignant_melanoma | COSMIC cancer mutations | skin-head_neck-malignant_melanoma | 6 | 1 | 16828 | 49 |
PREX2 |
1.735e-02 | -4.05 | skin-lower_leg-epidermal_nevus | COSMIC cancer mutations | skin-lower_leg-epidermal_nevus | 6 | 1 | 16828 | 49 |
FGFR3 |
1.738e-02 | -4.05 | regulation of behavior | biological process | GO:0050795 | 75 | 2 | 18204 | 49 |
PTGDS,APOE |
1.744e-02 | -4.05 | Bile Acid Indirect Signalling Pathway | SMPDB pathways | SMP0086851 | 8 | 1 | 1369 | 3 |
FGFR3 |
1.759e-02 | -4.04 | PRDM1 (PR/SET domain 1) | protein interactions | 639 | 79 | 2 | 19454 | 50 |
NFIA,TRPS1 |
1.782e-02 | -4.03 | regulation of axon extension | biological process | GO:0030516 | 76 | 2 | 18204 | 49 |
APOE,MACF1 |
1.783e-02 | -4.03 | Ectoderm Differentiation | WikiPathways | WP2858 | 143 | 3 | 5310 | 21 |
CTNND2,GLI3,CTNNA2 |
1.785e-02 | -4.03 | nitrogen compound transport | biological process | GO:0071705 | 1507 | 9 | 18204 | 49 |
MACF1,APOE,SLC1A3,GLI3,ATP13A4,CPE,SLC1A2,QKI,CLU |
1.786e-02 | -4.03 | Fbxo3 (F-box protein 3) | protein interactions | 57443 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | SLC16A5 (solute carrier family 16 member 5) | protein interactions | 9121 | 7 | 1 | 19454 | 50 |
PTPRZ1 |
1.786e-02 | -4.03 | RGMB (repulsive guidance molecule BMP co-receptor b) | protein interactions | 285704 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | Smurf1 (SMAD specific E3 ubiquitin protein ligase 1) | protein interactions | 75788 | 7 | 1 | 19454 | 50 |
GLIS3 |
1.786e-02 | -4.03 | Smad7 (SMAD family member 7) | protein interactions | 17131 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | C8B (complement C8 beta chain) | protein interactions | 732 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | SOAT2 (sterol O-acyltransferase 2) | protein interactions | 8435 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | Pum2 (pumilio RNA-binding family member 2) | protein interactions | 80913 | 7 | 1 | 19454 | 50 |
QKI |
1.786e-02 | -4.03 | ZNF701 (zinc finger protein 701) | protein interactions | 55762 | 7 | 1 | 19454 | 50 |
ARHGAP24 |
1.786e-02 | -4.03 | CYP4F8 (cytochrome P450 family 4 subfamily F member 8) | protein interactions | 11283 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | ZNF501 (zinc finger protein 501) | protein interactions | 115560 | 7 | 1 | 19454 | 50 |
ARHGAP24 |
1.786e-02 | -4.03 | C7 (complement C7) | protein interactions | 730 | 7 | 1 | 19454 | 50 |
CLU |
1.786e-02 | -4.03 | FGF5 (fibroblast growth factor 5) | protein interactions | 2250 | 7 | 1 | 19454 | 50 |
FGFR3 |
1.786e-02 | -4.03 | ABCC12 (ATP binding cassette subfamily C member 12) | protein interactions | 94160 | 7 | 1 | 19454 | 50 |
NPAS3 |
1.786e-02 | -4.03 | Uhmk1 (U2AF homology motif (UHM) kinase 1) | protein interactions | 16589 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.786e-02 | -4.03 | SASH3 (SAM and SH3 domain containing 3) | protein interactions | 54440 | 7 | 1 | 19454 | 50 |
BMPR1B |
1.801e-02 | -4.02 | MAP2 (microtubule associated protein 2) | protein interactions | 4133 | 80 | 2 | 19454 | 50 |
GPM6A,APOE |
1.811e-02 | -4.01 | Plakin repeat | gene3d domains | 3.90.1290.10 | 6 | 1 | 14470 | 44 |
MACF1 |
1.811e-02 | -4.01 | Gas2-like domain | gene3d domains | 3.30.920.20 | 6 | 1 | 14470 | 44 |
MACF1 |
1.811e-02 | -4.01 | IP3 receptor type 1 binding core, RIH domain | gene3d domains | 1.25.10.30 | 6 | 1 | 14470 | 44 |
RYR3 |
1.827e-02 | -4.00 | BMP signaling pathway | biological process | GO:0030509 | 77 | 2 | 18204 | 49 |
NFIA,BMPR1B |
1.837e-02 | -4.00 | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | oesophagus-middle_third-carcinoma-squamous_cell_carcinoma | 3531 | 17 | 16828 | 49 |
GPM6A,RYR3,CTNND2,PREX2,GPC5,SPARCL1,SLC4A4,NHSL1,PAMR1,COL5A3,SPON1,PCDH9,PTPRZ1,ABLIM1,MAML2,MACF1,PON2 |
1.840e-02 | -4.00 | actin filament binding | molecular function | GO:0051015 | 211 | 3 | 18094 | 48 |
CTNNA2,MACF1,ABLIM1 |
1.843e-02 | -3.99 | LBD domain binding | molecular function | GO:0050693 | 7 | 1 | 18094 | 48 |
SPON1 |
1.843e-02 | -3.99 | phosphatidic acid transfer activity | molecular function | GO:1990050 | 7 | 1 | 18094 | 48 |
PITPNC1 |
1.843e-02 | -3.99 | SOX17 (SRY-box transcription factor 17) | protein interactions | 64321 | 81 | 2 | 19454 | 50 |
NFIA,TRPS1 |
1.843e-02 | -3.99 | ARNT2 (aryl hydrocarbon receptor nuclear translocator 2) | protein interactions | 9915 | 81 | 2 | 19454 | 50 |
NPAS3,MEIS2 |
1.844e-02 | -3.99 | regulation of neurogenesis | biological process | GO:0050767 | 377 | 4 | 18204 | 49 |
GLI3,QKI,PTPRZ1,MACF1 |
1.847e-02 | -3.99 | middle_third | COSMIC cancer mutations | middle_third | 3533 | 17 | 16828 | 49 |
COL5A3,PTPRZ1,SPON1,PCDH9,PON2,MAML2,MACF1,ABLIM1,PREX2,CTNND2,RYR3,GPM6A,SPARCL1,GPC5,SLC4A4,PAMR1,NHSL1 |
1.869e-02 | -3.98 | glial cell fate specification | biological process | GO:0021780 | 7 | 1 | 18204 | 49 |
NFIA |
1.869e-02 | -3.98 | cellular response to magnesium ion | biological process | GO:0071286 | 7 | 1 | 18204 | 49 |
RYR3 |
1.869e-02 | -3.98 | cell fate specification involved in pattern specification | biological process | GO:0060573 | 7 | 1 | 18204 | 49 |
GLI3 |
1.869e-02 | -3.98 | chaperone-mediated autophagy | biological process | GO:0061684 | 7 | 1 | 18204 | 49 |
CLU |
1.869e-02 | -3.98 | ventral spinal cord interneuron specification | biological process | GO:0021521 | 7 | 1 | 18204 | 49 |
GLI3 |
1.869e-02 | -3.98 | forebrain dorsal/ventral pattern formation | biological process | GO:0021798 | 7 | 1 | 18204 | 49 |
GLI3 |
1.869e-02 | -3.98 | regulation of male germ cell proliferation | biological process | GO:2000254 | 7 | 1 | 18204 | 49 |
PTGDS |
1.869e-02 | -3.98 | regulation of 3'-UTR-mediated mRNA stabilization | biological process | GO:1905868 | 7 | 1 | 18204 | 49 |
QKI |
1.869e-02 | -3.98 | regulation of cardiac muscle myoblast proliferation | biological process | GO:0110022 | 7 | 1 | 18204 | 49 |
MEIS2 |
1.869e-02 | -3.98 | regulation of oligodendrocyte progenitor proliferation | biological process | GO:0070445 | 7 | 1 | 18204 | 49 |
PTPRZ1 |
1.869e-02 | -3.98 | negative regulation of ruffle assembly | biological process | GO:1900028 | 7 | 1 | 18204 | 49 |
ARHGAP24 |
1.869e-02 | -3.98 | forebrain radial glial cell differentiation | biological process | GO:0021861 | 7 | 1 | 18204 | 49 |
GLI3 |
1.869e-02 | -3.98 | high-density lipoprotein particle clearance | biological process | GO:0034384 | 7 | 1 | 18204 | 49 |
APOE |
1.869e-02 | -3.98 | negative regulation of Arp2/3 complex-mediated actin nucleation | biological process | GO:0034316 | 7 | 1 | 18204 | 49 |
CTNNA2 |
1.869e-02 | -3.98 | positive regulation of receptor catabolic process | biological process | GO:2000646 | 7 | 1 | 18204 | 49 |
APOE |
1.869e-02 | -3.98 | positive regulation of transcription of Notch receptor target | biological process | GO:0007221 | 7 | 1 | 18204 | 49 |
MAML2 |
1.869e-02 | -3.98 | very-low-density lipoprotein particle remodeling | biological process | GO:0034372 | 7 | 1 | 18204 | 49 |
APOE |
1.869e-02 | -3.98 | hindgut morphogenesis | biological process | GO:0007442 | 7 | 1 | 18204 | 49 |
GLI3 |
1.872e-02 | -3.98 | positive regulation of carbohydrate metabolic process | biological process | GO:0045913 | 78 | 2 | 18204 | 49 |
SLC4A4,SORBS1 |
1.872e-02 | -3.98 | regulation of glucose transmembrane transport | biological process | GO:0010827 | 78 | 2 | 18204 | 49 |
SLC1A2,SORBS1 |
1.872e-02 | -3.98 | dicarboxylic acid transport | biological process | GO:0006835 | 78 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
1.872e-02 | -3.98 | positive regulation of osteoblast differentiation | biological process | GO:0045669 | 78 | 2 | 18204 | 49 |
BMPR1B,GLI3 |
1.875e-02 | -3.98 | Plakophilin/d_Catenin | interpro domains | IPR028435 | 7 | 1 | 18521 | 50 |
CTNND2 |
1.875e-02 | -3.98 | SPARC/Testican_Ca-bd-dom | interpro domains | IPR019577 | 7 | 1 | 18521 | 50 |
SPARCL1 |
1.875e-02 | -3.98 | Aquaporin_transptr | interpro domains | IPR034294 | 7 | 1 | 18521 | 50 |
AQP4 |
1.875e-02 | -3.98 | Plakin_repeat_sf | interpro domains | IPR035915 | 7 | 1 | 18521 | 50 |
MACF1 |
1.875e-02 | -3.98 | Alpha-catenin/vinculin-like_sf | interpro domains | IPR036723 | 7 | 1 | 18521 | 50 |
CTNNA2 |
1.875e-02 | -3.98 | Plectin_repeat | interpro domains | IPR001101 | 7 | 1 | 18521 | 50 |
MACF1 |
1.875e-02 | -3.98 | GS_dom | interpro domains | IPR003605 | 7 | 1 | 18521 | 50 |
BMPR1B |
1.886e-02 | -3.97 | GSC (goosecoid homeobox) | protein interactions | 145258 | 82 | 2 | 19454 | 50 |
TRPS1,NFIA |
1.897e-02 | -3.96 | human chr9p24.2 | chromosome location | human chr9p24.2 | 10 | 1 | 26134 | 50 |
GLIS3 |
1.899e-02 | -3.96 | PITRANSFER | prints domains | PR00391 | 5 | 1 | 5227 | 20 |
PITPNC1 |
1.899e-02 | -3.96 | NAHCO3TRSPRT | prints domains | PR01232 | 5 | 1 | 5227 | 20 |
SLC4A4 |
1.914e-02 | -3.96 | central_nervous_system-brain-glioma-oligodendroglioma_Grade_II | COSMIC cancer mutations | central_nervous_system-brain-glioma-oligodendroglioma_Grade_II | 73 | 2 | 16828 | 49 |
FGFR3,MACF1 |
1.917e-02 | -3.95 | regulation of glial cell differentiation | biological process | GO:0045685 | 79 | 2 | 18204 | 49 |
PTPRZ1,QKI |
1.922e-02 | -3.95 | prostate | COSMIC cancer mutations | prostate | 13883 | 46 | 16828 | 49 |
SPARCL1,LSAMP,RYR3,SLC1A2,CPE,AQP4,BMPR1B,NFIA,TRPS1,GPM6A,SORBS1,NHSL1,MSI2,PAMR1,COL5A3,FBXL7,ACSS1,MAML2,CLU,ABLIM1,GPC5,CTNND2,NTM,MEIS2,NPAS3,ATP13A4,QKI,SLC4A4,NDRG2,PTPRZ1,SPON1,SLC1A3,GLIS3,PITPNC1,MACF1,PARD3B,PREX2,ARHGAP24,CDH20,FGFR3,GLI3,PCDH9,NKAIN3,APOE,PON2,DTNA |
1.930e-02 | -3.95 | PAX2 (paired box 2) | protein interactions | 5076 | 83 | 2 | 19454 | 50 |
TRPS1,NFIA |
1.930e-02 | -3.95 | DNM3 (dynamin 3) | protein interactions | 26052 | 83 | 2 | 19454 | 50 |
GPM6A,FGFR3 |
1.930e-02 | -3.95 | TM2D3 (TM2 domain containing 3) | protein interactions | 80213 | 83 | 2 | 19454 | 50 |
PON2,FGFR3 |
1.939e-02 | -3.94 | PSEN1 (presenilin 1) | protein interactions | 5663 | 222 | 3 | 19454 | 50 |
CTNND2,DTNA,APOE |
1.944e-02 | -3.94 | inorganic cation transmembrane transporter activity | molecular function | GO:0022890 | 589 | 5 | 18094 | 48 |
RYR3,SLC1A2,SLC1A3,SLC4A4,GPM6A |
1.951e-02 | -3.94 | Oncogenic MAPK signaling | REACTOME pathways | R-HSA-6802957 | 74 | 2 | 10285 | 30 |
QKI,MACF1 |
1.951e-02 | -3.94 | SPARC_Ca_bdg | pfam domains | PF10591 | 7 | 1 | 17795 | 50 |
SPARCL1 |
1.951e-02 | -3.94 | TGF_beta_GS | pfam domains | PF08515 | 7 | 1 | 17795 | 50 |
BMPR1B |
1.954e-02 | -3.94 | transmembrane receptor protein kinase activity | molecular function | GO:0019199 | 81 | 2 | 18094 | 48 |
FGFR3,BMPR1B |
1.955e-02 | -3.93 | sensory organ development | biological process | GO:0007423 | 581 | 5 | 18204 | 49 |
MEIS2,GPM6A,BMPR1B,NFIA,GLI3 |
1.964e-02 | -3.93 | oligodendroglioma_Grade_II | COSMIC cancer mutations | oligodendroglioma_Grade_II | 74 | 2 | 16828 | 49 |
MACF1,FGFR3 |
1.970e-02 | -3.93 | Bile secretion | KEGG pathways | ko04976 | 71 | 2 | 7161 | 22 |
AQP4,SLC4A4 |
1.970e-02 | -3.93 | Bile secretion | KEGG pathways | hsa04976 | 71 | 2 | 7161 | 22 |
SLC4A4,AQP4 |
1.977e-02 | -3.92 | chondrosarcoma | COSMIC cancer mutations | chondrosarcoma | 1181 | 8 | 16828 | 49 |
LSAMP,COL5A3,SPON1,NDRG2,PARD3B,SLC4A4,CPE,PON2 |
1.985e-02 | -3.92 | MAPRE3 (microtubule associated protein RP/EB family member 3) | protein interactions | 22924 | 224 | 3 | 19454 | 50 |
MACF1,ABLIM1,GPM6A |
1.991e-02 | -3.92 | FGFR1 (fibroblast growth factor receptor 1) | protein interactions | 2260 | 611 | 5 | 19454 | 50 |
ABLIM1,CLU,FGFR3,DTNA,NHSL1 |
2.004e-02 | -3.91 | somatodendritic compartment | cellular component | GO:0036477 | 842 | 6 | 19108 | 49 |
CTNND2,BMPR1B,GPM6A,APOE,SLC1A3,CLU |
2.018e-02 | -3.90 | CCND3 (cyclin D3) | protein interactions | 896 | 85 | 2 | 19454 | 50 |
CLU,QKI |
2.021e-02 | -3.90 | skin-shoulder-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-shoulder-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | urinary_tract-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-carcinoma-transitional_cell_carcinoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-adnexal_tumour-trichilemmoma | COSMIC cancer mutations | skin-adnexal_tumour-trichilemmoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-face-adnexal_tumour-malignant_adnexal_tumour | COSMIC cancer mutations | skin-face-adnexal_tumour-malignant_adnexal_tumour | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-chest-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-chest-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-neck-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-neck-other-seborrhoeic_keratosis | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-upper_leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma-nodular | 7 | 1 | 16828 | 49 |
PREX2 |
2.021e-02 | -3.90 | skin-benign_melanocytic_nevus-intradermal | COSMIC cancer mutations | skin-benign_melanocytic_nevus-intradermal | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-face-malignant_melanoma-nodular | COSMIC cancer mutations | skin-face-malignant_melanoma-nodular | 7 | 1 | 16828 | 49 |
PREX2 |
2.021e-02 | -3.90 | nevus_sebaceous | COSMIC cancer mutations | nevus_sebaceous | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-other-nevus_sebaceous | COSMIC cancer mutations | skin-other-nevus_sebaceous | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | trichilemmoma | COSMIC cancer mutations | trichilemmoma | 7 | 1 | 16828 | 49 |
FGFR3 |
2.021e-02 | -3.90 | skin-benign_melanocytic_nevus-compound | COSMIC cancer mutations | skin-benign_melanocytic_nevus-compound | 7 | 1 | 16828 | 49 |
FGFR3 |
2.023e-02 | -3.90 | Adherens junction | KEGG pathways | hsa04520 | 72 | 2 | 7161 | 22 |
CTNNA2,SORBS1 |
2.023e-02 | -3.90 | Adherens junction | KEGG pathways | ko04520 | 72 | 2 | 7161 | 22 |
SORBS1,CTNNA2 |
2.023e-02 | -3.90 | monoatomic ion transmembrane transport | biological process | GO:0034220 | 804 | 6 | 18204 | 49 |
GPM6A,RYR3,SLC1A2,SLC1A3,SLC4A4,ATP13A4 |
2.025e-02 | -3.90 | FGFR3b ligand binding and activation | REACTOME pathways | R-HSA-190371 | 7 | 1 | 10285 | 30 |
FGFR3 |
2.034e-02 | -3.90 | HFE-transferrin receptor complex | cellular component | GO:1990712 | 8 | 1 | 19108 | 49 |
BMPR1B |
2.034e-02 | -3.90 | spherical high-density lipoprotein particle | cellular component | GO:0034366 | 8 | 1 | 19108 | 49 |
CLU |
2.034e-02 | -3.90 | zonula adherens | cellular component | GO:0005915 | 8 | 1 | 19108 | 49 |
SORBS1 |
2.038e-02 | -3.89 | Chmp2a (charged multivesicular body protein 2A) | protein interactions | 68953 | 8 | 1 | 19454 | 50 |
CLU |
2.038e-02 | -3.89 | Rps27a (ribosomal protein S27A) | protein interactions | 78294 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.038e-02 | -3.89 | Rasd2 (RASD family, member 2) | protein interactions | 75141 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.038e-02 | -3.89 | INSM1 (INSM transcriptional repressor 1) | protein interactions | 3642 | 8 | 1 | 19454 | 50 |
SORBS1 |
2.038e-02 | -3.89 | Setdb1 (SET domain, bifurcated 1) | protein interactions | 84505 | 8 | 1 | 19454 | 50 |
AMZ2 |
2.038e-02 | -3.89 | BMP15 (bone morphogenetic protein 15) | protein interactions | 9210 | 8 | 1 | 19454 | 50 |
BMPR1B |
2.038e-02 | -3.89 | SCT (secretin) | protein interactions | 6343 | 8 | 1 | 19454 | 50 |
MEIS2 |
2.038e-02 | -3.89 | LHB (luteinizing hormone subunit beta) | protein interactions | 3972 | 8 | 1 | 19454 | 50 |
NTM |
2.038e-02 | -3.89 | ZNF236 (zinc finger protein 236) | protein interactions | 7776 | 8 | 1 | 19454 | 50 |
ARHGAP24 |
2.038e-02 | -3.89 | PTGER1 (prostaglandin E receptor 1) | protein interactions | 5731 | 8 | 1 | 19454 | 50 |
PTGDS |
2.038e-02 | -3.89 | CCK (cholecystokinin) | protein interactions | 885 | 8 | 1 | 19454 | 50 |
CPE |
2.038e-02 | -3.89 | ZNF28 (zinc finger protein 28) | protein interactions | 7576 | 8 | 1 | 19454 | 50 |
ARHGAP24 |
2.038e-02 | -3.89 | DEPP1 (DEPP autophagy regulator 1) | protein interactions | 11067 | 8 | 1 | 19454 | 50 |
QKI |
2.038e-02 | -3.89 | ZNF568 (zinc finger protein 568) | protein interactions | 374900 | 8 | 1 | 19454 | 50 |
ARHGAP24 |
2.051e-02 | -3.89 | GLYPICAN | prosite domains | PS01207 | 6 | 1 | 12186 | 42 |
GPC5 |
2.051e-02 | -3.89 | GAR | prosite domains | PS51460 | 6 | 1 | 12186 | 42 |
MACF1 |
2.053e-02 | -3.89 | contractile actin filament bundle | cellular component | GO:0097517 | 86 | 2 | 19108 | 49 |
ABLIM1,SORBS1 |
2.053e-02 | -3.89 | stress fiber | cellular component | GO:0001725 | 86 | 2 | 19108 | 49 |
SORBS1,ABLIM1 |
2.063e-02 | -3.88 | SYNJ1 (synaptojanin 1) | protein interactions | 8867 | 86 | 2 | 19454 | 50 |
SORBS1,GPM6A |
2.084e-02 | -3.87 | dendrite | cellular component | GO:0030425 | 620 | 5 | 19108 | 49 |
CTNND2,BMPR1B,CLU,GPM6A,APOE |
2.101e-02 | -3.86 | EF_hand_dom | interpro domains | IPR002048 | 218 | 3 | 18521 | 50 |
RYR3,MACF1,SPARCL1 |
2.103e-02 | -3.86 | BMP receptor activity | molecular function | GO:0098821 | 8 | 1 | 18094 | 48 |
BMPR1B |
2.103e-02 | -3.86 | glutamate binding | molecular function | GO:0016595 | 8 | 1 | 18094 | 48 |
SLC1A3 |
2.105e-02 | -3.86 | glutamatergic synapse | cellular component | GO:0098978 | 412 | 4 | 19108 | 49 |
SPARCL1,SLC1A2,GPM6A,APOE |
2.108e-02 | -3.86 | MIR141 (microRNA 141) | protein interactions | 406933 | 87 | 2 | 19454 | 50 |
QKI,MSI2 |
2.108e-02 | -3.86 | Kctd5 (potassium channel tetramerisation domain containing 5) | protein interactions | 69259 | 87 | 2 | 19454 | 50 |
TRPS1,SLC1A3 |
2.108e-02 | -3.86 | NHLH1 (nescient helix-loop-helix 1) | protein interactions | 4807 | 87 | 2 | 19454 | 50 |
TRPS1,NFIA |
2.110e-02 | -3.86 | dendritic tree | cellular component | GO:0097447 | 622 | 5 | 19108 | 49 |
CTNND2,BMPR1B,CLU,APOE,GPM6A |
2.123e-02 | -3.85 | clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | clear_cell_renal_cell_carcinoma | 13924 | 46 | 16828 | 49 |
DTNA,APOE,GLI3,FGFR3,NKAIN3,AMZ2,PCDH9,ARHGAP24,CDH20,PREX2,PARD3B,MACF1,PITPNC1,GLIS3,PTPRZ1,NDRG2,SLC1A3,SPON1,NPAS3,MEIS2,SLC4A4,QKI,ATP13A4,CTNND2,GPC5,MAML2,CLU,ABLIM1,FBXL7,ACSS1,COL5A3,PTGDS,MSI2,PAMR1,NHSL1,SORBS1,GPM6A,TRPS1,NFIA,BMPR1B,AQP4,CPE,LSAMP,SLC1A2,RYR3,SPARCL1 |
2.123e-02 | -3.85 | kidney-carcinoma-clear_cell_renal_cell_carcinoma | COSMIC cancer mutations | kidney-carcinoma-clear_cell_renal_cell_carcinoma | 13924 | 46 | 16828 | 49 |
FBXL7,ACSS1,COL5A3,AMZ2,NKAIN3,PCDH9,FGFR3,GLI3,DTNA,ABLIM1,CLU,MAML2,APOE,SORBS1,GPM6A,PREX2,TRPS1,NFIA,PARD3B,PTGDS,MSI2,PAMR1,CDH20,NHSL1,ARHGAP24,BMPR1B,GLIS3,SLC1A3,SPON1,NDRG2,PTPRZ1,MACF1,PITPNC1,CTNND2,SLC1A2,RYR3,LSAMP,SPARCL1,GPC5,SLC4A4,ATP13A4,CPE,AQP4,QKI,MEIS2,NPAS3 |
2.126e-02 | -3.85 | femur | COSMIC cancer mutations | femur | 1197 | 8 | 16828 | 49 |
RYR3,PTPRZ1,GLI3,PCDH9,GPC5,SPON1,PON2,SLC4A4 |
2.134e-02 | -3.85 | regulation of Cdc42 protein signal transduction | biological process | GO:0032489 | 8 | 1 | 18204 | 49 |
APOE |
2.134e-02 | -3.85 | insulin processing | biological process | GO:0030070 | 8 | 1 | 18204 | 49 |
CPE |
2.134e-02 | -3.85 | regulation of germ cell proliferation | biological process | GO:1905936 | 8 | 1 | 18204 | 49 |
PTGDS |
2.134e-02 | -3.85 | triglyceride-rich lipoprotein particle remodeling | biological process | GO:0034370 | 8 | 1 | 18204 | 49 |
APOE |
2.134e-02 | -3.85 | hindgut development | biological process | GO:0061525 | 8 | 1 | 18204 | 49 |
GLI3 |
2.134e-02 | -3.85 | gamma-aminobutyric acid metabolic process | biological process | GO:0009448 | 8 | 1 | 18204 | 49 |
SLC1A3 |
2.134e-02 | -3.85 | positive regulation of CoA-transferase activity | biological process | GO:1905920 | 8 | 1 | 18204 | 49 |
APOE |
2.134e-02 | -3.85 | regulation of synapse structural plasticity | biological process | GO:0051823 | 8 | 1 | 18204 | 49 |
CTNNA2 |
2.134e-02 | -3.85 | positive regulation of amyloid-beta clearance | biological process | GO:1900223 | 8 | 1 | 18204 | 49 |
APOE |
2.134e-02 | -3.85 | smooth muscle cell proliferation | biological process | GO:0048659 | 8 | 1 | 18204 | 49 |
NDRG2 |
2.137e-02 | -3.85 | Diseases of signal transduction | REACTOME pathways | R-HSA-5663202 | 369 | 4 | 10285 | 30 |
MAML2,FGFR3,QKI,MACF1 |
2.140e-02 | -3.84 | Villin_headpiece_dom_sf | interpro domains | IPR036886 | 8 | 1 | 18521 | 50 |
ABLIM1 |
2.140e-02 | -3.84 | Villin_headpiece | interpro domains | IPR003128 | 8 | 1 | 18521 | 50 |
ABLIM1 |
2.140e-02 | -3.84 | Plakin | interpro domains | IPR043197 | 8 | 1 | 18521 | 50 |
MACF1 |
2.142e-02 | -3.84 | GAS2 | smart domains | SM00243 | 6 | 1 | 9717 | 35 |
MACF1 |
2.151e-02 | -3.84 | L-amino acid transport | biological process | GO:0015807 | 84 | 2 | 18204 | 49 |
SLC1A2,SLC1A3 |
2.153e-02 | -3.84 | HSPG2 (heparan sulfate proteoglycan 2) | protein interactions | 3339 | 88 | 2 | 19454 | 50 |
GLI3,GPC5 |
2.175e-02 | -3.83 | CTSB (cathepsin B) | protein interactions | 1508 | 232 | 3 | 19454 | 50 |
MSI2,CST3,APOE |
2.199e-02 | -3.82 | SOX10 (SRY-box transcription factor 10) | protein interactions | 6663 | 89 | 2 | 19454 | 50 |
NFIA,TRPS1 |
2.201e-02 | -3.82 | organic anion transport | biological process | GO:0015711 | 398 | 4 | 18204 | 49 |
SLC4A4,SLC1A2,APOE,SLC1A3 |
2.226e-02 | -3.80 | VHP | pfam domains | PF02209 | 8 | 1 | 17795 | 50 |
ABLIM1 |
2.229e-02 | -3.80 | cell-cell signaling | biological process | GO:0007267 | 822 | 6 | 18204 | 49 |
SLC1A2,APOE,SLC1A3,DTNA,FGFR3,CPE |
2.232e-02 | -3.80 | lung-left_upper_lobe-carcinoma-adenocarcinoma | COSMIC cancer mutations | lung-left_upper_lobe-carcinoma-adenocarcinoma | 556 | 5 | 16828 | 49 |
CTNND2,SLC4A4,RYR3,FBXL7,TRPS1 |
2.247e-02 | -3.80 | Golgi apparatus | cellular component | GO:0005794 | 1645 | 9 | 19108 | 49 |
CPE,PTGDS,FGFR3,APOE,GPC5,MACF1,NDRG2,CST3,CLU |
2.262e-02 | -3.79 | left_upper_lobe | COSMIC cancer mutations | left_upper_lobe | 558 | 5 | 16828 | 49 |
TRPS1,CTNND2,SLC4A4,RYR3,FBXL7 |
2.272e-02 | -3.78 | human chr11p15.2 | chromosome location | human chr11p15.2 | 12 | 1 | 26134 | 50 |
SPON1 |
2.272e-02 | -3.78 | human chr6q26 | chromosome location | human chr6q26 | 12 | 1 | 26134 | 50 |
QKI |
2.274e-02 | -3.78 | CTSL (cathepsin L) | protein interactions | 1514 | 236 | 3 | 19454 | 50 |
CST3,CLU,PON2 |
2.275e-02 | -3.78 | ACTIVIN2R | prints domains | PR00653 | 6 | 1 | 5227 | 20 |
BMPR1B |
2.285e-02 | -3.78 | astrocyte end-foot | cellular component | GO:0097450 | 9 | 1 | 19108 | 49 |
AQP4 |
2.285e-02 | -3.78 | flotillin complex | cellular component | GO:0016600 | 9 | 1 | 19108 | 49 |
SORBS1 |
2.290e-02 | -3.78 | CACNA2D3 (calcium voltage-gated channel auxiliary subunit alpha2delta 3) | protein interactions | 55799 | 9 | 1 | 19454 | 50 |
APOE |
2.290e-02 | -3.78 | LINC02582 (long intergenic non-protein coding RNA 2582) | protein interactions | 100505817 | 9 | 1 | 19454 | 50 |
APOE |
2.290e-02 | -3.78 | GUSBP1 (GUSB pseudogene 1) | protein interactions | 728411 | 9 | 1 | 19454 | 50 |
FGFR3 |
2.290e-02 | -3.78 | Ywhag (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, gamma polypeptide) | protein interactions | 22628 | 9 | 1 | 19454 | 50 |
QKI |
2.290e-02 | -3.78 | ZNF766 (zinc finger protein 766) | protein interactions | 90321 | 9 | 1 | 19454 | 50 |
ARHGAP24 |
2.290e-02 | -3.78 | Tyw3 (tRNA-yW synthesizing protein 3 homolog (S. cerevisiae)) | protein interactions | 209584 | 9 | 1 | 19454 | 50 |
CTNNA2 |
2.290e-02 | -3.78 | VEPH1 (ventricular zone expressed PH domain containing 1) | protein interactions | 79674 | 9 | 1 | 19454 | 50 |
BMPR1B |
2.290e-02 | -3.78 | KCNV2 (potassium voltage-gated channel modifier subfamily V member 2) | protein interactions | 169522 | 9 | 1 | 19454 | 50 |
AMZ2 |
2.290e-02 | -3.78 | NRXN2 (neurexin 2) | protein interactions | 9379 | 9 | 1 | 19454 | 50 |
MACF1 |
2.292e-02 | -3.78 | DGUOK (deoxyguanosine kinase) | protein interactions | 1716 | 91 | 2 | 19454 | 50 |
GPM6A,NTM |
2.292e-02 | -3.78 | FOXI1 (forkhead box I1) | protein interactions | 2299 | 91 | 2 | 19454 | 50 |
NFIA,TRPS1 |
2.296e-02 | -3.77 | dorsal/ventral pattern formation | biological process | GO:0009953 | 87 | 2 | 18204 | 49 |
GLI3,BMPR1B |
2.306e-02 | -3.77 | trichoblastoma | COSMIC cancer mutations | trichoblastoma | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | cervical_intraepithelial_neoplasia_Grade_I | COSMIC cancer mutations | cervical_intraepithelial_neoplasia_Grade_I | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | central_nervous_system-chiasm-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-chiasm-glioma-astrocytoma_Grade_I | 8 | 1 | 16828 | 49 |
QKI |
2.306e-02 | -3.77 | skin-chest-malignant_melanoma-nodular | COSMIC cancer mutations | skin-chest-malignant_melanoma-nodular | 8 | 1 | 16828 | 49 |
PREX2 |
2.306e-02 | -3.77 | actinic_keratosis | COSMIC cancer mutations | actinic_keratosis | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_I | COSMIC cancer mutations | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_I | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | junctional | COSMIC cancer mutations | junctional | 8 | 1 | 16828 | 49 |
FGFR3 |
2.306e-02 | -3.77 | urinary_tract-ureter-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-ureter-carcinoma-transitional_cell_carcinoma | 8 | 1 | 16828 | 49 |
FGFR3 |
2.311e-02 | -3.77 | Release of Hh-Np from the secreting cell | REACTOME pathways | R-HSA-5362798 | 8 | 1 | 10285 | 30 |
GPC5 |
2.324e-02 | -3.76 | LCOR (ligand dependent nuclear receptor corepressor) | protein interactions | 84458 | 238 | 3 | 19454 | 50 |
SPARCL1,MACF1,CLU |
2.325e-02 | -3.76 | forearm | COSMIC cancer mutations | forearm | 81 | 2 | 16828 | 49 |
PREX2,FGFR3 |
2.329e-02 | -3.76 | actomyosin | cellular component | GO:0042641 | 92 | 2 | 19108 | 49 |
ABLIM1,SORBS1 |
2.330e-02 | -3.76 | RNF43 (ring finger protein 43) | protein interactions | 54894 | 424 | 4 | 19454 | 50 |
QKI,MACF1,ABLIM1,GLI3 |
2.339e-02 | -3.76 | RLN1 (relaxin 1) | protein interactions | 6013 | 92 | 2 | 19454 | 50 |
PON2,CPE |
2.339e-02 | -3.76 | POTEI (POTE ankyrin domain family member I) | protein interactions | 653269 | 92 | 2 | 19454 | 50 |
FGFR3,DTNA |
2.339e-02 | -3.76 | SOX9 (SRY-box transcription factor 9) | protein interactions | 6662 | 92 | 2 | 19454 | 50 |
TRPS1,NFIA |
2.341e-02 | -3.75 | skeletal system morphogenesis | biological process | GO:0048705 | 228 | 3 | 18204 | 49 |
BMPR1B,FGFR3,GLI3 |
2.350e-02 | -3.75 | Validated targets of C-MYC transcriptional repression | Pathway Interaction DB | myc_represspathway | 61 | 2 | 2226 | 9 |
NDRG2,CLU |
2.387e-02 | -3.74 | MIR19B2 (microRNA 19b-2) | protein interactions | 406981 | 93 | 2 | 19454 | 50 |
MSI2,QKI |
2.387e-02 | -3.74 | ARHGEF6 (Rac/Cdc42 guanine nucleotide exchange factor 6) | protein interactions | 9459 | 93 | 2 | 19454 | 50 |
ABLIM1,BMPR1B |
2.387e-02 | -3.74 | DMRTB1 (DMRT like family B with proline rich C-terminal 1) | protein interactions | 63948 | 93 | 2 | 19454 | 50 |
QKI,MSI2 |
2.388e-02 | -3.73 | GS | prosite domains | PS51256 | 7 | 1 | 12186 | 42 |
BMPR1B |
2.395e-02 | -3.73 | positive regulation of lipid biosynthetic process | biological process | GO:0046889 | 89 | 2 | 18204 | 49 |
SORBS1,APOE |
2.395e-02 | -3.73 | cell fate specification | biological process | GO:0001708 | 89 | 2 | 18204 | 49 |
GLI3,NFIA |
2.397e-02 | -3.73 | microglial cell proliferation | biological process | GO:0061518 | 9 | 1 | 18204 | 49 |
CLU |
2.397e-02 | -3.73 | cranial suture morphogenesis | biological process | GO:0060363 | 9 | 1 | 18204 | 49 |
GLI3 |
2.397e-02 | -3.73 | sterol catabolic process | biological process | GO:0016127 | 9 | 1 | 18204 | 49 |
APOE |
2.397e-02 | -3.73 | macrophage proliferation | biological process | GO:0061517 | 9 | 1 | 18204 | 49 |
CLU |
2.397e-02 | -3.73 | embryonic neurocranium morphogenesis | biological process | GO:0048702 | 9 | 1 | 18204 | 49 |
GLI3 |
2.397e-02 | -3.73 | release of sequestered calcium ion into cytosol by sarcoplasmic reticulum | biological process | GO:0014808 | 9 | 1 | 18204 | 49 |
RYR3 |
2.397e-02 | -3.73 | negative regulation of actin nucleation | biological process | GO:0051126 | 9 | 1 | 18204 | 49 |
CTNNA2 |
2.397e-02 | -3.73 | cholesterol catabolic process | biological process | GO:0006707 | 9 | 1 | 18204 | 49 |
APOE |
2.397e-02 | -3.73 | cyclooxygenase pathway | biological process | GO:0019371 | 9 | 1 | 18204 | 49 |
PTGDS |
2.397e-02 | -3.73 | hindbrain radial glia guided cell migration | biological process | GO:0021932 | 9 | 1 | 18204 | 49 |
CTNNA2 |
2.397e-02 | -3.73 | polyamine transmembrane transport | biological process | GO:1902047 | 9 | 1 | 18204 | 49 |
ATP13A4 |
2.397e-02 | -3.73 | semicircular canal development | biological process | GO:0060872 | 9 | 1 | 18204 | 49 |
GLI3 |
2.404e-02 | -3.73 | Activin_recp | interpro domains | IPR000472 | 9 | 1 | 18521 | 50 |
BMPR1B |
2.404e-02 | -3.73 | Band3_cytoplasmic_dom | interpro domains | IPR013769 | 9 | 1 | 18521 | 50 |
SLC4A4 |
2.404e-02 | -3.73 | Prot_inh_cystat_CS | interpro domains | IPR018073 | 9 | 1 | 18521 | 50 |
CST3 |
2.404e-02 | -3.73 | Fol_N | interpro domains | IPR003645 | 9 | 1 | 18521 | 50 |
SPARCL1 |
2.407e-02 | -3.73 | Villin headpiece domain | gene3d domains | 1.10.950.10 | 8 | 1 | 14470 | 44 |
ABLIM1 |
2.408e-02 | -3.73 | ion binding | molecular function | GO:0043167 | 6007 | 23 | 18094 | 48 |
DTNA,TRPS1,PITPNC1,APOE,PAMR1,ABLIM1,CPE,ACSS1,FGFR3,PCDH9,GLIS3,SLC1A2,AMZ2,RYR3,PON2,PTGDS,SLC1A3,SPARCL1,ATP13A4,MACF1,GLI3,BMPR1B,SPON1 |
2.422e-02 | -3.72 | calcium ion homeostasis | biological process | GO:0055074 | 231 | 3 | 18204 | 49 |
ATP13A4,RYR3,APOE |
2.430e-02 | -3.72 | protein binding | molecular function | GO:0005515 | 13983 | 43 | 18094 | 48 |
PITPNC1,AQP4,APOE,NFIA,TRPS1,DTNA,SORBS1,FGFR3,CTNND2,QKI,NDRG2,SLC1A3,CDH20,CLU,NTM,RYR3,PON2,MEIS2,BMPR1B,MACF1,LSAMP,FBXL7,NPAS3,COL5A3,CPE,ACSS1,ABLIM1,SLC1A2,GLIS3,PTGDS,SPARCL1,PTPRZ1,ARHGAP24,PARD3B,GLI3,CST3,SLC4A4,SPON1,MAML2,MSI2,CTNNA2,GPM6A,GPC5 |
2.435e-02 | -3.72 | TTR (transthyretin) | protein interactions | 7276 | 94 | 2 | 19454 | 50 |
CTNND2,CLU |
2.459e-02 | -3.71 | human chr5p15.1 | chromosome location | human chr5p15.1 | 13 | 1 | 26134 | 50 |
FBXL7 |
2.483e-02 | -3.70 | H2BC13 (H2B clustered histone 13) | protein interactions | 8340 | 95 | 2 | 19454 | 50 |
ARHGAP24,GPM6A |
2.495e-02 | -3.69 | PLEC | smart domains | SM00250 | 7 | 1 | 9717 | 35 |
MACF1 |
2.495e-02 | -3.69 | GS | smart domains | SM00467 | 7 | 1 | 9717 | 35 |
BMPR1B |
2.496e-02 | -3.69 | response to BMP | biological process | GO:0071772 | 91 | 2 | 18204 | 49 |
BMPR1B,NFIA |
2.496e-02 | -3.69 | cellular response to BMP stimulus | biological process | GO:0071773 | 91 | 2 | 18204 | 49 |
BMPR1B,NFIA |
2.501e-02 | -3.69 | Band_3_cyto | pfam domains | PF07565 | 9 | 1 | 17795 | 50 |
SLC4A4 |
2.501e-02 | -3.69 | Activin_recp | pfam domains | PF01064 | 9 | 1 | 17795 | 50 |
BMPR1B |
2.519e-02 | -3.68 | chemical synaptic transmission | biological process | GO:0007268 | 415 | 4 | 18204 | 49 |
SLC1A3,SLC1A2,APOE,DTNA |
2.519e-02 | -3.68 | anterograde trans-synaptic signaling | biological process | GO:0098916 | 415 | 4 | 18204 | 49 |
SLC1A2,APOE,SLC1A3,DTNA |
2.521e-02 | -3.68 | actin filament bundle | cellular component | GO:0032432 | 96 | 2 | 19108 | 49 |
ABLIM1,SORBS1 |
2.528e-02 | -3.68 | Diseases of glycosylation | REACTOME pathways | R-HSA-3781865 | 85 | 2 | 10285 | 30 |
GPC5,SPON1 |
2.532e-02 | -3.68 | PDIA5 (protein disulfide isomerase family A member 5) | protein interactions | 10954 | 96 | 2 | 19454 | 50 |
NTM,ARHGAP24 |
2.536e-02 | -3.67 | perineuronal net | cellular component | GO:0072534 | 10 | 1 | 19108 | 49 |
PTPRZ1 |
2.541e-02 | -3.67 | Hsp90aa1 (heat shock protein 90, alpha (cytosolic), class A member 1) | protein interactions | 15519 | 10 | 1 | 19454 | 50 |
QKI |
2.541e-02 | -3.67 | GSG1 (germ cell associated 1) | protein interactions | 83445 | 10 | 1 | 19454 | 50 |
PITPNC1 |
2.541e-02 | -3.67 | Smurf2 (SMAD specific E3 ubiquitin protein ligase 2) | protein interactions | 66313 | 10 | 1 | 19454 | 50 |
GLIS3 |
2.541e-02 | -3.67 | ALKAL2 (ALK and LTK ligand 2) | protein interactions | 285016 | 10 | 1 | 19454 | 50 |
PON2 |
2.541e-02 | -3.67 | TSHZ1 (teashirt zinc finger homeobox 1) | protein interactions | 10194 | 10 | 1 | 19454 | 50 |
MEIS2 |
2.541e-02 | -3.67 | CALB2 (calbindin 2) | protein interactions | 794 | 10 | 1 | 19454 | 50 |
GPM6A |
2.541e-02 | -3.67 | ZNF852 (zinc finger protein 852) | protein interactions | 285346 | 10 | 1 | 19454 | 50 |
ARHGAP24 |
2.541e-02 | -3.67 | SLC8A2 (solute carrier family 8 member A2) | protein interactions | 6543 | 10 | 1 | 19454 | 50 |
GPM6A |
2.541e-02 | -3.67 | Mrpl13 (mitochondrial ribosomal protein L13) | protein interactions | 68537 | 10 | 1 | 19454 | 50 |
QKI |
2.541e-02 | -3.67 | Vbp1 (von Hippel-Lindau binding protein 1) | protein interactions | 22327 | 10 | 1 | 19454 | 50 |
ABLIM1 |
2.541e-02 | -3.67 | ZNF606 (zinc finger protein 606) | protein interactions | 80095 | 10 | 1 | 19454 | 50 |
ARHGAP24 |
2.541e-02 | -3.67 | SERPINB11 (serpin family B member 11) | protein interactions | 89778 | 10 | 1 | 19454 | 50 |
CPE |
2.541e-02 | -3.67 | P2rx7 (purinergic receptor P2X 7) | protein interactions | 29665 | 10 | 1 | 19454 | 50 |
PTPRZ1 |
2.547e-02 | -3.67 | YWHAZ (tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta) | protein interactions | 7534 | 1138 | 7 | 19454 | 50 |
APOE,ABLIM1,MACF1,PITPNC1,PARD3B,SORBS1,NHSL1 |
2.548e-02 | -3.67 | protein tetramerization | biological process | GO:0051262 | 92 | 2 | 18204 | 49 |
AQP4,RYR3 |
2.581e-02 | -3.66 | BTG3 (BTG anti-proliferation factor 3) | protein interactions | 10950 | 97 | 2 | 19454 | 50 |
SPARCL1,CLU |
2.589e-02 | -3.65 | shoulder | COSMIC cancer mutations | shoulder | 387 | 4 | 16828 | 49 |
FGFR3,MACF1,PREX2,CPE |
2.591e-02 | -3.65 | in_situ_epithelial_neoplasm | COSMIC cancer mutations | in_situ_epithelial_neoplasm | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | compound | COSMIC cancer mutations | compound | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | ovary-low_malignant_potential_(borderline)_tumour-Brenner_tumour | COSMIC cancer mutations | ovary-low_malignant_potential_(borderline)_tumour-Brenner_tumour | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | epidermal_nevus | COSMIC cancer mutations | epidermal_nevus | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-chest-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-chest-malignant_melanoma-superficial_spreading | 9 | 1 | 16828 | 49 |
PREX2 |
2.591e-02 | -3.65 | Bowen_disease | COSMIC cancer mutations | Bowen_disease | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-benign_melanocytic_nevus-congenital | COSMIC cancer mutations | skin-benign_melanocytic_nevus-congenital | 9 | 1 | 16828 | 49 |
FGFR3 |
2.591e-02 | -3.65 | skin-upper_leg-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma-superficial_spreading | 9 | 1 | 16828 | 49 |
PREX2 |
2.591e-02 | -3.65 | skin-other-seborrhoeic_keratosis | COSMIC cancer mutations | skin-other-seborrhoeic_keratosis | 9 | 1 | 16828 | 49 |
FGFR3 |
2.596e-02 | -3.65 | Synthesis of 5-eicosatetraenoic acids | REACTOME pathways | R-HSA-2142688 | 9 | 1 | 10285 | 30 |
PON2 |
2.596e-02 | -3.65 | Terminal pathway of complement | REACTOME pathways | R-HSA-166665 | 9 | 1 | 10285 | 30 |
CLU |
2.599e-02 | -3.65 | regulation of extent of cell growth | biological process | GO:0061387 | 93 | 2 | 18204 | 49 |
MACF1,APOE |
2.612e-02 | -3.65 | transmembrane transporter activity | molecular function | GO:0022857 | 1110 | 7 | 18094 | 48 |
ATP13A4,SLC4A4,GPM6A,SLC1A3,SLC1A2,AQP4,RYR3 |
2.618e-02 | -3.64 | axon development | biological process | GO:0061564 | 420 | 4 | 18204 | 49 |
CTNNA2,BMPR1B,PTPRZ1,GLI3 |
2.622e-02 | -3.64 | polyamine transmembrane transporter activity | molecular function | GO:0015203 | 10 | 1 | 18094 | 48 |
ATP13A4 |
2.622e-02 | -3.64 | phosphatidylinositol transfer activity | molecular function | GO:0008526 | 10 | 1 | 18094 | 48 |
PITPNC1 |
2.624e-02 | -3.64 | SYNE3 (spectrin repeat containing nuclear envelope family member 3) | protein interactions | 161176 | 440 | 4 | 19454 | 50 |
ABLIM1,MACF1,GLI3,SORBS1 |
2.631e-02 | -3.64 | FRS2 (fibroblast growth factor receptor substrate 2) | protein interactions | 10818 | 98 | 2 | 19454 | 50 |
SORBS1,FGFR3 |
2.631e-02 | -3.64 | DNAAF2 (dynein axonemal assembly factor 2) | protein interactions | 55172 | 98 | 2 | 19454 | 50 |
GPM6A,LSAMP |
2.653e-02 | -3.63 | haematopoietic_neoplasm | COSMIC cancer mutations | haematopoietic_neoplasm | 11082 | 39 | 16828 | 49 |
MACF1,PTPRZ1,SPON1,SLC1A3,GLIS3,BMPR1B,NTM,MEIS2,NPAS3,QKI,ATP13A4,CPE,SLC4A4,GPC5,SPARCL1,LSAMP,RYR3,CTNND2,SLC1A2,MAML2,PON2,ABLIM1,DTNA,GLI3,FGFR3,PCDH9,NKAIN3,AMZ2,COL5A3,ACSS1,FBXL7,ARHGAP24,NHSL1,CDH20,MSI2,PAMR1,PARD3B,NFIA,PREX2 |
2.660e-02 | -3.63 | negative regulation of sterol biosynthetic process | biological process | GO:0106119 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | high-density lipoprotein particle assembly | biological process | GO:0034380 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | regulation of CoA-transferase activity | biological process | GO:1905918 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | regulation of bone development | biological process | GO:1903010 | 10 | 1 | 18204 | 49 |
GLI3 |
2.660e-02 | -3.63 | release of sequestered calcium ion into cytosol by endoplasmic reticulum | biological process | GO:1903514 | 10 | 1 | 18204 | 49 |
RYR3 |
2.660e-02 | -3.63 | negative regulation of cholesterol biosynthetic process | biological process | GO:0045541 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | spinal cord motor neuron cell fate specification | biological process | GO:0021520 | 10 | 1 | 18204 | 49 |
GLI3 |
2.660e-02 | -3.63 | nitric oxide-cGMP-mediated signaling | biological process | GO:0038060 | 10 | 1 | 18204 | 49 |
APOE |
2.660e-02 | -3.63 | establishment of centrosome localization | biological process | GO:0051660 | 10 | 1 | 18204 | 49 |
PARD3B |
2.660e-02 | -3.63 | regulation of behavioral fear response | biological process | GO:2000822 | 10 | 1 | 18204 | 49 |
APOE |
2.666e-02 | -3.62 | TGFBR1 (transforming growth factor beta receptor 1) | protein interactions | 7046 | 251 | 3 | 19454 | 50 |
PREX2,CLU,BMPR1B |
2.666e-02 | -3.62 | Ig_sub2 | interpro domains | IPR003598 | 239 | 3 | 18521 | 50 |
LSAMP,FGFR3,NTM |
2.668e-02 | -3.62 | MIR_motif | interpro domains | IPR016093 | 10 | 1 | 18521 | 50 |
RYR3 |
2.668e-02 | -3.62 | MIP_CS | interpro domains | IPR022357 | 10 | 1 | 18521 | 50 |
AQP4 |
2.668e-02 | -3.62 | PAS_fold_3 | interpro domains | IPR013655 | 10 | 1 | 18521 | 50 |
NPAS3 |
2.668e-02 | -3.62 | MIR_dom_sf | interpro domains | IPR036300 | 10 | 1 | 18521 | 50 |
RYR3 |
2.668e-02 | -3.62 | HCO3_transpt-like_TM_dom | interpro domains | IPR011531 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | HCO3_transpt_euk | interpro domains | IPR003020 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | PTrfase/Anion_transptr | interpro domains | IPR016152 | 10 | 1 | 18521 | 50 |
SLC4A4 |
2.668e-02 | -3.62 | Endochondral Ossification | WikiPathways | WP474 | 65 | 2 | 5310 | 21 |
GLI3,FGFR3 |
2.680e-02 | -3.62 | TPP1 (tripeptidyl peptidase 1) | protein interactions | 1200 | 99 | 2 | 19454 | 50 |
PON2,APOE |
2.698e-02 | -3.61 | developmental growth | biological process | GO:0048589 | 424 | 4 | 18204 | 49 |
GLI3,FGFR3,BMPR1B,SLC1A2 |
2.698e-02 | -3.61 | growth | biological process | GO:0040007 | 424 | 4 | 18204 | 49 |
BMPR1B,SLC1A2,GLI3,FGFR3 |
2.720e-02 | -3.60 | skin-mucosal-malignant_melanoma | COSMIC cancer mutations | skin-mucosal-malignant_melanoma | 2009 | 11 | 16828 | 49 |
PCDH9,FGFR3,BMPR1B,COL5A3,ABLIM1,SPARCL1,CTNND2,SORBS1,PREX2,ATP13A4,CPE |
2.720e-02 | -3.60 | mucosal | COSMIC cancer mutations | mucosal | 2009 | 11 | 16828 | 49 |
CTNND2,BMPR1B,SORBS1,COL5A3,PREX2,PCDH9,SPARCL1,FGFR3,ABLIM1,ATP13A4,CPE |
2.725e-02 | -3.60 | GATA_ZN_FINGER_1 | prosite domains | PS00344 | 8 | 1 | 12186 | 42 |
TRPS1 |
2.725e-02 | -3.60 | HP | prosite domains | PS51089 | 8 | 1 | 12186 | 42 |
ABLIM1 |
2.731e-02 | -3.60 | SUFU (SUFU negative regulator of hedgehog signaling) | protein interactions | 51684 | 100 | 2 | 19454 | 50 |
GLI3,GLIS3 |
2.737e-02 | -3.60 | pancreas-other-adenoma | COSMIC cancer mutations | pancreas-other-adenoma | 224 | 3 | 16828 | 49 |
CTNND2,BMPR1B,PCDH9 |
2.758e-02 | -3.59 | monoatomic cation transmembrane transport | biological process | GO:0098655 | 636 | 5 | 18204 | 49 |
GPM6A,RYR3,SLC1A3,SLC4A4,ATP13A4 |
2.767e-02 | -3.59 | cellular component organization | biological process | GO:0016043 | 5636 | 22 | 18204 | 49 |
NFIA,AQP4,PREX2,SLC1A2,BMPR1B,GLI3,SORBS1,RYR3,PARD3B,GPM6A,CTNNA2,ABLIM1,SPARCL1,COL5A3,CLU,CDH20,PTPRZ1,MACF1,CTNND2,APOE,CST3,PITPNC1 |
2.771e-02 | -3.59 | actin binding | molecular function | GO:0003779 | 434 | 4 | 18094 | 48 |
CTNNA2,ABLIM1,SORBS1,MACF1 |
2.775e-02 | -3.58 | PAS_3 | pfam domains | PF08447 | 10 | 1 | 17795 | 50 |
NPAS3 |
2.775e-02 | -3.58 | HCO3_cotransp | pfam domains | PF00955 | 10 | 1 | 17795 | 50 |
SLC4A4 |
2.775e-02 | -3.58 | MIR | pfam domains | PF02815 | 10 | 1 | 17795 | 50 |
RYR3 |
2.776e-02 | -3.58 | DYNLL2 (dynein light chain LC8-type 2) | protein interactions | 140735 | 255 | 3 | 19454 | 50 |
TRPS1,NHSL1,NFIA |
2.780e-02 | -3.58 | signaling | biological process | GO:0023052 | 4968 | 20 | 18204 | 49 |
SLC1A3,MACF1,CTNND2,APOE,PITPNC1,CPE,CLU,ARHGAP24,SPARCL1,RYR3,SORBS1,GLI3,DTNA,MAML2,SLC1A2,BMPR1B,NDRG2,NFIA,FGFR3,PREX2 |
2.781e-02 | -3.58 | CLEC4A (C-type lectin domain family 4 member A) | protein interactions | 50856 | 101 | 2 | 19454 | 50 |
FGFR3,CTNNA2 |
2.786e-02 | -3.58 | perisynaptic extracellular matrix | cellular component | GO:0098966 | 11 | 1 | 19108 | 49 |
PTPRZ1 |
2.792e-02 | -3.58 | CCDC17 (coiled-coil domain containing 17) | protein interactions | 149483 | 11 | 1 | 19454 | 50 |
FGFR3 |
2.792e-02 | -3.58 | MSRB1 (methionine sulfoxide reductase B1) | protein interactions | 51734 | 11 | 1 | 19454 | 50 |
CLU |
2.792e-02 | -3.58 | SYN3 (synapsin III) | protein interactions | 8224 | 11 | 1 | 19454 | 50 |
GPM6A |
2.792e-02 | -3.58 | NTS (neurotensin) | protein interactions | 4922 | 11 | 1 | 19454 | 50 |
CPE |
2.792e-02 | -3.58 | IL7 (interleukin 7) | protein interactions | 3574 | 11 | 1 | 19454 | 50 |
QKI |
2.792e-02 | -3.58 | Batf3 (basic leucine zipper transcription factor, ATF-like 3) | protein interactions | 381319 | 11 | 1 | 19454 | 50 |
MACF1 |
2.792e-02 | -3.58 | Gtf2e2 (general transcription factor II E, polypeptide 2 (beta subunit)) | protein interactions | 68153 | 11 | 1 | 19454 | 50 |
NHSL1 |
2.792e-02 | -3.58 | DAZ1 (deleted in azoospermia 1) | protein interactions | 1617 | 11 | 1 | 19454 | 50 |
QKI |
2.792e-02 | -3.58 | Wipi2 (WD repeat domain, phosphoinositide interacting 2) | protein interactions | 74781 | 11 | 1 | 19454 | 50 |
MACF1 |
2.792e-02 | -3.58 | Cobll1 (Cobl-like 1) | protein interactions | 319876 | 11 | 1 | 19454 | 50 |
ABLIM1 |
2.792e-02 | -3.58 | PTGDR (prostaglandin D2 receptor) | protein interactions | 5729 | 11 | 1 | 19454 | 50 |
PTGDS |
2.792e-02 | -3.58 | ZNF726 (zinc finger protein 726) | protein interactions | 730087 | 11 | 1 | 19454 | 50 |
ARHGAP24 |
2.810e-02 | -3.57 | nerve development | biological process | GO:0021675 | 97 | 2 | 18204 | 49 |
GLI3,SLC1A3 |
2.810e-02 | -3.57 | amino acid transmembrane transport | biological process | GO:0003333 | 97 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
2.832e-02 | -3.56 | human chr8q12.3 | chromosome location | human chr8q12.3 | 15 | 1 | 26134 | 50 |
NKAIN3 |
2.832e-02 | -3.56 | MIR7-1 (microRNA 7-1) | protein interactions | 407043 | 102 | 2 | 19454 | 50 |
MSI2,QKI |
2.832e-02 | -3.56 | KRTAP6-1 (keratin associated protein 6-1) | protein interactions | 337966 | 102 | 2 | 19454 | 50 |
MEIS2,GLIS3 |
2.832e-02 | -3.56 | TMPRSS13 (transmembrane serine protease 13) | protein interactions | 84000 | 102 | 2 | 19454 | 50 |
SPON1,CPE |
2.842e-02 | -3.56 | SFN (stratifin) | protein interactions | 2810 | 671 | 5 | 19454 | 50 |
ABLIM1,MACF1,NFIA,SORBS1,PARD3B |
2.842e-02 | -3.56 | trans-synaptic signaling | biological process | GO:0099537 | 431 | 4 | 18204 | 49 |
DTNA,SLC1A3,SLC1A2,APOE |
2.846e-02 | -3.56 | VHP | smart domains | SM00153 | 8 | 1 | 9717 | 35 |
ABLIM1 |
2.847e-02 | -3.56 | regulation of synapse organization | biological process | GO:0050807 | 246 | 3 | 18204 | 49 |
GPM6A,APOE,CTNNA2 |
2.875e-02 | -3.55 | kidney-carcinoma-renal_cell_carcinoma_unclassified | COSMIC cancer mutations | kidney-carcinoma-renal_cell_carcinoma_unclassified | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | chiasm | COSMIC cancer mutations | chiasm | 10 | 1 | 16828 | 49 |
QKI |
2.875e-02 | -3.55 | cervical_intraepithelial_neoplasia_Grade_III | COSMIC cancer mutations | cervical_intraepithelial_neoplasia_Grade_III | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | lung-carcinoma-pleomorphic_carcinoma | COSMIC cancer mutations | lung-carcinoma-pleomorphic_carcinoma | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_III | COSMIC cancer mutations | cervix-in_situ_neoplasm-cervical_intraepithelial_neoplasia_Grade_III | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | renal_cell_carcinoma_unclassified | COSMIC cancer mutations | renal_cell_carcinoma_unclassified | 10 | 1 | 16828 | 49 |
FGFR3 |
2.875e-02 | -3.55 | skin-back-malignant_melanoma-nodular | COSMIC cancer mutations | skin-back-malignant_melanoma-nodular | 10 | 1 | 16828 | 49 |
PREX2 |
2.875e-02 | -3.55 | intradermal | COSMIC cancer mutations | intradermal | 10 | 1 | 16828 | 49 |
FGFR3 |
2.879e-02 | -3.55 | FLOT1 (flotillin 1) | protein interactions | 10211 | 453 | 4 | 19454 | 50 |
SORBS1,DTNA,ABLIM1,MACF1 |
2.880e-02 | -3.55 | Bicarbonate transporters | REACTOME pathways | R-HSA-425381 | 10 | 1 | 10285 | 30 |
SLC4A4 |
2.880e-02 | -3.55 | Signaling by FGFR3 fusions in cancer | REACTOME pathways | R-HSA-8853334 | 10 | 1 | 10285 | 30 |
FGFR3 |
2.880e-02 | -3.55 | sulfur amino acid transmembrane transporter activity | molecular function | GO:0000099 | 11 | 1 | 18094 | 48 |
SLC1A2 |
2.884e-02 | -3.55 | RAB6B (RAB6B, member RAS oncogene family) | protein interactions | 51560 | 103 | 2 | 19454 | 50 |
GPM6A,BMPR1B |
2.885e-02 | -3.55 | inorganic ion homeostasis | biological process | GO:0098771 | 433 | 4 | 18204 | 49 |
RYR3,APOE,SLC1A3,ATP13A4 |
2.893e-02 | -3.54 | amino acid transmembrane transporter activity | molecular function | GO:0015171 | 100 | 2 | 18094 | 48 |
SLC1A3,SLC1A2 |
2.917e-02 | -3.53 | phospholipid transport | biological process | GO:0015914 | 99 | 2 | 18204 | 49 |
APOE,PITPNC1 |
2.922e-02 | -3.53 | regulation of fear response | biological process | GO:1903365 | 11 | 1 | 18204 | 49 |
APOE |
2.922e-02 | -3.53 | cell fate commitment involved in pattern specification | biological process | GO:0060581 | 11 | 1 | 18204 | 49 |
GLI3 |
2.922e-02 | -3.53 | antral ovarian follicle growth | biological process | GO:0001547 | 11 | 1 | 18204 | 49 |
BMPR1B |
2.922e-02 | -3.53 | thymocyte apoptotic process | biological process | GO:0070242 | 11 | 1 | 18204 | 49 |
GLI3 |
2.922e-02 | -3.53 | regulation of receptor catabolic process | biological process | GO:2000644 | 11 | 1 | 18204 | 49 |
APOE |
2.922e-02 | -3.53 | intracellular mRNA localization | biological process | GO:0008298 | 11 | 1 | 18204 | 49 |
QKI |
2.922e-02 | -3.53 | cellular response to caffeine | biological process | GO:0071313 | 11 | 1 | 18204 | 49 |
RYR3 |
2.922e-02 | -3.53 | ventral spinal cord interneuron fate commitment | biological process | GO:0060579 | 11 | 1 | 18204 | 49 |
GLI3 |
2.922e-02 | -3.53 | polyamine transport | biological process | GO:0015846 | 11 | 1 | 18204 | 49 |
ATP13A4 |
2.922e-02 | -3.53 | negative regulation of cholesterol metabolic process | biological process | GO:0090206 | 11 | 1 | 18204 | 49 |
APOE |
2.927e-02 | -3.53 | Post-translational modification: synthesis of GPI-anchored proteins | REACTOME pathways | R-HSA-163125 | 92 | 2 | 10285 | 30 |
NTM,LSAMP |
2.931e-02 | -3.53 | Fib_collagen_C | interpro domains | IPR000885 | 11 | 1 | 18521 | 50 |
COL5A3 |
2.936e-02 | -3.53 | MFHAS1 (multifunctional ROCO family signaling regulator 1) | protein interactions | 9258 | 104 | 2 | 19454 | 50 |
ARHGAP24,ABLIM1 |
2.975e-02 | -3.52 | amide binding | molecular function | GO:0033218 | 254 | 3 | 18094 | 48 |
CST3,APOE,CLU |
2.979e-02 | -3.51 | active transmembrane transporter activity | molecular function | GO:0022804 | 444 | 4 | 18094 | 48 |
SLC1A2,SLC1A3,SLC4A4,ATP13A4 |
2.988e-02 | -3.51 | ABCA2 (ATP binding cassette subfamily A member 2) | protein interactions | 20 | 105 | 2 | 19454 | 50 |
FGFR3,PON2 |
3.000e-02 | -3.51 | Helical hairpin bin | gene3d domains | 1.10.287.570 | 10 | 1 | 14470 | 44 |
SLC4A4 |
3.022e-02 | -3.50 | GATAZNFINGER | prints domains | PR00619 | 8 | 1 | 5227 | 20 |
TRPS1 |
3.022e-02 | -3.50 | LIPOCALIN | prints domains | PR00179 | 8 | 1 | 5227 | 20 |
PTGDS |
3.027e-02 | -3.50 | regulation of synapse structure or activity | biological process | GO:0050803 | 252 | 3 | 18204 | 49 |
CTNNA2,APOE,GPM6A |
3.030e-02 | -3.50 | cell communication | biological process | GO:0007154 | 5010 | 20 | 18204 | 49 |
PREX2,NDRG2,FGFR3,NFIA,MAML2,BMPR1B,SLC1A2,DTNA,GLI3,SPARCL1,RYR3,SORBS1,CLU,ARHGAP24,CPE,SLC1A3,APOE,PITPNC1,CTNND2,MACF1 |
3.035e-02 | -3.49 | synapse-associated extracellular matrix | cellular component | GO:0099535 | 12 | 1 | 19108 | 49 |
PTPRZ1 |
3.035e-02 | -3.49 | banded collagen fibril | cellular component | GO:0098643 | 12 | 1 | 19108 | 49 |
COL5A3 |
3.035e-02 | -3.49 | fibrillar collagen trimer | cellular component | GO:0005583 | 12 | 1 | 19108 | 49 |
COL5A3 |
3.040e-02 | -3.49 | USP30 (ubiquitin specific peptidase 30) | protein interactions | 84749 | 106 | 2 | 19454 | 50 |
FGFR3,QKI |
3.042e-02 | -3.49 | UGT1A9 (UDP glucuronosyltransferase family 1 member A9) | protein interactions | 54600 | 12 | 1 | 19454 | 50 |
PON2 |
3.042e-02 | -3.49 | ZNF235 (zinc finger protein 235) | protein interactions | 9310 | 12 | 1 | 19454 | 50 |
ARHGAP24 |
3.042e-02 | -3.49 | MMP25 (matrix metallopeptidase 25) | protein interactions | 64386 | 12 | 1 | 19454 | 50 |
CLU |
3.042e-02 | -3.49 | BAMBI (BMP and activin membrane bound inhibitor) | protein interactions | 25805 | 12 | 1 | 19454 | 50 |
BMPR1B |
3.042e-02 | -3.49 | LOC102724560 (cystathionine beta-synthase like) | protein interactions | 102724560 | 12 | 1 | 19454 | 50 |
ARHGAP24 |
3.042e-02 | -3.49 | FAM222A (family with sequence similarity 222 member A) | protein interactions | 84915 | 12 | 1 | 19454 | 50 |
MEIS2 |
3.042e-02 | -3.49 | CA4 (carbonic anhydrase 4) | protein interactions | 762 | 12 | 1 | 19454 | 50 |
SLC4A4 |
3.042e-02 | -3.49 | ART4 (ADP-ribosyltransferase 4 (inactive) (Dombrock blood group)) | protein interactions | 420 | 12 | 1 | 19454 | 50 |
GPM6A |
3.042e-02 | -3.49 | PROK2 (prokineticin 2) | protein interactions | 60675 | 12 | 1 | 19454 | 50 |
CPE |
3.042e-02 | -3.49 | ZNF91 (zinc finger protein 91) | protein interactions | 7644 | 12 | 1 | 19454 | 50 |
ARHGAP24 |
3.042e-02 | -3.49 | upper_aerodigestive_tract | COSMIC cancer mutations | upper_aerodigestive_tract | 13181 | 44 | 16828 | 49 |
LSAMP,RYR3,SLC1A2,BMPR1B,PTGDS,NHSL1,PAMR1,MSI2,GPM6A,SORBS1,NFIA,TRPS1,MAML2,CLU,ABLIM1,COL5A3,FBXL7,ACSS1,CST3,NPAS3,QKI,ATP13A4,SLC4A4,NTM,CTNND2,GPC5,MACF1,PITPNC1,GLIS3,PTPRZ1,NDRG2,SPON1,SLC1A3,ARHGAP24,CDH20,PREX2,PARD3B,DTNA,APOE,GLI3,FGFR3,PCDH9,NKAIN3,AMZ2 |
3.049e-02 | -3.49 | COLFI | pfam domains | PF01410 | 11 | 1 | 17795 | 50 |
COL5A3 |
3.060e-02 | -3.49 | CYSTATIN | prosite domains | PS00287 | 9 | 1 | 12186 | 42 |
CST3 |
3.066e-02 | -3.48 | Salivary secretion | KEGG pathways | hsa04970 | 90 | 2 | 7161 | 22 |
CST3,RYR3 |
3.066e-02 | -3.48 | Salivary secretion | KEGG pathways | ko04970 | 90 | 2 | 7161 | 22 |
RYR3,CST3 |
3.082e-02 | -3.48 | artery development | biological process | GO:0060840 | 102 | 2 | 18204 | 49 |
APOE,GLI3 |
3.092e-02 | -3.48 | POMK (protein O-mannose kinase) | protein interactions | 84197 | 266 | 3 | 19454 | 50 |
CLU,PON2,BMPR1B |
3.095e-02 | -3.48 | peptide binding | molecular function | GO:0042277 | 258 | 3 | 18094 | 48 |
CLU,APOE,CST3 |
3.122e-02 | -3.47 | cellular response to endogenous stimulus | biological process | GO:0071495 | 1135 | 7 | 18204 | 49 |
BMPR1B,SLC1A2,FGFR3,NFIA,RYR3,SORBS1,SLC1A3 |
3.122e-02 | -3.47 | Phase I biotransformations, non P450 | WikiPathways | WP136 | 8 | 1 | 5310 | 21 |
PON2 |
3.138e-02 | -3.46 | regulation of neural precursor cell proliferation | biological process | GO:2000177 | 103 | 2 | 18204 | 49 |
GLI3,PTPRZ1 |
3.147e-02 | -3.46 | BIN1 (bridging integrator 1) | protein interactions | 274 | 108 | 2 | 19454 | 50 |
GPM6A,CLU |
3.147e-02 | -3.46 | FKBP1A (FKBP prolyl isomerase 1A) | protein interactions | 2280 | 108 | 2 | 19454 | 50 |
RYR3,MSI2 |
3.147e-02 | -3.46 | EN1 (engrailed homeobox 1) | protein interactions | 2019 | 108 | 2 | 19454 | 50 |
NFIA,TRPS1 |
3.147e-02 | -3.46 | GGT7 (gamma-glutamyltransferase 7) | protein interactions | 2686 | 108 | 2 | 19454 | 50 |
ARHGAP24,NDRG2 |
3.147e-02 | -3.46 | PAX8 (paired box 8) | protein interactions | 7849 | 108 | 2 | 19454 | 50 |
TRPS1,NFIA |
3.149e-02 | -3.46 | PFN1 (profilin 1) | protein interactions | 5216 | 466 | 4 | 19454 | 50 |
NHSL1,ABLIM1,ARHGAP24,MACF1 |
3.151e-02 | -3.46 | VCL (vinculin) | protein interactions | 7414 | 268 | 3 | 19454 | 50 |
ARHGAP24,MACF1,SORBS1 |
3.151e-02 | -3.46 | protein complex oligomerization | biological process | GO:0051259 | 256 | 3 | 18204 | 49 |
AQP4,SLC1A2,RYR3 |
3.158e-02 | -3.46 | skin-hand-malignant_melanoma-acral_lentiginous | COSMIC cancer mutations | skin-hand-malignant_melanoma-acral_lentiginous | 11 | 1 | 16828 | 49 |
PREX2 |
3.158e-02 | -3.46 | congenital | COSMIC cancer mutations | congenital | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | pleomorphic_carcinoma | COSMIC cancer mutations | pleomorphic_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | oncocytoma | COSMIC cancer mutations | oncocytoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | skin-neck-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-neck-carcinoma-basal_cell_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | kidney-other-oncocytoma | COSMIC cancer mutations | kidney-other-oncocytoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | prostate-hyperplasia | COSMIC cancer mutations | prostate-hyperplasia | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | skin-back-malignant_melanoma-superficial_spreading | COSMIC cancer mutations | skin-back-malignant_melanoma-superficial_spreading | 11 | 1 | 16828 | 49 |
PREX2 |
3.158e-02 | -3.46 | skin-scalp-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-basal_cell_carcinoma | 11 | 1 | 16828 | 49 |
FGFR3 |
3.158e-02 | -3.46 | seborrhoeic_keratosis | COSMIC cancer mutations | seborrhoeic_keratosis | 11 | 1 | 16828 | 49 |
FGFR3 |
3.184e-02 | -3.45 | neurotransmitter-gated ion channel clustering | biological process | GO:0072578 | 12 | 1 | 18204 | 49 |
APOE |
3.184e-02 | -3.45 | negative thymic T cell selection | biological process | GO:0045060 | 12 | 1 | 18204 | 49 |
GLI3 |
3.184e-02 | -3.45 | microglia differentiation | biological process | GO:0014004 | 12 | 1 | 18204 | 49 |
QKI |
3.184e-02 | -3.45 | negative regulation of collagen metabolic process | biological process | GO:0010713 | 12 | 1 | 18204 | 49 |
CST3 |
3.184e-02 | -3.45 | auditory behavior | biological process | GO:0031223 | 12 | 1 | 18204 | 49 |
SLC1A3 |
3.184e-02 | -3.45 | sulfur amino acid transport | biological process | GO:0000101 | 12 | 1 | 18204 | 49 |
SLC1A2 |
3.184e-02 | -3.45 | positive regulation of extrinsic apoptotic signaling pathway via death domain receptors | biological process | GO:1902043 | 12 | 1 | 18204 | 49 |
BMPR1B |
3.184e-02 | -3.45 | mammalian oogenesis stage | biological process | GO:0022605 | 12 | 1 | 18204 | 49 |
BMPR1B |
3.184e-02 | -3.45 | regulation of blood vessel remodeling | biological process | GO:0060312 | 12 | 1 | 18204 | 49 |
CST3 |
3.193e-02 | -3.44 | Lipocalin | interpro domains | IPR002345 | 12 | 1 | 18521 | 50 |
PTGDS |
3.193e-02 | -3.44 | MAD_homology1_Dwarfin-type | interpro domains | IPR003619 | 12 | 1 | 18521 | 50 |
NFIA |
3.193e-02 | -3.44 | Lipocalin_CS | interpro domains | IPR022272 | 12 | 1 | 18521 | 50 |
PTGDS |
3.193e-02 | -3.44 | TGFB_receptor | interpro domains | IPR000333 | 12 | 1 | 18521 | 50 |
BMPR1B |
3.197e-02 | -3.44 | FOLN | smart domains | SM00274 | 9 | 1 | 9717 | 35 |
SPARCL1 |
3.200e-02 | -3.44 | MIR34B (microRNA 34b) | protein interactions | 407041 | 109 | 2 | 19454 | 50 |
MSI2,QKI |
3.213e-02 | -3.44 | ATXN1 (ataxin 1) | protein interactions | 6310 | 469 | 4 | 19454 | 50 |
PTGDS,QKI,NFIA,CST3 |
3.251e-02 | -3.43 | neural precursor cell proliferation | biological process | GO:0061351 | 105 | 2 | 18204 | 49 |
GLI3,NFIA |
3.254e-02 | -3.43 | SCARB1 (scavenger receptor class B member 1) | protein interactions | 949 | 110 | 2 | 19454 | 50 |
PON2,APOE |
3.254e-02 | -3.43 | LZTR1 (leucine zipper like post translational regulator 1) | protein interactions | 8216 | 110 | 2 | 19454 | 50 |
PARD3B,BMPR1B |
3.275e-02 | -3.42 | regulation of plasma membrane bounded cell projection organization | biological process | GO:0120035 | 666 | 5 | 18204 | 49 |
ARHGAP24,GPM6A,APOE,MACF1,CTNNA2 |
3.276e-02 | -3.42 | prostate-carcinoma-adenocarcinoma | COSMIC cancer mutations | prostate-carcinoma-adenocarcinoma | 12379 | 42 | 16828 | 49 |
SLC1A3,SPON1,NDRG2,PTPRZ1,BMPR1B,GLIS3,PITPNC1,MACF1,SPARCL1,GPC5,SLC1A2,CTNND2,RYR3,LSAMP,NTM,CPE,ATP13A4,AQP4,QKI,NPAS3,MEIS2,NKAIN3,PCDH9,GLI3,FGFR3,FBXL7,ACSS1,COL5A3,CLU,ABLIM1,PON2,MAML2,TRPS1,NFIA,PARD3B,SORBS1,GPM6A,PREX2,CDH20,PAMR1,NHSL1,ARHGAP24 |
3.281e-02 | -3.42 | distal axon | cellular component | GO:0150034 | 273 | 3 | 19108 | 49 |
NDRG2,PCDH9,GPM6A |
3.284e-02 | -3.42 | chylomicron | cellular component | GO:0042627 | 13 | 1 | 19108 | 49 |
APOE |
3.291e-02 | -3.41 | ANKH (ANKH inorganic pyrophosphate transport regulator) | protein interactions | 56172 | 13 | 1 | 19454 | 50 |
APOE |
3.291e-02 | -3.41 | RAB3C (RAB3C, member RAS oncogene family) | protein interactions | 115827 | 13 | 1 | 19454 | 50 |
GPM6A |
3.291e-02 | -3.41 | ST3GAL5 (ST3 beta-galactoside alpha-2,3-sialyltransferase 5) | protein interactions | 8869 | 13 | 1 | 19454 | 50 |
PON2 |
3.291e-02 | -3.41 | Pias1 (protein inhibitor of activated STAT 1) | protein interactions | 56469 | 13 | 1 | 19454 | 50 |
GLI3 |
3.291e-02 | -3.41 | TBCC (tubulin folding cofactor C) | protein interactions | 6903 | 13 | 1 | 19454 | 50 |
NTM |
3.291e-02 | -3.41 | MAB21L1 (mab-21 like 1) | protein interactions | 4081 | 13 | 1 | 19454 | 50 |
MEIS2 |
3.291e-02 | -3.41 | Rbm47 (RNA binding motif protein 47) | protein interactions | 245945 | 13 | 1 | 19454 | 50 |
QKI |
3.291e-02 | -3.41 | CCN5 (cellular communication network factor 5) | protein interactions | 8839 | 13 | 1 | 19454 | 50 |
AMZ2 |
3.291e-02 | -3.41 | ZNF718 (zinc finger protein 718) | protein interactions | 255403 | 13 | 1 | 19454 | 50 |
ARHGAP24 |
3.291e-02 | -3.41 | PCDHA2 (protocadherin alpha 2) | protein interactions | 56146 | 13 | 1 | 19454 | 50 |
NFIA |
3.296e-02 | -3.41 | Carboxypeptidase-like, regulatory domain | gene3d domains | 2.60.40.1120 | 11 | 1 | 14470 | 44 |
CPE |
3.302e-02 | -3.41 | endoplasmic reticulum | cellular component | GO:0005783 | 2051 | 10 | 19108 | 49 |
SPON1,ATP13A4,COL5A3,CLU,CST3,RYR3,SPARCL1,PTGDS,APOE,FGFR3 |
3.307e-02 | -3.41 | pigmentation | biological process | GO:0043473 | 106 | 2 | 18204 | 49 |
GLI3,APOE |
3.309e-02 | -3.41 | cell-cell adhesion via plasma-membrane adhesion molecules | biological process | GO:0098742 | 261 | 3 | 18204 | 49 |
PCDH9,CDH20,SPARCL1 |
3.321e-02 | -3.40 | CarboxypepD_reg | pfam domains | PF13620 | 12 | 1 | 17795 | 50 |
CPE |
3.321e-02 | -3.40 | MH1 | pfam domains | PF03165 | 12 | 1 | 17795 | 50 |
NFIA |
3.330e-02 | -3.40 | Hedgehog signaling | KEGG pathways | hsa_M00678 | 11 | 1 | 7161 | 22 |
GLI3 |
3.330e-02 | -3.40 | Hedgehog signaling | KEGG pathways | M00678 | 11 | 1 | 7161 | 22 |
GLI3 |
3.363e-02 | -3.39 | TBR1 (T-box brain transcription factor 1) | protein interactions | 10716 | 112 | 2 | 19454 | 50 |
NFIA,TRPS1 |
3.363e-02 | -3.39 | TSC22D4 (TSC22 domain family member 4) | protein interactions | 81628 | 112 | 2 | 19454 | 50 |
ABLIM1,CLU |
3.363e-02 | -3.39 | CEP170P1 (centrosomal protein 170 pseudogene 1) | protein interactions | 645455 | 112 | 2 | 19454 | 50 |
TRPS1,MACF1 |
3.387e-02 | -3.39 | skin-arm-malignant_melanoma | COSMIC cancer mutations | skin-arm-malignant_melanoma | 1308 | 8 | 16828 | 49 |
SORBS1,COL5A3,TRPS1,PARD3B,SLC4A4,MACF1,NPAS3,NTM |
3.389e-02 | -3.38 | human chr7q31.32 | chromosome location | human chr7q31.32 | 18 | 1 | 26134 | 50 |
PTPRZ1 |
3.389e-02 | -3.38 | human chr18q21.33 | chromosome location | human chr18q21.33 | 18 | 1 | 26134 | 50 |
CDH20 |
3.394e-02 | -3.38 | NAKATPASE | prints domains | PR00121 | 9 | 1 | 5227 | 20 |
ATP13A4 |
3.395e-02 | -3.38 | MIP | prosite domains | PS00221 | 10 | 1 | 12186 | 42 |
AQP4 |
3.395e-02 | -3.38 | MIR | prosite domains | PS50919 | 10 | 1 | 12186 | 42 |
RYR3 |
3.395e-02 | -3.38 | transforming growth factor beta receptor activity | molecular function | GO:0005024 | 13 | 1 | 18094 | 48 |
BMPR1B |
3.395e-02 | -3.38 | monoatomic cation:bicarbonate symporter activity | molecular function | GO:0140410 | 13 | 1 | 18094 | 48 |
SLC4A4 |
3.396e-02 | -3.38 | regulation of nervous system development | biological process | GO:0051960 | 456 | 4 | 18204 | 49 |
MACF1,GLI3,PTPRZ1,QKI |
3.400e-02 | -3.38 | calcium ion binding | molecular function | GO:0005509 | 683 | 5 | 18094 | 48 |
MACF1,RYR3,PAMR1,PCDH9,SPARCL1 |
3.405e-02 | -3.38 | NR3C1 (nuclear receptor subfamily 3 group C member 1) | protein interactions | 2908 | 950 | 6 | 19454 | 50 |
PON2,ATP13A4,NFIA,TRPS1,SLC1A3,CTNND2 |
3.408e-02 | -3.38 | organic anion transmembrane transporter activity | molecular function | GO:0008514 | 268 | 3 | 18094 | 48 |
SLC1A2,SLC1A3,SLC4A4 |
3.440e-02 | -3.37 | skin-face-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-face-carcinoma-basal_cell_carcinoma | 12 | 1 | 16828 | 49 |
FGFR3 |
3.440e-02 | -3.37 | skin-benign_melanocytic_nevus | COSMIC cancer mutations | skin-benign_melanocytic_nevus | 12 | 1 | 16828 | 49 |
FGFR3 |
3.440e-02 | -3.37 | cervix-carcinoma-mixed_adenosquamous_carcinoma | COSMIC cancer mutations | cervix-carcinoma-mixed_adenosquamous_carcinoma | 12 | 1 | 16828 | 49 |
FGFR3 |
3.440e-02 | -3.37 | central_nervous_system-fourth_ventricle-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-fourth_ventricle-glioma-astrocytoma_Grade_I | 12 | 1 | 16828 | 49 |
QKI |
3.440e-02 | -3.37 | skin-abdomen-malignant_melanoma-nodular | COSMIC cancer mutations | skin-abdomen-malignant_melanoma-nodular | 12 | 1 | 16828 | 49 |
PREX2 |
3.443e-02 | -3.37 | positive regulation of cell development | biological process | GO:0010720 | 458 | 4 | 18204 | 49 |
GLI3,PTPRZ1,QKI,MACF1 |
3.444e-02 | -3.37 | ventral spinal cord interneuron differentiation | biological process | GO:0021514 | 13 | 1 | 18204 | 49 |
GLI3 |
3.444e-02 | -3.37 | prepulse inhibition | biological process | GO:0060134 | 13 | 1 | 18204 | 49 |
CTNNA2 |
3.444e-02 | -3.37 | negative T cell selection | biological process | GO:0043383 | 13 | 1 | 18204 | 49 |
GLI3 |
3.444e-02 | -3.37 | regulation of dendritic spine maintenance | biological process | GO:1902950 | 13 | 1 | 18204 | 49 |
APOE |
3.444e-02 | -3.37 | glial cell fate commitment | biological process | GO:0021781 | 13 | 1 | 18204 | 49 |
NFIA |
3.444e-02 | -3.37 | phospholipid efflux | biological process | GO:0033700 | 13 | 1 | 18204 | 49 |
APOE |
3.446e-02 | -3.37 | FGFR3 mutant receptor activation | REACTOME pathways | R-HSA-2033514 | 12 | 1 | 10285 | 30 |
FGFR3 |
3.446e-02 | -3.37 | Signaling by activated point mutants of FGFR3 | REACTOME pathways | R-HSA-1839130 | 12 | 1 | 10285 | 30 |
FGFR3 |
3.446e-02 | -3.37 | Defective EXT2 causes exostoses 2 | REACTOME pathways | R-HSA-3656237 | 12 | 1 | 10285 | 30 |
GPC5 |
3.446e-02 | -3.37 | Defective EXT1 causes exostoses 1, TRPS2 and CHDS | REACTOME pathways | R-HSA-3656253 | 12 | 1 | 10285 | 30 |
GPC5 |
3.446e-02 | -3.37 | Ethanol oxidation | REACTOME pathways | R-HSA-71384 | 12 | 1 | 10285 | 30 |
ACSS1 |
3.456e-02 | -3.37 | animal organ development | biological process | GO:0048513 | 2846 | 13 | 18204 | 49 |
CPE,COL5A3,GPM6A,MEIS2,CTNNA2,ABLIM1,PCDH9,GLI3,BMPR1B,SLC1A2,NFIA,FGFR3,NDRG2 |
3.459e-02 | -3.36 | small molecule binding | molecular function | GO:0036094 | 6197 | 23 | 18094 | 48 |
PTGDS,SLC1A3,SPARCL1,ATP13A4,RYR3,PON2,BMPR1B,GLI3,MACF1,SPON1,PITPNC1,APOE,TRPS1,DTNA,PAMR1,ACSS1,CPE,FGFR3,PCDH9,ABLIM1,SLC1A2,AMZ2,GLIS3 |
3.466e-02 | -3.36 | synaptic signaling | biological process | GO:0099536 | 459 | 4 | 18204 | 49 |
SLC1A2,APOE,SLC1A3,DTNA |
3.466e-02 | -3.36 | small molecule biosynthetic process | biological process | GO:0044283 | 459 | 4 | 18204 | 49 |
PTGDS,SLC1A3,ACSS1,QKI |
3.474e-02 | -3.36 | ORF3b (ORF3b protein) | protein interactions | 1489670 | 114 | 2 | 19454 | 50 |
PCDH9,MACF1 |
3.475e-02 | -3.36 | Visual phototransduction | REACTOME pathways | R-HSA-2187338 | 101 | 2 | 10285 | 30 |
GPC5,APOE |
3.481e-02 | -3.36 | postsynapse organization | biological process | GO:0099173 | 109 | 2 | 18204 | 49 |
CTNND2,APOE |
3.481e-02 | -3.36 | long-chain fatty acid metabolic process | biological process | GO:0001676 | 109 | 2 | 18204 | 49 |
QKI,PTGDS |
3.481e-02 | -3.36 | Disease | REACTOME pathways | R-HSA-1643685 | 858 | 6 | 10285 | 30 |
MAML2,FGFR3,MACF1,SPON1,QKI,GPC5 |
3.500e-02 | -3.35 | Cadherin_CS | interpro domains | IPR020894 | 109 | 2 | 18521 | 50 |
PCDH9,CDH20 |
3.506e-02 | -3.35 | chemical homeostasis | biological process | GO:0048878 | 914 | 6 | 18204 | 49 |
AQP4,SLC4A4,ATP13A4,SLC1A3,APOE,RYR3 |
3.506e-02 | -3.35 | Tgif disruption of Shh signaling | WikiPathways | WP3674 | 9 | 1 | 5310 | 21 |
GLI3 |
3.530e-02 | -3.34 | SULF2 (sulfatase 2) | protein interactions | 55959 | 115 | 2 | 19454 | 50 |
SPON1,PON2 |
3.530e-02 | -3.34 | TBXT (T-box transcription factor T) | protein interactions | 6862 | 115 | 2 | 19454 | 50 |
TRPS1,NFIA |
3.532e-02 | -3.34 | chromaffin granule | cellular component | GO:0042583 | 14 | 1 | 19108 | 49 |
CLU |
3.540e-02 | -3.34 | Stag2 (STAG2 cohesin complex component) | protein interactions | 20843 | 14 | 1 | 19454 | 50 |
CLU |
3.540e-02 | -3.34 | RHEBL1 (RHEB like 1) | protein interactions | 121268 | 14 | 1 | 19454 | 50 |
BMPR1B |
3.540e-02 | -3.34 | FGF7 (fibroblast growth factor 7) | protein interactions | 2252 | 14 | 1 | 19454 | 50 |
FGFR3 |
3.540e-02 | -3.34 | Aifm1 (apoptosis-inducing factor, mitochondrion-associated 1) | protein interactions | 26926 | 14 | 1 | 19454 | 50 |
CLU |
3.540e-02 | -3.34 | KRTAP22-1 (keratin associated protein 22-1) | protein interactions | 337979 | 14 | 1 | 19454 | 50 |
MEIS2 |
3.540e-02 | -3.34 | SLC1A2 (solute carrier family 1 member 2) | protein interactions | 6506 | 14 | 1 | 19454 | 50 |
SLC1A2 |
3.540e-02 | -3.34 | MB (myoglobin) | protein interactions | 4151 | 14 | 1 | 19454 | 50 |
MAML2 |
3.540e-02 | -3.34 | Asap1 (ArfGAP with SH3 domain, ankyrin repeat and PH domain1) | protein interactions | 13196 | 14 | 1 | 19454 | 50 |
MACF1 |
3.540e-02 | -3.34 | IFNA8 (interferon alpha 8) | protein interactions | 3445 | 14 | 1 | 19454 | 50 |
APOE |
3.540e-02 | -3.34 | Nedd4 (neural precursor cell expressed, developmentally down-regulated 4) | protein interactions | 17999 | 14 | 1 | 19454 | 50 |
GLIS3 |
3.546e-02 | -3.34 | MIR | smart domains | SM00472 | 10 | 1 | 9717 | 35 |
RYR3 |
3.558e-02 | -3.34 | LYN (LYN proto-oncogene, Src family tyrosine kinase) | protein interactions | 4067 | 713 | 5 | 19454 | 50 |
ABLIM1,MACF1,DTNA,MSI2,SLC1A3 |
3.559e-02 | -3.34 | side of membrane | cellular component | GO:0098552 | 715 | 5 | 19108 | 49 |
AQP4,LSAMP,DTNA,GPC5,NTM |
3.570e-02 | -3.33 | blood microparticle | cellular component | GO:0072562 | 116 | 2 | 19108 | 49 |
CLU,APOE |
3.573e-02 | -3.33 | positive regulation of cellular metabolic process | biological process | GO:0031325 | 3164 | 14 | 18204 | 49 |
MEIS2,SORBS1,NPAS3,GLI3,SPON1,BMPR1B,MAML2,GLIS3,SLC4A4,FGFR3,NFIA,QKI,APOE,CLU |
3.574e-02 | -3.33 | human chr6q24.1 | chromosome location | human chr6q24.1 | 19 | 1 | 26134 | 50 |
NHSL1 |
3.574e-02 | -3.33 | human chr5p15.2 | chromosome location | human chr5p15.2 | 19 | 1 | 26134 | 50 |
CTNND2 |
3.574e-02 | -3.33 | human chr11q25 | chromosome location | human chr11q25 | 19 | 1 | 26134 | 50 |
NTM |
3.586e-02 | -3.33 | RBBP8 (RB binding protein 8, endonuclease) | protein interactions | 5932 | 116 | 2 | 19454 | 50 |
CLU,CTNNA2 |
3.586e-02 | -3.33 | SKIL (SKI like proto-oncogene) | protein interactions | 6498 | 116 | 2 | 19454 | 50 |
SPARCL1,MACF1 |
3.590e-02 | -3.33 | Alpha-catenin/vinculin-like | gene3d domains | 1.20.120.230 | 12 | 1 | 14470 | 44 |
CTNNA2 |
3.593e-02 | -3.33 | regulation of cell projection organization | biological process | GO:0031344 | 683 | 5 | 18204 | 49 |
ARHGAP24,CTNNA2,GPM6A,APOE,MACF1 |
3.593e-02 | -3.33 | skin-upper_leg-malignant_melanoma | COSMIC cancer mutations | skin-upper_leg-malignant_melanoma | 850 | 6 | 16828 | 49 |
PREX2,ACSS1,GLIS3,PCDH9,NFIA,PAMR1 |
3.619e-02 | -3.32 | cell migration | biological process | GO:0016477 | 921 | 6 | 18204 | 49 |
GPM6A,GPC5,CTNNA2,CDH20,GLI3,ARHGAP24 |
3.642e-02 | -3.31 | ELK3 (ETS transcription factor ELK3) | protein interactions | 2004 | 117 | 2 | 19454 | 50 |
TRPS1,NFIA |
3.642e-02 | -3.31 | ZMYND19 (zinc finger MYND-type containing 19) | protein interactions | 116225 | 117 | 2 | 19454 | 50 |
SPON1,CTNND2 |
3.646e-02 | -3.31 | skin-scalp-malignant_melanoma | COSMIC cancer mutations | skin-scalp-malignant_melanoma | 634 | 5 | 16828 | 49 |
PREX2,SORBS1,PTPRZ1,NTM,NFIA |
3.647e-02 | -3.31 | HYOU1 (hypoxia up-regulated 1) | protein interactions | 10525 | 284 | 3 | 19454 | 50 |
FGFR3,CPE,CLU |
3.652e-02 | -3.31 | microtubule minus-end binding | molecular function | GO:0051011 | 14 | 1 | 18094 | 48 |
MACF1 |
3.657e-02 | -3.31 | regulation of gliogenesis | biological process | GO:0014013 | 112 | 2 | 18204 | 49 |
QKI,PTPRZ1 |
3.661e-02 | -3.31 | SNX27 (sorting nexin 27) | protein interactions | 81609 | 489 | 4 | 19454 | 50 |
CLU,ABLIM1,COL5A3,SLC1A3 |
3.680e-02 | -3.30 | P4HA1 (prolyl 4-hydroxylase subunit alpha 1) | protein interactions | 5033 | 285 | 3 | 19454 | 50 |
APOE,PON2,DTNA |
3.704e-02 | -3.30 | cell surface receptor signaling pathway | biological process | GO:0007166 | 1992 | 10 | 18204 | 49 |
CPE,GLI3,MACF1,SORBS1,CTNND2,NFIA,FGFR3,NDRG2,MAML2,BMPR1B |
3.704e-02 | -3.30 | negative regulation of long-term synaptic potentiation | biological process | GO:1900272 | 14 | 1 | 18204 | 49 |
APOE |
3.704e-02 | -3.30 | cerebrospinal fluid circulation | biological process | GO:0090660 | 14 | 1 | 18204 | 49 |
AQP4 |
3.704e-02 | -3.30 | sodium ion export across plasma membrane | biological process | GO:0036376 | 14 | 1 | 18204 | 49 |
SLC4A4 |
3.704e-02 | -3.30 | positive regulation of phospholipid transport | biological process | GO:2001140 | 14 | 1 | 18204 | 49 |
APOE |
3.704e-02 | -3.30 | radial glial cell differentiation | biological process | GO:0060019 | 14 | 1 | 18204 | 49 |
GLI3 |
3.704e-02 | -3.30 | cellular response to purine-containing compound | biological process | GO:0071415 | 14 | 1 | 18204 | 49 |
RYR3 |
3.704e-02 | -3.30 | layer formation in cerebral cortex | biological process | GO:0021819 | 14 | 1 | 18204 | 49 |
GLI3 |
3.704e-02 | -3.30 | acetyl-CoA biosynthetic process | biological process | GO:0006085 | 14 | 1 | 18204 | 49 |
ACSS1 |
3.704e-02 | -3.30 | mechanosensory behavior | biological process | GO:0007638 | 14 | 1 | 18204 | 49 |
SLC1A3 |
3.704e-02 | -3.30 | positive regulation of myoblast proliferation | biological process | GO:2000288 | 14 | 1 | 18204 | 49 |
MEIS2 |
3.704e-02 | -3.30 | glutathione biosynthetic process | biological process | GO:0006750 | 14 | 1 | 18204 | 49 |
SLC1A2 |
3.715e-02 | -3.29 | Aquaporin-like | interpro domains | IPR023271 | 14 | 1 | 18521 | 50 |
AQP4 |
3.715e-02 | -3.29 | MIP | interpro domains | IPR000425 | 14 | 1 | 18521 | 50 |
AQP4 |
3.721e-02 | -3.29 | Brenner_tumour | COSMIC cancer mutations | Brenner_tumour | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | skin-scalp-malignant_melanoma-nodular | COSMIC cancer mutations | skin-scalp-malignant_melanoma-nodular | 13 | 1 | 16828 | 49 |
PREX2 |
3.721e-02 | -3.29 | central_nervous_system-hypothalamus-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-hypothalamus-glioma-astrocytoma_Grade_I | 13 | 1 | 16828 | 49 |
QKI |
3.721e-02 | -3.29 | skin-shoulder-malignant_melanoma-nodular | COSMIC cancer mutations | skin-shoulder-malignant_melanoma-nodular | 13 | 1 | 16828 | 49 |
PREX2 |
3.721e-02 | -3.29 | skin-back-carcinoma-basal_cell_carcinoma | COSMIC cancer mutations | skin-back-carcinoma-basal_cell_carcinoma | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | endometrium-ovary-endometriosis | COSMIC cancer mutations | endometrium-ovary-endometriosis | 13 | 1 | 16828 | 49 |
FGFR3 |
3.721e-02 | -3.29 | cervix-carcinoma-adenocarcinoma | COSMIC cancer mutations | cervix-carcinoma-adenocarcinoma | 13 | 1 | 16828 | 49 |
FGFR3 |
3.728e-02 | -3.29 | GATA_ZN_FINGER_2 | prosite domains | PS50114 | 11 | 1 | 12186 | 42 |
TRPS1 |
3.728e-02 | -3.29 | LIPOCALIN | prosite domains | PS00213 | 11 | 1 | 12186 | 42 |
PTGDS |
3.728e-02 | -3.29 | NC1_FIB | prosite domains | PS51461 | 11 | 1 | 12186 | 42 |
COL5A3 |
3.728e-02 | -3.29 | FGFR3 ligand binding and activation | REACTOME pathways | R-HSA-190239 | 13 | 1 | 10285 | 30 |
FGFR3 |
3.728e-02 | -3.29 | Passive transport by Aquaporins | REACTOME pathways | R-HSA-432047 | 13 | 1 | 10285 | 30 |
AQP4 |
3.728e-02 | -3.29 | NOTCH2 intracellular domain regulates transcription | REACTOME pathways | R-HSA-2197563 | 13 | 1 | 10285 | 30 |
MAML2 |
3.728e-02 | -3.29 | Phospholipase C-mediated cascade; FGFR3 | REACTOME pathways | R-HSA-5654227 | 13 | 1 | 10285 | 30 |
FGFR3 |
3.728e-02 | -3.29 | Notch-HLH transcription pathway | REACTOME pathways | R-HSA-350054 | 13 | 1 | 10285 | 30 |
MAML2 |
3.728e-02 | -3.29 | FGFR3c ligand binding and activation | REACTOME pathways | R-HSA-190372 | 13 | 1 | 10285 | 30 |
FGFR3 |
3.745e-02 | -3.28 | HSPA1B (heat shock protein family A (Hsp70) member 1B) | protein interactions | 3304 | 287 | 3 | 19454 | 50 |
NDRG2,ARHGAP24,FGFR3 |
3.745e-02 | -3.28 | PARD3 (par-3 family cell polarity regulator) | protein interactions | 56288 | 287 | 3 | 19454 | 50 |
PARD3B,SORBS1,DTNA |
3.750e-02 | -3.28 | central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-cerebellum-glioma-astrocytoma_Grade_I | 105 | 2 | 16828 | 49 |
QKI,GPC5 |
3.754e-02 | -3.28 | basal plasma membrane | cellular component | GO:0009925 | 288 | 3 | 19108 | 49 |
SLC4A4,SLC1A3,AQP4 |
3.757e-02 | -3.28 | EF_HAND_2 | prosite domains | PS50222 | 215 | 3 | 12186 | 42 |
MACF1,SPARCL1,RYR3 |
3.759e-02 | -3.28 | human chr8p21.1 | chromosome location | human chr8p21.1 | 20 | 1 | 26134 | 50 |
CLU |
3.764e-02 | -3.28 | HCO3TRNSPORT | prints domains | PR01231 | 10 | 1 | 5227 | 20 |
SLC4A4 |
3.777e-02 | -3.28 | DDX27 (DEAD-box helicase 27) | protein interactions | 55661 | 288 | 3 | 19454 | 50 |
NTM,FGFR3,ARHGAP24 |
3.780e-02 | -3.28 | axolemma | cellular component | GO:0030673 | 15 | 1 | 19108 | 49 |
SLC1A2 |
3.780e-02 | -3.28 | low-density lipoprotein particle | cellular component | GO:0034362 | 15 | 1 | 19108 | 49 |
APOE |
3.788e-02 | -3.27 | ZNF714 (zinc finger protein 714) | protein interactions | 148206 | 15 | 1 | 19454 | 50 |
ARHGAP24 |
3.788e-02 | -3.27 | ZNF813 (zinc finger protein 813) | protein interactions | 126017 | 15 | 1 | 19454 | 50 |
ARHGAP24 |
3.788e-02 | -3.27 | ZNF616 (zinc finger protein 616) | protein interactions | 90317 | 15 | 1 | 19454 | 50 |
ARHGAP24 |
3.788e-02 | -3.27 | TMEM255B (transmembrane protein 255B) | protein interactions | 348013 | 15 | 1 | 19454 | 50 |
AMZ2 |
3.788e-02 | -3.27 | FGF9 (fibroblast growth factor 9) | protein interactions | 2254 | 15 | 1 | 19454 | 50 |
FGFR3 |
3.788e-02 | -3.27 | IGSF1 (immunoglobulin superfamily member 1) | protein interactions | 3547 | 15 | 1 | 19454 | 50 |
BMPR1B |
3.798e-02 | -3.27 | Cadherin-like_dom | interpro domains | IPR002126 | 114 | 2 | 18521 | 50 |
CDH20,PCDH9 |
3.808e-02 | -3.27 | learning or memory | biological process | GO:0007611 | 276 | 3 | 18204 | 49 |
PTPRZ1,MEIS2,APOE |
3.809e-02 | -3.27 | thyroid-carcinoma | COSMIC cancer mutations | thyroid-carcinoma | 4126 | 18 | 16828 | 49 |
ATP13A4,AQP4,CPE,SPARCL1,TRPS1,GPC5,NFIA,LSAMP,CTNND2,RYR3,MACF1,DTNA,PTPRZ1,FGFR3,PCDH9,ACSS1,GLIS3,COL5A3 |
3.855e-02 | -3.26 | calcium channel activity | molecular function | GO:0005262 | 117 | 2 | 18094 | 48 |
RYR3,GPM6A |
3.864e-02 | -3.25 | MIP | pfam domains | PF00230 | 14 | 1 | 17795 | 50 |
AQP4 |
3.864e-02 | -3.25 | GATA | pfam domains | PF00320 | 14 | 1 | 17795 | 50 |
TRPS1 |
3.872e-02 | -3.25 | MED15 (mediator complex subunit 15) | protein interactions | 51586 | 121 | 2 | 19454 | 50 |
QKI,NFIA |
3.880e-02 | -3.25 | skin-scalp-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | skin-scalp-carcinoma-squamous_cell_carcinoma | 1596 | 9 | 16828 | 49 |
SLC4A4,ATP13A4,MACF1,TRPS1,GPC5,PTPRZ1,FGFR3,LSAMP,COL5A3 |
3.886e-02 | -3.25 | positive regulation of macromolecule biosynthetic process | biological process | GO:0010557 | 2592 | 12 | 18204 | 49 |
APOE,CLU,GLI3,SPON1,SORBS1,MEIS2,NPAS3,GLIS3,QKI,NFIA,BMPR1B,MAML2 |
3.888e-02 | -3.25 | Composition of Lipid Particles | WikiPathways | WP3601 | 10 | 1 | 5310 | 21 |
APOE |
3.894e-02 | -3.25 | COLFI | smart domains | SM00038 | 11 | 1 | 9717 | 35 |
COL5A3 |
3.896e-02 | -3.25 | Propanoate Metabolism | SMPDB pathways | SMP0000016 | 18 | 1 | 1369 | 3 |
ACSS1 |
3.896e-02 | -3.25 | Methylmalonic Aciduria Due to Cobalamin-Related Disorders | SMPDB pathways | SMP0000201 | 18 | 1 | 1369 | 3 |
ACSS1 |
3.896e-02 | -3.25 | Malonic Aciduria | SMPDB pathways | SMP0000198 | 18 | 1 | 1369 | 3 |
ACSS1 |
3.896e-02 | -3.25 | Malonyl-CoA Decarboxylase Deficiency | SMPDB pathways | SMP0000502 | 18 | 1 | 1369 | 3 |
ACSS1 |
3.908e-02 | -3.24 | AMP binding | molecular function | GO:0016208 | 15 | 1 | 18094 | 48 |
ACSS1 |
3.908e-02 | -3.24 | neurexin family protein binding | molecular function | GO:0042043 | 15 | 1 | 18094 | 48 |
CPE |
3.908e-02 | -3.24 | phosphatidylglycerol binding | molecular function | GO:1901611 | 15 | 1 | 18094 | 48 |
PITPNC1 |
3.914e-02 | -3.24 | skin-leg-malignant_melanoma-nodular | COSMIC cancer mutations | skin-leg-malignant_melanoma-nodular | 258 | 3 | 16828 | 49 |
ATP13A4,SLC4A4,PTPRZ1 |
3.920e-02 | -3.24 | Cadherin-like_sf | interpro domains | IPR015919 | 116 | 2 | 18521 | 50 |
CDH20,PCDH9 |
3.930e-02 | -3.24 | BRK1 (BRICK1 subunit of SCAR/WAVE actin nucleating complex) | protein interactions | 55845 | 122 | 2 | 19454 | 50 |
DTNA,NHSL1 |
3.930e-02 | -3.24 | MED31 (mediator complex subunit 31) | protein interactions | 51003 | 122 | 2 | 19454 | 50 |
QKI,CPE |
3.935e-02 | -3.24 | perinuclear region of cytoplasm | cellular component | GO:0048471 | 735 | 5 | 19108 | 49 |
MEIS2,PTGDS,NDRG2,SLC1A3,CLU |
3.943e-02 | -3.23 | human chr13q31.3 | chromosome location | human chr13q31.3 | 21 | 1 | 26134 | 50 |
GPC5 |
3.943e-02 | -3.23 | human chr4q32.3 | chromosome location | human chr4q32.3 | 21 | 1 | 26134 | 50 |
CPE |
3.954e-02 | -3.23 | Cadherin | pfam domains | PF00028 | 112 | 2 | 17795 | 50 |
CDH20,PCDH9 |
3.963e-02 | -3.23 | lung-carcinoma-squamous_cell_carcinoma | COSMIC cancer mutations | lung-carcinoma-squamous_cell_carcinoma | 14664 | 47 | 16828 | 49 |
PON2,DTNA,APOE,GLI3,FGFR3,PCDH9,AMZ2,NKAIN3,ARHGAP24,CDH20,PREX2,PARD3B,MACF1,PITPNC1,GLIS3,PTPRZ1,SPON1,SLC1A3,NPAS3,MEIS2,ATP13A4,QKI,SLC4A4,NTM,CTNND2,GPC5,MAML2,ABLIM1,CLU,COL5A3,FBXL7,ACSS1,PTGDS,NHSL1,MSI2,PAMR1,GPM6A,SORBS1,NFIA,TRPS1,BMPR1B,CPE,AQP4,LSAMP,RYR3,SLC1A2,SPARCL1 |
3.964e-02 | -3.23 | exit from mitosis | biological process | GO:0010458 | 15 | 1 | 18204 | 49 |
NFIA |
3.964e-02 | -3.23 | regulation of phospholipid transport | biological process | GO:2001138 | 15 | 1 | 18204 | 49 |
APOE |
3.964e-02 | -3.23 | regulation of neuron projection arborization | biological process | GO:0150011 | 15 | 1 | 18204 | 49 |
MACF1 |
3.964e-02 | -3.23 | positive regulation of cholesterol metabolic process | biological process | GO:0090205 | 15 | 1 | 18204 | 49 |
APOE |
3.964e-02 | -3.23 | positive regulation of glycogen biosynthetic process | biological process | GO:0045725 | 15 | 1 | 18204 | 49 |
SORBS1 |
3.964e-02 | -3.23 | chondrocyte proliferation | biological process | GO:0035988 | 15 | 1 | 18204 | 49 |
FGFR3 |
3.964e-02 | -3.23 | protein homotrimerization | biological process | GO:0070207 | 15 | 1 | 18204 | 49 |
SLC1A2 |
3.964e-02 | -3.23 | lipoprotein catabolic process | biological process | GO:0042159 | 15 | 1 | 18204 | 49 |
APOE |
3.964e-02 | -3.23 | dorsal/ventral neural tube patterning | biological process | GO:0021904 | 15 | 1 | 18204 | 49 |
GLI3 |
3.964e-02 | -3.23 | sarcoplasmic reticulum calcium ion transport | biological process | GO:0070296 | 15 | 1 | 18204 | 49 |
RYR3 |
3.964e-02 | -3.23 | regulation of circadian sleep/wake cycle, sleep | biological process | GO:0045187 | 15 | 1 | 18204 | 49 |
PTGDS |
3.964e-02 | -3.23 | synapse maturation | biological process | GO:0060074 | 15 | 1 | 18204 | 49 |
NFIA |
3.964e-02 | -3.23 | response to caffeine | biological process | GO:0031000 | 15 | 1 | 18204 | 49 |
RYR3 |
3.975e-02 | -3.23 | Znf_GATA | interpro domains | IPR000679 | 15 | 1 | 18521 | 50 |
TRPS1 |
3.988e-02 | -3.22 | PAX7 (paired box 7) | protein interactions | 5081 | 123 | 2 | 19454 | 50 |
TRPS1,NFIA |
4.002e-02 | -3.22 | soft_tissue-small_round_cell_tumour | COSMIC cancer mutations | soft_tissue-small_round_cell_tumour | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | endometriosis | COSMIC cancer mutations | endometriosis | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | in_situ_neoplasm | COSMIC cancer mutations | in_situ_neoplasm | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | small_round_cell_tumour | COSMIC cancer mutations | small_round_cell_tumour | 14 | 1 | 16828 | 49 |
FGFR3 |
4.002e-02 | -3.22 | urinary_tract-renal_pelvis-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-renal_pelvis-carcinoma-transitional_cell_carcinoma | 14 | 1 | 16828 | 49 |
FGFR3 |
4.010e-02 | -3.22 | DCC mediated attractive signaling | REACTOME pathways | R-HSA-418885 | 14 | 1 | 10285 | 30 |
ABLIM1 |
4.035e-02 | -3.21 | CDH12 (cadherin 12) | protein interactions | 1010 | 16 | 1 | 19454 | 50 |
CTNNA2 |
4.035e-02 | -3.21 | CTSK (cathepsin K) | protein interactions | 1513 | 16 | 1 | 19454 | 50 |
FGFR3 |
4.035e-02 | -3.21 | FNDC8 (fibronectin type III domain containing 8) | protein interactions | 54752 | 16 | 1 | 19454 | 50 |
SPARCL1 |
4.035e-02 | -3.21 | HLA-H (major histocompatibility complex, class I, H (pseudogene)) | protein interactions | 3136 | 16 | 1 | 19454 | 50 |
FGFR3 |
4.035e-02 | -3.21 | SAPCD1 (suppressor APC domain containing 1) | protein interactions | 401251 | 16 | 1 | 19454 | 50 |
CTNNA2 |
4.035e-02 | -3.21 | VGLL1 (vestigial like family member 1) | protein interactions | 51442 | 16 | 1 | 19454 | 50 |
MEIS2 |
4.035e-02 | -3.21 | AMMECR1L (AMMECR1 like) | protein interactions | 83607 | 16 | 1 | 19454 | 50 |
MACF1 |
4.035e-02 | -3.21 | CYP2C8 (cytochrome P450 family 2 subfamily C member 8) | protein interactions | 1558 | 16 | 1 | 19454 | 50 |
APOE |
4.035e-02 | -3.21 | GMPR2 (guanosine monophosphate reductase 2) | protein interactions | 51292 | 16 | 1 | 19454 | 50 |
ARHGAP24 |
4.060e-02 | -3.20 | protein maturation | biological process | GO:0051604 | 483 | 4 | 18204 | 49 |
GLI3,CPE,CLU,SPON1 |
4.065e-02 | -3.20 | membrane protein complex | cellular component | GO:0098796 | 1261 | 7 | 19108 | 49 |
SORBS1,BMPR1B,SLC1A3,CDH20,RYR3,CTNNA2,SLC1A2 |
4.079e-02 | -3.20 | SP7 (Sp7 transcription factor) | protein interactions | 121340 | 297 | 3 | 19454 | 50 |
NFIA,TRPS1,QKI |
4.079e-02 | -3.20 | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | COSMIC cancer mutations | urinary_tract-bladder-carcinoma-transitional_cell_carcinoma | 6040 | 24 | 16828 | 49 |
GPC5,SPARCL1,ATP13A4,SLC4A4,GLIS3,SLC1A3,PTPRZ1,MACF1,GPM6A,SORBS1,PREX2,NFIA,TRPS1,PARD3B,CDH20,COL5A3,ACSS1,PCDH9,FGFR3,GLI3,ABLIM1,CLU,DTNA,PON2 |
4.095e-02 | -3.20 | transitional_cell_carcinoma | COSMIC cancer mutations | transitional_cell_carcinoma | 6042 | 24 | 16828 | 49 |
DTNA,ABLIM1,CLU,PON2,ACSS1,COL5A3,PCDH9,GLI3,FGFR3,CDH20,SORBS1,GPM6A,PREX2,TRPS1,NFIA,PARD3B,MACF1,GLIS3,SLC1A3,PTPRZ1,SLC4A4,ATP13A4,SPARCL1,GPC5 |
4.115e-02 | -3.19 | negative regulation of cellular component organization | biological process | GO:0051129 | 709 | 5 | 18204 | 49 |
CLU,ARHGAP24,CTNNA2,APOE,CST3 |
4.117e-02 | -3.19 | secondary active transmembrane transporter activity | molecular function | GO:0015291 | 289 | 3 | 18094 | 48 |
SLC1A2,SLC1A3,SLC4A4 |
4.118e-02 | -3.19 | skin-extremity-malignant_melanoma | COSMIC cancer mutations | skin-extremity-malignant_melanoma | 1875 | 10 | 16828 | 49 |
ACSS1,FBXL7,COL5A3,PREX2,RYR3,PTPRZ1,PCDH9,ATP13A4,CDH20,PITPNC1 |
4.121e-02 | -3.19 | basal_(triple-negative)_carcinoma | COSMIC cancer mutations | basal_(triple-negative)_carcinoma | 2981 | 14 | 16828 | 49 |
PON2,MAML2,MACF1,NDRG2,GLI3,FGFR3,BMPR1B,MSI2,NTM,ARHGAP24,SLC4A4,NPAS3,MEIS2,SPARCL1 |
4.121e-02 | -3.19 | breast-carcinoma-basal_(triple-negative)_carcinoma | COSMIC cancer mutations | breast-carcinoma-basal_(triple-negative)_carcinoma | 2981 | 14 | 16828 | 49 |
MACF1,MAML2,PON2,BMPR1B,GLI3,FGFR3,NDRG2,SLC4A4,MEIS2,NPAS3,MSI2,ARHGAP24,NTM,SPARCL1 |
4.126e-02 | -3.19 | cell junction assembly | biological process | GO:0034329 | 285 | 3 | 18204 | 49 |
CDH20,GPM6A,SORBS1 |
4.127e-02 | -3.19 | human chr3q13.31 | chromosome location | human chr3q13.31 | 22 | 1 | 26134 | 50 |
LSAMP |
4.144e-02 | -3.18 | striated muscle contraction | biological process | GO:0006941 | 120 | 2 | 18204 | 49 |
DTNA,RYR3 |
4.156e-02 | -3.18 | cellular component organization or biogenesis | biological process | GO:0071840 | 5850 | 22 | 18204 | 49 |
GLI3,ABLIM1,CTNNA2,SPARCL1,RYR3,SORBS1,GPM6A,PARD3B,NFIA,PREX2,AQP4,SLC1A2,BMPR1B,PTPRZ1,CDH20,MACF1,CTNND2,APOE,PITPNC1,CST3,CLU,COL5A3 |
4.163e-02 | -3.18 | water channel activity | molecular function | GO:0015250 | 16 | 1 | 18094 | 48 |
AQP4 |
4.163e-02 | -3.18 | misfolded protein binding | molecular function | GO:0051787 | 16 | 1 | 18094 | 48 |
CLU |
4.166e-02 | -3.18 | SYP (synaptophysin) | protein interactions | 6855 | 126 | 2 | 19454 | 50 |
GPM6A,PITPNC1 |
4.166e-02 | -3.18 | RNF115 (ring finger protein 115) | protein interactions | 27246 | 126 | 2 | 19454 | 50 |
NDRG2,CST3 |
4.176e-02 | -3.18 | Glycerol uptake facilitator protein | gene3d domains | 1.20.1080.10 | 14 | 1 | 14470 | 44 |
AQP4 |
4.198e-02 | -3.17 | ossification | biological process | GO:0001503 | 287 | 3 | 18204 | 49 |
BMPR1B,GLI3,FGFR3 |
4.223e-02 | -3.16 | insulin metabolic process | biological process | GO:1901142 | 16 | 1 | 18204 | 49 |
CPE |
4.223e-02 | -3.16 | locomotory exploration behavior | biological process | GO:0035641 | 16 | 1 | 18204 | 49 |
APOE |
4.223e-02 | -3.16 | nonribosomal peptide biosynthetic process | biological process | GO:0019184 | 16 | 1 | 18204 | 49 |
SLC1A2 |
4.223e-02 | -3.16 | nose development | biological process | GO:0043584 | 16 | 1 | 18204 | 49 |
GLI3 |
4.223e-02 | -3.16 | positive regulation of membrane protein ectodomain proteolysis | biological process | GO:0051044 | 16 | 1 | 18204 | 49 |
APOE |
4.223e-02 | -3.16 | low-density lipoprotein particle remodeling | biological process | GO:0034374 | 16 | 1 | 18204 | 49 |
APOE |
4.223e-02 | -3.16 | non-proteinogenic amino acid biosynthetic process | biological process | GO:0170043 | 16 | 1 | 18204 | 49 |
SLC1A3 |
4.223e-02 | -3.16 | spinal cord dorsal/ventral patterning | biological process | GO:0021513 | 16 | 1 | 18204 | 49 |
GLI3 |
4.223e-02 | -3.16 | cardiac left ventricle morphogenesis | biological process | GO:0003214 | 16 | 1 | 18204 | 49 |
CPE |
4.223e-02 | -3.16 | wound healing, spreading of epidermal cells | biological process | GO:0035313 | 16 | 1 | 18204 | 49 |
ARHGAP24 |
4.223e-02 | -3.16 | short-chain fatty acid metabolic process | biological process | GO:0046459 | 16 | 1 | 18204 | 49 |
ACSS1 |
4.235e-02 | -3.16 | CarboxyPept-like_regulatory | interpro domains | IPR008969 | 16 | 1 | 18521 | 50 |
CPE |
4.240e-02 | -3.16 | DWA | smart domains | SM00523 | 12 | 1 | 9717 | 35 |
NFIA |
4.240e-02 | -3.16 | ZnF_GATA | smart domains | SM00401 | 12 | 1 | 9717 | 35 |
TRPS1 |
4.273e-02 | -3.15 | apical dendrite | cellular component | GO:0097440 | 17 | 1 | 19108 | 49 |
CLU |
4.282e-02 | -3.15 | ureter | COSMIC cancer mutations | ureter | 15 | 1 | 16828 | 49 |
FGFR3 |
4.282e-02 | -3.15 | hypothalamus | COSMIC cancer mutations | hypothalamus | 15 | 1 | 16828 | 49 |
QKI |
4.282e-02 | -3.15 | Pef1 (penta-EF hand domain containing 1) | protein interactions | 67898 | 17 | 1 | 19454 | 50 |
QKI |
4.282e-02 | -3.15 | RASL12 (RAS like family 12) | protein interactions | 51285 | 17 | 1 | 19454 | 50 |
BMPR1B |
4.282e-02 | -3.15 | TAGAP (T cell activation RhoGTPase activating protein) | protein interactions | 117289 | 17 | 1 | 19454 | 50 |
DTNA |
4.282e-02 | -3.15 | Shcbp1 (Shc SH2-domain binding protein 1) | protein interactions | 20419 | 17 | 1 | 19454 | 50 |
GPC5 |
4.282e-02 | -3.15 | DPP6 (dipeptidyl peptidase like 6) | protein interactions | 1804 | 17 | 1 | 19454 | 50 |
GPM6A |
4.282e-02 | -3.15 | SEPSECS (Sep (O-phosphoserine) tRNA:Sec (selenocysteine) tRNA synthase) | protein interactions | 51091 | 17 | 1 | 19454 | 50 |
ABLIM1 |
4.282e-02 | -3.15 | ZNF557 (zinc finger protein 557) | protein interactions | 79230 | 17 | 1 | 19454 | 50 |
ARHGAP24 |
4.282e-02 | -3.15 | Sqstm1 (sequestosome 1) | protein interactions | 18412 | 17 | 1 | 19454 | 50 |
BMPR1B |
4.282e-02 | -3.15 | C16orf92 (chromosome 16 open reading frame 92) | protein interactions | 146378 | 17 | 1 | 19454 | 50 |
APOE |
4.282e-02 | -3.15 | NOTCH4 (notch receptor 4) | protein interactions | 4855 | 17 | 1 | 19454 | 50 |
MAML2 |
4.282e-02 | -3.15 | PAX4 (paired box 4) | protein interactions | 5078 | 17 | 1 | 19454 | 50 |
NTM |
4.286e-02 | -3.15 | MYB (MYB proto-oncogene, transcription factor) | protein interactions | 4602 | 128 | 2 | 19454 | 50 |
NFIA,TRPS1 |
4.290e-02 | -3.15 | Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | REACTOME pathways | R-HSA-2162123 | 15 | 1 | 10285 | 30 |
PTGDS |
4.346e-02 | -3.14 | POLA2 (DNA polymerase alpha 2, accessory subunit) | protein interactions | 23649 | 129 | 2 | 19454 | 50 |
FGFR3,CPE |
4.362e-02 | -3.13 | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | COSMIC cancer mutations | bone-extraskeletal-Ewings_sarcoma-peripheral_primitive_neuroectodermal_tumour | 891 | 6 | 16828 | 49 |
FGFR3,PTPRZ1,SPARCL1,NPAS3,ABLIM1,PTGDS |
4.367e-02 | -3.13 | monoatomic ion transport | biological process | GO:0006811 | 964 | 6 | 18204 | 49 |
SLC4A4,SLC1A2,ATP13A4,RYR3,GPM6A,SLC1A3 |
4.389e-02 | -3.13 | actin cytoskeleton | cellular component | GO:0015629 | 520 | 4 | 19108 | 49 |
CTNNA2,MACF1,SORBS1,ABLIM1 |
4.391e-02 | -3.13 | CARBOXYPEPT_ZN_2 | prosite domains | PS00133 | 13 | 1 | 12186 | 42 |
CPE |
4.391e-02 | -3.13 | CARBOXYPEPT_ZN_1 | prosite domains | PS00132 | 13 | 1 | 12186 | 42 |
CPE |
4.397e-02 | -3.12 | positive regulation of lipid metabolic process | biological process | GO:0045834 | 124 | 2 | 18204 | 49 |
SORBS1,APOE |
4.400e-02 | -3.12 | basal part of cell | cellular component | GO:0045178 | 307 | 3 | 19108 | 49 |
SLC4A4,SLC1A3,AQP4 |
4.415e-02 | -3.12 | establishment of localization | biological process | GO:0051234 | 3887 | 16 | 18204 | 49 |
GLI3,PARD3B,GPM6A,RYR3,AQP4,SLC4A4,QKI,SLC1A2,CPE,ATP13A4,PITPNC1,APOE,MACF1,SLC1A3,PTGDS,CLU |
4.417e-02 | -3.12 | transmembrane receptor protein tyrosine phosphatase activity | molecular function | GO:0005001 | 17 | 1 | 18094 | 48 |
PTPRZ1 |
4.417e-02 | -3.12 | transmembrane receptor protein phosphatase activity | molecular function | GO:0019198 | 17 | 1 | 18094 | 48 |
PTPRZ1 |
4.472e-02 | -3.11 | middle_lobe | COSMIC cancer mutations | middle_lobe | 1382 | 8 | 16828 | 49 |
MACF1,ATP13A4,CPE,CTNND2,RYR3,FGFR3,PARD3B,PCDH9 |
4.481e-02 | -3.11 | cell population proliferation | biological process | GO:0008283 | 726 | 5 | 18204 | 49 |
GLI3,NDRG2,NFIA,FGFR3,CLU |
4.481e-02 | -3.11 | embryonic digestive tract morphogenesis | biological process | GO:0048557 | 17 | 1 | 18204 | 49 |
GLI3 |
4.481e-02 | -3.11 | specification of animal organ identity | biological process | GO:0010092 | 17 | 1 | 18204 | 49 |
GLI3 |
4.481e-02 | -3.11 | high-density lipoprotein particle remodeling | biological process | GO:0034375 | 17 | 1 | 18204 | 49 |
APOE |
4.481e-02 | -3.11 | positive regulation of vascular permeability | biological process | GO:0043117 | 17 | 1 | 18204 | 49 |
APOE |
4.481e-02 | -3.11 | negative regulation of triglyceride metabolic process | biological process | GO:0090209 | 17 | 1 | 18204 | 49 |
APOE |
4.481e-02 | -3.11 | positive regulation of glycogen metabolic process | biological process | GO:0070875 | 17 | 1 | 18204 | 49 |
SORBS1 |
4.481e-02 | -3.11 | viral genome replication | biological process | GO:0019079 | 17 | 1 | 18204 | 49 |
NFIA |
4.481e-02 | -3.11 | cell migration in hindbrain | biological process | GO:0021535 | 17 | 1 | 18204 | 49 |
CTNNA2 |
4.481e-02 | -3.11 | fatty acid homeostasis | biological process | GO:0055089 | 17 | 1 | 18204 | 49 |
APOE |
4.481e-02 | -3.11 | protein trimerization | biological process | GO:0070206 | 17 | 1 | 18204 | 49 |
SLC1A2 |
4.481e-02 | -3.11 | regulation of inclusion body assembly | biological process | GO:0090083 | 17 | 1 | 18204 | 49 |
CLU |
4.481e-02 | -3.11 | ureter development | biological process | GO:0072189 | 17 | 1 | 18204 | 49 |
NFIA |
4.481e-02 | -3.11 | cellular response to ATP | biological process | GO:0071318 | 17 | 1 | 18204 | 49 |
RYR3 |
4.493e-02 | -3.10 | regulation of ERK1 and ERK2 cascade | biological process | GO:0070372 | 295 | 3 | 18204 | 49 |
APOE,NDRG2,FGFR3 |
4.493e-02 | -3.10 | AMP-bd_C | interpro domains | IPR025110 | 17 | 1 | 18521 | 50 |
ACSS1 |
4.493e-02 | -3.10 | CA_dom_sf | interpro domains | IPR036398 | 17 | 1 | 18521 | 50 |
PTPRZ1 |
4.493e-02 | -3.10 | CA_dom | interpro domains | IPR001148 | 17 | 1 | 18521 | 50 |
PTPRZ1 |
4.493e-02 | -3.10 | Cystatin_dom | interpro domains | IPR000010 | 17 | 1 | 18521 | 50 |
CST3 |
4.499e-02 | -3.10 | AFDN (afadin, adherens junction formation factor) | protein interactions | 4301 | 309 | 3 | 19454 | 50 |
SORBS1,DTNA,MACF1 |
4.525e-02 | -3.10 | positive regulation of cellular biosynthetic process | biological process | GO:0031328 | 2652 | 12 | 18204 | 49 |
APOE,CLU,NPAS3,MEIS2,SORBS1,SPON1,GLI3,MAML2,BMPR1B,NFIA,QKI,GLIS3 |
4.529e-02 | -3.09 | Tgfbr1 (transforming growth factor, beta receptor I) | protein interactions | 21812 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.529e-02 | -3.09 | OPCML (opioid binding protein/cell adhesion molecule like) | protein interactions | 4978 | 18 | 1 | 19454 | 50 |
NTM |
4.529e-02 | -3.09 | ZNF100 (zinc finger protein 100) | protein interactions | 163227 | 18 | 1 | 19454 | 50 |
ARHGAP24 |
4.529e-02 | -3.09 | NKIRAS1 (NFKB inhibitor interacting Ras like 1) | protein interactions | 28512 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.529e-02 | -3.09 | NECTIN1 (nectin cell adhesion molecule 1) | protein interactions | 5818 | 18 | 1 | 19454 | 50 |
FGFR3 |
4.529e-02 | -3.09 | TTC29 (tetratricopeptide repeat domain 29) | protein interactions | 83894 | 18 | 1 | 19454 | 50 |
MACF1 |
4.529e-02 | -3.09 | KLHL1 (kelch like family member 1) | protein interactions | 57626 | 18 | 1 | 19454 | 50 |
BMPR1B |
4.529e-02 | -3.09 | Lck (lymphocyte protein tyrosine kinase) | protein interactions | 16818 | 18 | 1 | 19454 | 50 |
APOE |
4.529e-02 | -3.09 | AK9 (adenylate kinase 9) | protein interactions | 221264 | 18 | 1 | 19454 | 50 |
ARHGAP24 |
4.529e-02 | -3.09 | Cnot2 (CCR4-NOT transcription complex, subunit 2) | protein interactions | 72068 | 18 | 1 | 19454 | 50 |
MACF1 |
4.529e-02 | -3.09 | PTGFR (prostaglandin F receptor) | protein interactions | 5737 | 18 | 1 | 19454 | 50 |
PTGDS |
4.529e-02 | -3.09 | CYP2E1 (cytochrome P450 family 2 subfamily E member 1) | protein interactions | 1571 | 18 | 1 | 19454 | 50 |
CLU |
4.530e-02 | -3.09 | GPIHBP1 (glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1) | protein interactions | 338328 | 132 | 2 | 19454 | 50 |
CPE,FGFR3 |
4.535e-02 | -3.09 | C11orf52 (chromosome 11 open reading frame 52) | protein interactions | 91894 | 310 | 3 | 19454 | 50 |
DTNA,ABLIM1,MACF1 |
4.557e-02 | -3.09 | cytoskeletal protein binding | molecular function | GO:0008092 | 989 | 6 | 18094 | 48 |
CLU,APOE,CTNNA2,ABLIM1,SORBS1,MACF1 |
4.561e-02 | -3.09 | normal | COSMIC cancer mutations | normal | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | urinary_tract-carcinoma | COSMIC cancer mutations | urinary_tract-carcinoma | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | flank | COSMIC cancer mutations | flank | 16 | 1 | 16828 | 49 |
FGFR3 |
4.561e-02 | -3.09 | renal_pelvis | COSMIC cancer mutations | renal_pelvis | 16 | 1 | 16828 | 49 |
FGFR3 |
4.569e-02 | -3.09 | carboxylic acid transport | biological process | GO:0046942 | 297 | 3 | 18204 | 49 |
SLC1A3,APOE,SLC1A2 |
4.606e-02 | -3.08 | extraskeletal | COSMIC cancer mutations | extraskeletal | 903 | 6 | 16828 | 49 |
ABLIM1,PTGDS,NPAS3,SPARCL1,FGFR3,PTPRZ1 |
4.607e-02 | -3.08 | organic acid transport | biological process | GO:0015849 | 298 | 3 | 18204 | 49 |
APOE,SLC1A2,SLC1A3 |
4.613e-02 | -3.08 | PDZ | pfam domains | PF00595 | 122 | 2 | 17795 | 50 |
PARD3B,PREX2 |
4.649e-02 | -3.07 | MFAP5-mediated ovarian cancer cell motility and invasiveness | WikiPathways | WP3301 | 12 | 1 | 5310 | 21 |
RYR3 |
4.649e-02 | -3.07 | Bone Morphogenic Protein (BMP) Signalling and Regulation | WikiPathways | WP1425 | 12 | 1 | 5310 | 21 |
BMPR1B |
4.652e-02 | -3.07 | cellular response to organonitrogen compound | biological process | GO:0071417 | 505 | 4 | 18204 | 49 |
RYR3,SORBS1,SLC1A2,SLC1A3 |
4.655e-02 | -3.07 | myelination | biological process | GO:0042552 | 128 | 2 | 18204 | 49 |
QKI,CLU |
4.671e-02 | -3.06 | intracellularly gated calcium channel activity | molecular function | GO:0015278 | 18 | 1 | 18094 | 48 |
RYR3 |
4.671e-02 | -3.06 | phosphatidylcholine transporter activity | molecular function | GO:0008525 | 18 | 1 | 18094 | 48 |
PITPNC1 |
4.671e-02 | -3.06 | heparan sulfate proteoglycan binding | molecular function | GO:0043395 | 18 | 1 | 18094 | 48 |
APOE |
4.673e-02 | -3.06 | ZZ | pfam domains | PF00569 | 17 | 1 | 17795 | 50 |
DTNA |
4.673e-02 | -3.06 | AMP-binding_C | pfam domains | PF13193 | 17 | 1 | 17795 | 50 |
ACSS1 |
4.673e-02 | -3.06 | Carb_anhydrase | pfam domains | PF00194 | 17 | 1 | 17795 | 50 |
PTPRZ1 |
4.673e-02 | -3.06 | Cystatin | pfam domains | PF00031 | 17 | 1 | 17795 | 50 |
CST3 |
4.674e-02 | -3.06 | GRB2 (growth factor receptor bound protein 2) | protein interactions | 2885 | 769 | 5 | 19454 | 50 |
SLC1A2,MSI2,CLU,PON2,FGFR3 |
4.696e-02 | -3.06 | Cadherins | gene3d domains | 2.60.40.60 | 114 | 2 | 14470 | 44 |
PCDH9,CDH20 |
4.716e-02 | -3.05 | NTRK2 (neurotrophic receptor tyrosine kinase 2) | protein interactions | 4915 | 135 | 2 | 19454 | 50 |
ABLIM1,DTNA |
4.716e-02 | -3.05 | BMP4 (bone morphogenetic protein 4) | protein interactions | 652 | 135 | 2 | 19454 | 50 |
CLU,BMPR1B |
4.716e-02 | -3.05 | SOX15 (SRY-box transcription factor 15) | protein interactions | 6665 | 135 | 2 | 19454 | 50 |
TRPS1,NFIA |
4.716e-02 | -3.05 | Myo1c (myosin IC) | protein interactions | 17913 | 135 | 2 | 19454 | 50 |
TRPS1,ABLIM1 |
4.718e-02 | -3.05 | Glutamatergic synapse | KEGG pathways | hsa04724 | 114 | 2 | 7161 | 22 |
SLC1A2,SLC1A3 |
4.718e-02 | -3.05 | Glutamatergic synapse | KEGG pathways | ko04724 | 114 | 2 | 7161 | 22 |
SLC1A3,SLC1A2 |
4.721e-02 | -3.05 | regulation of cell population proliferation | biological process | GO:0042127 | 1790 | 9 | 18204 | 49 |
CLU,FGFR3,NDRG2,BMPR1B,PTPRZ1,GLI3,PTGDS,APOE,MEIS2 |
4.722e-02 | -3.05 | central_nervous_system-brain-glioma-astrocytoma_Grade_IV | COSMIC cancer mutations | central_nervous_system-brain-glioma-astrocytoma_Grade_IV | 15813 | 49 | 16828 | 49 |
PREX2,PARD3B,CDH20,ARHGAP24,AMZ2,NKAIN3,PCDH9,GLI3,FGFR3,DTNA,PON2,APOE,CTNND2,GPC5,SLC4A4,ATP13A4,QKI,NPAS3,MEIS2,NTM,GLIS3,SLC1A3,SPON1,NDRG2,PTPRZ1,MACF1,PITPNC1,SORBS1,GPM6A,TRPS1,NFIA,PTGDS,PAMR1,MSI2,NHSL1,ACSS1,FBXL7,COL5A3,CST3,CLU,ABLIM1,MAML2,SLC1A2,RYR3,LSAMP,SPARCL1,AQP4,CPE,BMPR1B |
4.737e-02 | -3.05 | circulatory system process | biological process | GO:0003013 | 508 | 4 | 18204 | 49 |
SLC4A4,SLC1A3,APOE,SLC1A2 |
4.738e-02 | -3.05 | myelin maintenance | biological process | GO:0043217 | 18 | 1 | 18204 | 49 |
CLU |
4.738e-02 | -3.05 | dendritic spine morphogenesis | biological process | GO:0060997 | 18 | 1 | 18204 | 49 |
CTNND2 |
4.738e-02 | -3.05 | negative regulation of platelet activation | biological process | GO:0010544 | 18 | 1 | 18204 | 49 |
APOE |
4.738e-02 | -3.05 | spinal cord patterning | biological process | GO:0021511 | 18 | 1 | 18204 | 49 |
GLI3 |
4.738e-02 | -3.05 | response to misfolded protein | biological process | GO:0051788 | 18 | 1 | 18204 | 49 |
CLU |
4.738e-02 | -3.05 | regulation of extracellular matrix disassembly | biological process | GO:0010715 | 18 | 1 | 18204 | 49 |
CST3 |
4.752e-02 | -3.05 | ATPase_P-typ_cation-transptr_N | interpro domains | IPR004014 | 18 | 1 | 18521 | 50 |
ATP13A4 |
4.752e-02 | -3.05 | Leu-rich_rpt_Cys-con_subtyp | interpro domains | IPR006553 | 18 | 1 | 18521 | 50 |
FBXL7 |
4.754e-02 | -3.05 | ZYX (zyxin) | protein interactions | 7791 | 316 | 3 | 19454 | 50 |
MACF1,ABLIM1,SORBS1 |
4.764e-02 | -3.04 | parallel fiber to Purkinje cell synapse | cellular component | GO:0098688 | 19 | 1 | 19108 | 49 |
GPM6A |
4.774e-02 | -3.04 | CCL14 (C-C motif chemokine ligand 14) | protein interactions | 6358 | 19 | 1 | 19454 | 50 |
AMZ2 |
4.774e-02 | -3.04 | SPZ1 (spermatogenic leucine zipper 1) | protein interactions | 84654 | 19 | 1 | 19454 | 50 |
DTNA |
4.774e-02 | -3.04 | FBXO27 (F-box protein 27) | protein interactions | 126433 | 19 | 1 | 19454 | 50 |
CLU |
4.774e-02 | -3.04 | CNTNAP4 (contactin associated protein family member 4) | protein interactions | 85445 | 19 | 1 | 19454 | 50 |
MACF1 |
4.774e-02 | -3.04 | TNR (tenascin R) | protein interactions | 7143 | 19 | 1 | 19454 | 50 |
PTPRZ1 |
4.774e-02 | -3.04 | PHYHIPL (phytanoyl-CoA 2-hydroxylase interacting protein like) | protein interactions | 84457 | 19 | 1 | 19454 | 50 |
GPM6A |
4.774e-02 | -3.04 | ZNF138 (zinc finger protein 138) | protein interactions | 7697 | 19 | 1 | 19454 | 50 |
ARHGAP24 |
4.786e-02 | -3.04 | ensheathment of neurons | biological process | GO:0007272 | 130 | 2 | 18204 | 49 |
CLU,QKI |
4.786e-02 | -3.04 | axon ensheathment | biological process | GO:0008366 | 130 | 2 | 18204 | 49 |
CLU,QKI |
4.804e-02 | -3.04 | acute_lymphoblastic_leukaemia | COSMIC cancer mutations | acute_lymphoblastic_leukaemia | 2197 | 11 | 16828 | 49 |
ARHGAP24,DTNA,SLC4A4,PTPRZ1,PARD3B,GLI3,FGFR3,TRPS1,NFIA,PREX2,BMPR1B |
4.839e-02 | -3.03 | skin-other-verrucal_keratosis_BRAF_inhibitor_related | COSMIC cancer mutations | skin-other-verrucal_keratosis_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | central_nervous_system-optic_nerve-glioma-astrocytoma_Grade_I | COSMIC cancer mutations | central_nervous_system-optic_nerve-glioma-astrocytoma_Grade_I | 17 | 1 | 16828 | 49 |
QKI |
4.839e-02 | -3.03 | optic_nerve | COSMIC cancer mutations | optic_nerve | 17 | 1 | 16828 | 49 |
QKI |
4.839e-02 | -3.03 | breast-carcinoma-neuroendocrine_carcinoma | COSMIC cancer mutations | breast-carcinoma-neuroendocrine_carcinoma | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | non_chronically_sun_exposed_site | COSMIC cancer mutations | non_chronically_sun_exposed_site | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | skin-carcinoma-squamous_cell_carcinoma_BRAF_inhibitor_related | COSMIC cancer mutations | skin-carcinoma-squamous_cell_carcinoma_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | squamous_cell_carcinoma_BRAF_inhibitor_related | COSMIC cancer mutations | squamous_cell_carcinoma_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | skin-non_chronically_sun_exposed_site-malignant_melanoma | COSMIC cancer mutations | skin-non_chronically_sun_exposed_site-malignant_melanoma | 17 | 1 | 16828 | 49 |
FGFR3 |
4.839e-02 | -3.03 | verrucal_keratosis_BRAF_inhibitor_related | COSMIC cancer mutations | verrucal_keratosis_BRAF_inhibitor_related | 17 | 1 | 16828 | 49 |
FGFR3 |
4.852e-02 | -3.03 | carboxylic acid transmembrane transport | biological process | GO:1905039 | 131 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
4.859e-02 | -3.02 | human chr18q12.1 | chromosome location | human chr18q12.1 | 26 | 1 | 26134 | 50 |
DTNA |
4.879e-02 | -3.02 | transport | biological process | GO:0006810 | 3615 | 15 | 18204 | 49 |
CLU,MACF1,PITPNC1,APOE,PTGDS,SLC1A3,ATP13A4,CPE,SLC1A2,QKI,SLC4A4,AQP4,RYR3,GPM6A,GLI3 |
4.893e-02 | -3.02 | kidney-other-neoplasm | COSMIC cancer mutations | kidney-other-neoplasm | 10653 | 37 | 16828 | 49 |
MACF1,SPON1,SLC1A3,PTPRZ1,QKI,ATP13A4,AQP4,CPE,MEIS2,NPAS3,RYR3,CTNND2,SLC1A2,LSAMP,GPC5,SPARCL1,ABLIM1,CLU,DTNA,MAML2,PON2,COL5A3,ACSS1,FBXL7,PCDH9,NKAIN3,AMZ2,FGFR3,GLI3,NHSL1,PAMR1,CDH20,ARHGAP24,GPM6A,SORBS1,PREX2,TRPS1 |
4.905e-02 | -3.01 | NFIB (nuclear factor I B) | protein interactions | 4781 | 138 | 2 | 19454 | 50 |
NFIA,TRPS1 |
4.916e-02 | -3.01 | regulation of small GTPase mediated signal transduction | biological process | GO:0051056 | 306 | 3 | 18204 | 49 |
ARHGAP24,PREX2,APOE |
4.918e-02 | -3.01 | amino acid transport | biological process | GO:0006865 | 132 | 2 | 18204 | 49 |
SLC1A3,SLC1A2 |
4.924e-02 | -3.01 | transmembrane receptor protein serine/threonine kinase activity | molecular function | GO:0004675 | 19 | 1 | 18094 | 48 |
BMPR1B |
4.924e-02 | -3.01 | water transmembrane transporter activity | molecular function | GO:0005372 | 19 | 1 | 18094 | 48 |
AQP4 |
4.931e-02 | -3.01 | TRIM67 (tripartite motif containing 67) | protein interactions | 440730 | 4804 | 18 | 19454 | 50 |
APOE,CTNNA2,SLC4A4,CLU,CST3,QKI,SLC1A3,MACF1,DTNA,CTNND2,GPM6A,MSI2,LSAMP,PON2,NTM,PTPRZ1,PITPNC1,ACSS1 |
4.940e-02 | -3.01 | ACTA1 (actin alpha 1, skeletal muscle) | protein interactions | 58 | 321 | 3 | 19454 | 50 |
DTNA,MACF1,SORBS1 |
4.941e-02 | -3.01 | Cation_ATPase_N | pfam domains | PF00690 | 18 | 1 | 17795 | 50 |
ATP13A4 |
4.962e-02 | -3.00 | thalamus | COSMIC cancer mutations | thalamus | 284 | 3 | 16828 | 49 |
QKI,DTNA,FGFR3 |
4.968e-02 | -3.00 | DUSP22 (dual specificity phosphatase 22) | protein interactions | 56940 | 139 | 2 | 19454 | 50 |
QKI,CTNNA2 |
4.995e-02 | -3.00 | negative regulation of alcohol biosynthetic process | biological process | GO:1902931 | 19 | 1 | 18204 | 49 |
APOE |
4.995e-02 | -3.00 | craniofacial suture morphogenesis | biological process | GO:0097094 | 19 | 1 | 18204 | 49 |
GLI3 |
4.995e-02 | -3.00 | regulation of circadian sleep/wake cycle | biological process | GO:0042749 | 19 | 1 | 18204 | 49 |
PTGDS |
4.995e-02 | -3.00 | vocalization behavior | biological process | GO:0071625 | 19 | 1 | 18204 | 49 |
GLI3 |
4.995e-02 | -3.00 | cartilage condensation | biological process | GO:0001502 | 19 | 1 | 18204 | 49 |
BMPR1B |
4.995e-02 | -3.00 | vascular associated smooth muscle cell differentiation | biological process | GO:0035886 | 19 | 1 | 18204 | 49 |
QKI |